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General  introduction
Magnetic resonance imaging (MRI) is a diagnostic modality with high inherent contrast 
resolution and multiplanar imaging capability. Advances in MR technology and image 
processing have increased the utility and availability of this technique in the past two 
decades. MRI has become one of the leading modalities in current diagnostic imaging, 
combining soft tissue contrast with high anatomic and temporal resolution. MRI is now a 
widely employed diagnostic method for the clinical evaluation of tumors.
 
One of the most recent applications of MRI is the investigation of angiogenesis using 
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).  DCE-MRI represents 
the acquisition of serial MR images before, during, and after the administration of an 
intravenous contrast agent. The use of contrast enhancement in conjunction with magnetic 
resonance imaging provides a means to evaluate tissue function, as well as morphology. 
Tissue blood volume, blood fl ow, perfusion and capillary permeability represent indicators 
of the status of the vasculature that can be investigated with DCE-MRI. Use of such 
quantitation potentially allows tumors to be characterized in terms of pathophysiology 
and to be monitored over time, during the course of therapeutic interventions. The 
understanding of the angiogenesis process and the evaluation of new drugs that inhibit 
or stimulate angiogenesis are directly related to the development of an imaging assay of 
angiogenic activity. This method should provide functionally relevant and quantitative 
images, should be high in spatial resolution, should sample the entire tumor and could be 
repeated at frequent intervals.
DCE-MRI has grown in importance with the development of antiangiogenic and 
neoadjuvant strategies for tumor therapy. Dedicated software makes it possible to 
interpret imaging pharmacokinetics and aid the assessment of physiological parameters 
such as capillary permeability and tissue perfusion. For instance, the permeability of 
functional tumor microvessels can be assessed noninvasively by dynamic MRI of contrast 
agent uptake in the tumor tissue (1-4). The analysis of contrast kinetics can be applied 
to differentiate between a malignant and a benign lesion and to determine whether a 
tumor is responding to treatment (5). It has been demonstrated that the permeability of 
blood vessels correlates with the ability of the tumor to metastasize, and with its response 
to treatment (6, 7). Thus, information concerning the status of vascular permeability 
might help assessing the metastatic potential of tumors and predict the sensitivity to 
chemotherapy or to antiangiogenic treatment.
 
MRI enhanced with low molecular contrast media has being used to estimate permeability 
and perfusion (8-11). However, the standard low molecular contrast agents for MR imaging, 
such as gadopentetate dimeglumine, extravasate nonselectively to the interstitium of nearly 
any extracerebral organ (12, 13). High transendothelial permeability of small molecular 
contrast media has been observed in both normal and tumor microvessels; thus, reliable 
differentiation of normal and diseased tissue may be problematic (4, 14). In order to assess 
tissue permeability and perfusion, the search for contrast agents with prolonged vascular 
residence time has been extensive (15). Macromolecular contrast media (MMCM) represent 
a new class of diagnostic drugs that can be applied with dynamic MRI to obtain physiologic 
Introduction 1
12
and morphologic information on tissue properties. MMCM distribute predominantly in 
the blood volume of the healthy tissues (16-18). In addition, they extravasate in conditions 
with pathologically increased microvascular permeability and thus may be helpful in 
evaluation of neoplasia, infl ammation and ischemia (15, 19-22). MMCM may also be more 
specifi c for distinguishing benign from malignant tumor tissue, since they extravasate 
across the discontinuos capillaries of malignant tumors, but not, or to a substantial lower 
extent, across the intact endothelium of benign lesions (4). 
Purpose and outl ine of  this  thesis
The purpose of this thesis was to evaluate the role of dynamic MRI enhanced with MMCM 
for the assessment of the tumor microvessels and for the monitoring of response to therapy 
with various antiangiogenesis drugs. In the fi rst part, several new developed MMCM 
have been investigated with respect to the potential for differentiation of benign from 
malignant tumors, or for tumor grading. The capability of DCE-MRI enhanced with MMCM 
for defi ning changes in the microvascular characteristics as a result of antiangiogenesis 
therapy and for monitoring the effect of treatment was evaluated in the second part of 
this thesis.
 
Several macromolecular contrast agents with molecular weight between 10 kDa and 100 
kDa are under development and have been tested experimentally, some clinically, over the 
past years. Several macromolecular contrast media are at the moment in clinical trials or 
in the registration process. Chapter 2 gives an overview of the potential applications and 
limitations of various MMCM for the evaluation of tumor microvessels.
  
DCE-MRI has become an increasingly used method for evaluation of tumors. The choice 
of the area (region of interest-ROI) to be analyzed within the tumor margins may have a 
substantial infl uence on accuracy of MRI predictors on tumor status. At present, there is 
no standardized method for ROI assignment in DCE-MRI. The goal of the study described 
in chapter 3 was to analyze whether the choice of ROI in which contrast kinetics are 
determined with DCE-MRI has an effect on the outcome of the kinetic analysis. For this 
purpose we analyzed MRI microvascular characteristics obtained from the kinetic analysis 
of DCE-MRI image data from the whole tumor and compared it with microvascular 
characteristics derived from data obtained from the tumor periphery.  The study was based 
on a meta-analysis of 98 quantitative MRI breast tumor characterizations, acquired in three 
separate experimental studies using identical methods for tumor induction and contrast 
enhancement. The specifi c MRI-derived measures for comparison to histologic grade were 
the tumor fractional plasma volume and the endothelial transfer coeffi cient KPS, refl ecting 
the endothelial leakiness of the tumor vessels.
Currently, a major research goal is to identify one or more MMCM that can safely be used 
clinically for tumor characterization and monitoring treatment response. Albumin-(Gd-
DTPA)
30
  is a prototype MMCM that has been used successfully to quantitatively defi ne 
the characteristics of tumor microvessels in experimental studies (3, 4, 21-26). However, 
albumin-(Gd-DTPA)
30
 is considered an unlikely candidate for human use due to its potential 
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immunogenic properties and its prolonged partial retention in the body (27, 28). New 
MMCM candidates must be examined for their potential as MRI probes for assaying tumor 
microvessels. Three novel contrast agents (P792, carboxymethyldextran-A2-Gd-DOTA 
and SHU555C) were tested to defi ne their ability to noninvasively characterize tumor 
microvessels and to differentiate between a malignant and a benign lesion. In chapter 4, 
a new rapid clearance blood pool contrast medium, P792, was compared to albumin-
(Gd-DTPA)
30
 in chemically induced rat breast tumors, based on quantitative estimates of 
microvascular permeability and fractional plasma volume of tumor tissue using a two-
compartment model. The MR-derived estimates of microvascular characteristics using each 
contrast agent were correlated to the histologic tumor grade and microvascular density 
counts. 
  
Chapter 5 describes a study designed to analyze the role of carboxymethyldextran-A2-Gd-
DOTA, a slow clearance blood pool contrast agent, for characterization and differentiation 
of the microvessels of malignant and benign breast tumors. DCE-MRI was undertaken in 
rats with a chemically induced mammary tumor. The endothelial transfer coeffi cient KPS 
and fractional plasma volume of the breast tumors were estimated from the DCE-MRI data, 
using a two-compartment model of tumor tissue. The MRI microvascular characteristics 
were correlated with the histopathologic tumor grade. 
Recently, the capability of ultrasmall superparamagnetic iron oxide particles (USPIO) 
to characterize tumor microvessels has been demonstrated in an experimental study 
performed in a rodent breast cancer model (24). However, one limitation of the study was 
the minimal enhancement of the tumors after intravenous administration of contrast 
medium, probably due to a low-dose USPIO (1 mg Fe/kg). For this reason, the objective 
of the study described in chapter 6 was to investigate if the use of a different USPIO 
with a higher dose (5 mg of Fe/kg) in the same tumor model could improve the tumor 
enhancement.  Additionally possible dose dependencies of USPIO for characterization of 
tumor microvessels were assessed. The values of the transendothelial permeability and 
fractional plasma volume of the tumors derived from kinetic analysis of dynamic MRI data 
were compared to albumin-(Gd-DTPA)
30,
 a prototype macromolecular contrast medium 
standard and correlated with tumor histopathology and microvascular density counts. 
In the second part of this thesis, the ability of DCE-MRI used in combination with MMCM to 
monitor changes in the tumor microvasculature following therapeutic interventions with 
antiangiogenic drugs was investigated. The aim of the study described in chapter 7 was 
to evaluate the potential of dynamic MRI enhanced by macromolecular contrast agents to 
monitor noninvasively the therapeutic effect of an antiangiogenesis VEGF receptor kinase 
inhibitor in an experimental human breast cancer model. Dynamic MRI was performed at 
baseline using albumin-(Gd-DTPA)
30
 and ultrasmall superparamagnetic iron oxide particles 
(USPIO). Subjects were treated for 1 week either with PTK787/ZK222584, a VEGF receptor 
tyrosine kinase inhibitor or with saline, followed by repeat MRI examinations serially using 
each contrast agent. Tumor microvessel characteristics including fractional plasma volume 
and transendothelial permeability were estimated for each contrast medium employing a 
kinetic model comprising the plasma and interstitial water compartments. Tumor growth 
and the microvascular density, a histologic surrogate of angiogenesis, were also measured.
I n t r o d u c t i o n
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Chapter 8 presents a study conducted with the purpose of testing several MR contrast 
media of different molecular weights for their potential to noninvasively characterize 
microvascular changes in an experimental treatment model. The study was performed in 
a human breast cancer xenograft, implanted in athymic rats. The animals were assigned 
randomly to a control (saline) or drug treatment group (anti-VEGF antibody). In both 
groups, DCE-MRI was performed in each animal using six different contrast media on 
sequential days at baseline and follow-up examination. The molecular weights of the used 
contrast media ranged from 557 Da to 92 kDa. Using a bidirectional kinetic model, tumor 
microvascular characteristics, including fractional plasma volume and transendothelial 
permeability, were estimated for each contrast medium. These microvascular characteristics 
were compared between drug and control groups and between contrast media of different 
molecular weights. 
Chapter 9 investigates the diagnostic and prognostic potential of a novel protein-binding 
MR contrast medium, B22956/1, for quantitative characterization of tumor microvessels 
by DCE-MRI and for monitoring the tumor response to antiangiogenic therapy with 
Avastin™￦, a humanized anti-vascular endothelial growth factor antibody (anti-VEGF). 
DCE-MRI was performed in an experimental human breast cancer model, using B22956/1, 
a low molecular contrast agent (ProHance￦™), and a prototype macromolecular contrast 
medium, albumin-(Gd-DTPA). The animals, assigned randomly to a control (saline) or 
drug-treated group (Avastin￦™), were imaged at baseline and after nine days of treatment. 
The transendothelial permeability and the fractional blood volume of the tumors were 
estimated from the kinetic analysis of the dynamic MR data using a two-compartment 
tissue model. Tumor growth was also measured from volumetric MRI. 
During the antitumor therapy with a combination of a cytostatic drug like melphalan and 
tumor necrosis factor alpha (TNF-α￦, a cytokine with established antitumor properties), a 
synergistic effect on tumor activity can be obtained. An immediate TNF-α mediated tumor-
selective enhanced uptake of the cytostatic agent (29, 30), dependent of the vascularity of 
the tumor (31) is followed by a tumor-selective eradication of tumor-associated vasculature 
(32). TNF-α￦ cannot be used systemically in doses high enough to obtain tumor response. 
However, in isolated limb perfusion (ILP), tumors can be exposed to local drug concentrations 
up to 15-20 times higher than those reached after systemic administration without major 
side effects (33). In chapter 10, the method of DCE-MRI was applied for assessment of 
treatment response in isolated limb perfusion with TNF-α￦ and melphalan. DCE-MRI was 
performed in an experimental cancer model of soft-tissue sarcoma implanted in rats, using 
a macromolecular contrast medium, albumin-(Gd-DTPA)45. The subjects were randomly 
assigned to a control (Haemaccel) or drug-treated group (TNF-α￦/melphalan). DCE-MRI was 
performed at baseline and 24 hours after isolated limb perfusion. The transendothelial 
permeability and the fractional plasma volume of the tumor tissue were estimated from 
the kinetic analysis of MR data using a two-compartment model. 
A summary of this thesis and the general conclusions are presented in chapter 11.          
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Abstract
 Dynamic contrast-enhanced MRI (DCE-MRI) using macromolecular contrast media enables 
assessment of the tumor vasculature based upon the differential distribution of the contrast 
agent within normal and pathological tissues. Quantitative assays of both morphological 
and functional properties can provide useful diagnostic insights into tissue angiogenesis. 
The utility of MRI enhanced with macromolecular agents for the characterization of tumor 
microvessels has been experimentally demonstrated in a range of malignant tumor types. 
Kinetic analysis of DCE-MRI data can be used to estimate microvascular permeability 
and tumor blood volume. By measuring these functional tumor properties, an accurate, 
noninvasive, and quantitative description of the microcirculation of individual tumors can 
be acquired, improving the specifi city of imaging examinations for cancer diagnosis and 
for treatment and follow-up. The noninvasive MRI assessment of tumor angiogenesis can 
be applied in the diagnostic differentiation between benign and malignant tumors and 
can also provide means for in vivo monitoring of anti-tumor therapy. In this review, the 
potential clinical applications and limitations of various macromolecular contrast agents 
applied for evaluations of tumor angiogenesis, with and without drug interventions will 
be discussed. 
Introduction
Angiogenesis plays a key role in the pathogenesis of tumors and is essential to tumor 
growth and metastasis (1, 2). Without angiogenesis, solid tumors cannot grow beyond 
2 mm in diameter due to hypoxia; angiogenically supplied new vessels derived from 
host tissues permit tumors to grow exponentially. Recent developments in anti-cancer 
therapies directed against the tumor neovasculature (3, 4) have heightened the need for 
angiogenesis imaging markers. Quantifi cation of tumor angiogenesis status might serve 
both as a prognostic index for the specifi c tumor examined as a tool for monitoring the 
effects of antiangiogenesis treatment. Dynamic contrast-enhanced MRI can be applied to 
quantitatively characterize certain tumor microvascular properties including richness of 
vascular supply and vascular endothelial leakiness, or permeability, and thereby to assess 
angiogenesis. Microvascular characteristics of tumor tissue such as capillary permeability 
and fractional blood volume can be estimated by contrast-enhanced MRI, based on kinetic 
analyses of contrast agent distribution over time between the vascular and interstitial 
spaces within the tumor. A simple two compartment model is appropriate for this analysis 
and can be readily adapted to computerized analysis.
Low molecular weight gadolinium chelates used as contrast media, like Gd-DTPA 
(gadopentetate dimeglumine, Magnevist molecular weight 567 Da), are now widely 
available, governmentally approved for humans, and have been applied to estimate 
permeability and perfusion  (5-8). One major limitation for low molecular contrast agents 
is that exclusive of the brain, where the specialized blood-brain-barrier prevents contrast 
agent extravasation or leak, these small molecular weight probes are known to diffuse 
quickly from the blood into the extracellular space for both normal and pathological tissues. 
For tumor microvessels extravasation rates for Gd-DTPA as great as 45% for each pass 
25
through the capillary bed have been measured (9), similarly leak rates in normal vessels 
can be very high. With the exception of the central nervous system, the differentiation of 
benign and malignant tissue might thus be problematic using small molecular weight 
contrast media. 
Macromolecular contrast media (MMCM), with molecular sizes approximating the size of 
serum proteins (up to 70 kDa or 7 nm in diameter), have been shown to remain largely 
confi ned within the intravascular space of normal tissues, with single-pass extraction 
fractions far below 1% (10, 11). However, these agents do extravasate and accumulate 
interstitially within tissues with damaged or otherwise hyperpermeable microvessels (12-
14). Tumor microvessels have been long recognized to be hyperpermeable to macromolecular 
solutes as shown for many tumor types and by a variety of invasive techniques (15). 
Correspondingly, published results from preclinical studies in cancer models indicate 
that MMCM are well suited for the detection and measurement of this characteristic 
macromolecular leakiness of malignant tumors (16). Macromolecular MRI contrast agents, 
as a class of agents, have been variably defi ned as paramagnetic or superparamagnetic 
probes with molecular weights higher than 10 kDa (17) or 30 kDa (18). Intermediate-sized 
molecules (molecular weight between 10 and 50 kDa) have been included by some authors 
in the class of MMCM. Ultrasmall superparamagnetic iron oxide (USPIO) particles have 
also been investigated as MMCM, although their size is considerably larger than human 
albumin (molecular weight 69000) or albumin-(Gd-DTPA)
35
, (a prototype MMCM with 
molecular weight of 92 kDa). Recently, contrast agents with low molecular weights but 
high binding affi nity to plasma proteins have been evaluated for potential to characterize 
tumor microvessels.
Dynamic magnetic resonance imaging (MRI) enhanced with MMCM has previously been 
used to measure specifi cally defi ned characteristics of tumor microvessels, namely the 
endothelial transfer coeffi cient, KPS, (leakiness) and fractional plasma volume (fPV) (13). A 
dynamic series of T1-weighted images was used to generate signal enhancement data that 
were furthered analyzed using pharmacokinetic modeling techniques. The contrast agent 
concentration, modeled as a function of time, could be derived from MR signal intensity 
data, assuming that changes in longitudinal relaxation rates R1 (1/T1) after administration 
of contrast medium are proportional with contrast agent concentration (19). The analysis 
of MMCM-enhanced MRI data within this context of a mathematical two compartment 
model of vascular permeability provides estimates of permeability, expressed as the 
endothelial transfer coeffi cient KPS (units mL min-1 per volume of tissue) and fPV (mL per 
volume of tissue), which have been assumed to closely correlate with the angiogenesis 
process.  KPS represents the rate of diffusive transfer of contrast agent from the blood to the 
interstitial space and it is dependent on both the permeability/leakiness of the capillaries 
and available surface area of the endothelium across which it can leak. Usually a two-
compartment, bidirectional or for relatively slow leak rates a unidirectional kinetic model 
representing the blood plasma and the extravascular extracellular spaces have been used. 
Several macromolecular contrast agents with molecular weight between 10 kDa and 100 kDa 
are under development and have been tested experimentally, some clinically. The optimal 
size for a contrast medium suited for the assessment of tumor microvasculature, however, 
C h a p t e r  2
26
C h a p t e r  2
has yet to be determined. The contrast agent should be suffi ciently large not to leak across 
the normal vascular endothelium and small enough to be eliminated through glomerular 
capillaries. A near-exclusive vascular distribution has been shown for large molecular tracers 
with sizes between 70 and 150 kDa, whereas free glomerular fi ltration by the kidneys was 
only possible for smaller molecules below 70 kDa (20). Several macromolecular contrast 
agents are at the moment in clinical trials or in the registration process.
Albumin-(Gd-DTPA)n
Albumin-(Gd-DTPA)
n
 consisting of a human protein backbone with multiple (typically 30-
35) covalently bound gadolinium chelates, is a prototype of a water-soluble macromolecular 
contrast medium having a molecular weight of 92 kDa (10, 11, 21). It has a distribution 
volume of 0.05 liter/kg (which closely approximates the body’s relative blood volume 
indicating its vascular distribution) and a plasma half-life of three hours in rats, which 
produces nearly constant enhancement of normal, non-leaky tissues for 30 minutes or 
longer after injection (22). The T1 relaxivity (R1) of albumin-(Gd-DTPA)
n
 is substantially 
higher compared to low molecular gadolinium chelates. The R1 of albumin-(Gd-DTPA)
n
 is 
14.8 mM-1 s-1 relative to gadolinium concentration (21). For comparison, the R1 value of Gd-
DTPA is 4.9 mM-1 s-1 (23). Thus by binding it to human albumin, the molar relaxivity of each 
Gd-DTPA chelate is approximately three-fold increased (21). 
The ability of dynamic MRI enhanced with albumin-(Gd-DTPA)
30
 to quantitatively defi ne 
the characteristics of tumor microvessels, including transendothelial permeability and 
fractional plasma volume has been shown in several experimental cancer models, including 
breast, prostate and ovarian adenocarcinomas (24-31). Experimental studies performed in 
chemically induced rodent mammary tumors showed a higher specifi city of albumin-(Gd-
DTPA)
30
 kinetic behavior for differentiation of malignant from benign tumors with a strong 
correlation (R2=0.76, P<0.01) of tumor microvascular MMCM permeability (KPS ) with the 
tumor histopathologic grade as measured by the Scarff-Bloom-Richardson method (24). 
Similar strong correlations between tumor histopathologic grade of mammary tumors 
and permeability to albumin-(Gd-DTPA)
30
 have been shown in several additional studies 
(27-29, 31). 
Albumin-(Gd-DTPA)
30
-enhanced MRI has also the potential to monitor the effect of 
antiangiogenesis therapy exemplifi ed by anti-VEGF (vascular endothelial growth factor) 
antibody (30, 32-34) (AvastinTM, Genetech, South San Francisco, CA); this antibody is 
worldwide the fi rst governmentally-approved angiogenesis inhibiting drug. Tumor 
microvascular permeability of human mammary tumors (30, 32, 33) or human 
ovarian carcinoma (34) decreased signifi cant (P<0.05) after ultiple anti-VEGF antibody 
administrations (32-34) or after only a single dose (30). 
The effects of an antiangiogenesis treatment with PTK787/ZK222584, an orally 
administrated VEGF receptor tyrosine kinase inhibitor, have also been monitored by 
dynamic MMCM-enhanced MRI using albumin-(Gd-DTPA)
30 
in a breast cancer xenograft 
(35). In this study endothelial transfer coeffi cient KPS decreased in the group treated with 
27
PTK787/ZK222584, while the control group had a signifi cant increase in permeability 
values; differences between the treated and control group were also signifi cant. 
Albumin-(Gd-DTPA)
n
 is  however considered an unlikely candidate for clinical use due to 
its potential immunogenic properties and its prolonged partial retention in the body, 17% 
at two weeks (36, 37). Additionally, MRI enhanced with albumin-(Gd-DTPA)
n
 with a low 
0.03 mmol Gd/dose, yields a relatively low contrast to noise ratio in tumors. Relatively long 
scan serial times (30-45 minutes) have been chosen to resolve the progressive extravasation 
of albumin-(Gd-DTPA)
n
 molecule, but the minimum duration of scanning has not be 
addressed and likely is considerably shorter. 
Macromolecular gadolinium chelates 
Macromolecular gadolinium chelates are typically based on a polymeric backbone, such as 
a polypeptide or polysaccharide to which are bound multiple gadolinium chelates such as 
Gd-DTPA or Gd-DOTA; other types of polymers including dendrimers have been considered 
as candidates for this class of agents. The compounds with a molecular weight of more than 
69 kDa, the weight of human albumin, that cannot be eliminated by glomerular fi ltration 
have been classifi ed as “slow-clearance blood pool contrast agents” (38). Contrast agents that 
can be included in this group are polylysine polymers of varying lengths, to which multiple 
gadolinium chelates have been bound (29, 39). Other large molecules that are used for 
binding of gadolinium chelates include polysaccharides (40), polyglycol polyethyleneimine 
(12) as well as paramagnetic dextrans (41). A new formulation of a slow-clearance dextran-
based contrast medium with a favorable toxicity profi le is carboxymethyldextran-Gd-DOTA 
(Guerbet Laboratories, Aulnay-Sous-Bois, France), with a molecular weight of 52.1 kDa 
(41). One exception to this problem are the ultrasmall superparamagnetic iron particles, 
approximately 30 nm in diameter, that have been applied clinically as a macromolecular 
probe. Polymer-based soluble macromolecular formulations will have to undergo chemical 
improvements to solve the problem of elimination. If these agents could be metabolized to 
components smaller than 50 kDa (for urinary excretion) or if they could be eliminated by 
other routes, they might be applied for clinical testing. 
Intermediate-sized gadolinium chelates 
Intermediate-sized contrast media with a molecular weight between 30 and 69 kDa, that 
are eliminated from the body by renal glomerular fi ltration, have been termed “rapid 
clearance blood pool agents” (38). They act as blood pool agents during the fi rst pass. Their 
diffusion through the normal vascular endothelial membrane is partly limited by their 
size, but these compounds can still pass the glomerular membrane. 
Three different intermediate sized contrast media have been under investigation recently: 
Gadomer 17, P792 and ZK181220. Gadomer-17 (Schering AG, Berlin, Germany) is a 
dendritic gadolinium chelate containing 24 Gd ions (42) with a total molecular weight 
of about 17 kDa. Gadomer 17 is exclusively eliminated by the kidney through glomerular 
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fi ltration within 24 hours from intravenous administration (42). Due to the globular shape 
of the molecule, the apparent molecular weight is larger than the true weight, more like 
a 30 kDa molecule, resulting in a retarded diffusion into the extravascular compartment. 
Gadomer 17 provides a high R1 relaxivity, approximately fi ve times higher than that of 
gadopentetate dimeglumine. 
The value of Gadomer 17-enhanced MRI for differentiation between benign and 
malignant breast tumors was investigated in two studies performed in a chemically 
induced rodent mammary tumor model (43, 44). Both reports revealed a limited capability 
for tumor characterization. Su et al (43) showed that Gadomer 17-enhanced MRI was able 
to distinguish low-grade from high-grade cancers based on fractional vascular volume 
(v
b
) and extravascular and whole tumor kinetics (derived from pharmacokinetic analysis 
of the relative contrast agent concentration curves), but unable to differentiate benign 
tumors from low-grade carcinomas, because of permeability range overlap. In the study of 
Daldrup-Link et al (44) the mean values for transendothelial permeability and fractional 
plasma volume estimated from Gadomer 17-enhanced MRI data were signifi cantly higher 
in malignant than in benign tumors. However, none of the quantitative microvascular 
parameters was signifi cantly correlated with histopathologic tumor grade. In dog tumor 
models, Gadomer 17 provided a higher specifi city for breast tumor characterization as 
compared with gadopentetate dimeglumine (45-47). 
The potential of dynamic MRI enhanced with Gadomer 17 to monitor the therapeutic effects 
of an anti-VEGF antibody on microvascular characteristics has been recently demonstrated 
using a human breast cancer line implanted in rats (33). Gadomer 17 revealed a statistically 
signifi cant difference in permeability and fractional plasma volume between pre- and post-
treatment examinations. This high specifi city for the differentiation of responders from 
non-responders was also shown after therapy with Mytomicin C in a rodent R3230 AC 
mammary adenocarcinoma model (48). In a different study performed in the same rodent 
R3230 AC mammary adenocarcinoma model, Gadomer 17 revealed signifi cant changes in 
vascular properties, specifi cally vascular volume index and out-fl ux transport rate K (2) of 
the tumors treated with chemotherapy (Taxotere, docetaxel, Aventis Pharmaceutical Inc.; 
Bridgewater, NJ) (49). 
P792 (Vistarem, Guerbet, Aulnay-Sous-Bois, France) is a rapid-clearance contrast agent 
with a molecular weight of 6.47 kDa (50). It contains a single gadolinium ion in a four-
armed gadolinium chelate. P792 has a plasma half-life in rats of approximately 20 minutes 
and a R1 relaxivity of 39 mM-1 s-1 at 20 MHz and 37 °C. 
Using P792 and Gd-DTPA in a rodent prostate tumor model it was shown to be possible 
to differentiate metastatic from nonmetastatic tumors based on contrast agent wash-
out rates, when the concentration vs. time curves were analyzed employing an empirical 
mathematical model to improve fi tting of the DCE-MRI data (51). However, when analyzing 
the DCE-MRI data using a two-compartment kinetic model, it was not possible to reliably 
discriminate between metastatic and nonmetastatic tumors. In an experimental model of 
human prostate tumors using P792, signifi cant reductions in this agent’s tumor vascular 
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permeability, tumor blood volume and tumor blood fl ow were demonstrated following 
treatment with ZD4190, a VEGF receptor tyrosine kinase inhibitor (52). In a different 
experimental study performed in chemically induced rodent mammary tumor, P792 
showed a lack of feasibility for the differentiation of benign from malignant tumors, based 
on estimates of permeability or tumor blood volume (28). 
ZK181220 (Schering AG, Berlin, Germany) is a prototype MR contrast agent with an 
intermediate size (molecular weight of 25.9 kDa). In an experimental study performed 
in a human breast cancer xenograft, the microvascular permeability and the fPV derived 
from ZK181220-enhanced MRI data decreased signifi cantly (P < 0.05) after therapy with 
anti-VEGF antibody compared with the control group (33). Although the values of KPS and 
fPV were generally higher compared to the estimated values for the two larger agents 
investigated in the same study, USPIO SHU555C (Schering AG, Berlin, Germany) and 
albumin-(Gd-DTPA)
30
, MR-based monitoring of  anti-VEGF drug effect was still feasible.
Low molecular weight gadolinium chelates with reversible 
binding to plasma proteins
Small molecular gadolinium chelates with high binding affi nity for plasma proteins 
represent a new class of MR contrast agents that undergo reversible interactions with 
circulating albumin. The contrast medium becomes associated with a macromolecular 
carrier. The bound form assumes the macromolecular attributes of albumin and remains 
intravascular, while the non-bound minor component (with the low relaxivity typical of 
small Gd-chelates) is free in the plasma and extravasates readily. These molecules have 
been recently extensively studied, and their blood persistence has been demonstrated in 
experimental models (31, 53-58). The long intravascular residence of the albumin-bound 
contrast media serves as an aid in delineating abnormal vascular beds and increased 
vascularization associated with fast-growing tumors.  
B22956/1, a new protein-binding contrast agent (Bracco S.p.A., Milan, Italy) is a Gd-
chelate with a low molecular weight (1059 Da). B22956/1 is the trisodium salt of a 
polyaminocarboxylate Gd complex linked to deoxycholic acid (58). It has a high affi nity for 
serum proteins (94% for a 0.5mM solution in Seronorm for human serum albumin, and 
84% for rat serum albumin). The relaxivity of B22956/1 is 27 mM-1 s-1 at 20 MHz in human 
serum, which is almost six-fold higher than that of conventional extravascular contrast 
agents. Experimental studies performed in human mammary tumors demonstrated the 
effects of an antiangiogenesis therapy with anti-VEGF monoclonal antibody (59). The 
microvascular permeability KPS estimated from B22956/1-MRI data decreased signifi cantly 
in the drug-treated group compared to baseline and progressed signifi cantly in the control 
group. B22956/1 demonstrated a number of favorable imaging characteristics. In a short 
examination time, substantial progressive enhancement of the tumors was observed, 
allowing clear visualization of the effects of anti-VEGF therapy on the permeability of 
tumor blood vessels. The dynamic range of observed permeability changes spanned a wide 
range, rendering observation of progressive disease and the permeability reducing effects of 
successful antiangiogenic therapy readily resolved. 
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MS-325 (Angiomark, Schering AG, Berlin, Germany) is a non-covalent protein-bound 
small molecular gadolinium chelate (MW 957 Da) with a relaxivity of 35 mM-1 s-1. After 
intravenous administration, this agent binds reversibly to plasma albumin to form a MS-
325-albumin complex with a molecular weight of roughly 70 kDa. This macromolecular 
complex acts as a blood pool-enhancing agent with a plasma half-life of 2-3 hours in 
humans (60). The bound form is in equilibrium with a small amount of free from, which 
is eliminated by glomerular fi ltration. The affi nity of MS-325 binding for albumin varies 
with species: it is approximately 95% in humans and 75% in rats (31, 54, 57). The prolonged 
half-life of MS-325 provides excellent properties for use as a MR angiography agent (58, 
61). 
Initial studies performed in chemically induced rodent mammary tumors (31) did not 
show a signifi cant correlation between MS-325-enhanced microvascular assays with 
either tumor histopathologic grade or microvascular counts, a surrogate of angiogenesis. 
A likely explanation for the lack of feasibility for tumor microvessel characterization, 
at least in this specifi c animal tumor model, was the inability to extract the particular 
pharmacokinetics of the macromolecular protein-bound component from MR data, since 
both the bound and unbound form of MS-325 are present in plasma at all times diffusing 
through vessel endothelium independently.  
MP-2269 is another protein-binding small molecular gadolinium chelate of potential 
clinical signifi cance. MP-2269 (Mallinckrodt Inc., St. Louis, MO) is an experimental 
monomeric Gd-DTPA –derived blood pool agent which binds non-covalently and reversibly 
(80%) to human serum albumin (53, 62). A recent study performed in an intracranial 
mouse glioma model using MP-2269, MS 325 and extracellular contrast agent OptiMARK 
(Mallinckrodt, Inc., St Louis, MO) demonstrated that the blood pool contrast agents had 
an approximately threefold increased dose-effectiveness and a lengthened window of 
contrast enhancement in comparison to extracellular agent (62). 
Macromolecular iron oxide compounds 
Superparamagnetic iron oxide particles (SPIO; > 100 nm diameters), which are currently 
clinically applied for imaging the reticuloendothelial system, specifi cally the liver and 
spleen, are cleared too rapidly from the blood stream (plasma half-life of 8 minutes) and 
thus are not well-suited for characterization of tumor microvessels. On the other hand, the 
ultrasmall superparamagnetic iron oxide particles (USPIO; < 30 nm diameters), initially 
developed for MR lymphography, have an intravascular half-life of approximately 1-3 
hours, allowing maintenance of a high blood concentration and a strong enhancement of 
the blood pool. These nanoparticles decrease T1 and T2 relaxation times of tissues, and thus 
they can act either as positive or negative contrast agents, according to their concentration 
(63). 
The strong T2 and T2* relaxivity when compared to the T1 relaxivity of USPIO results in 
the fact that positive enhancement due to T1 shortening effect is limited to relatively low 
tissue concentrations and that this positive T1 enhancement is overwhelmed at higher 
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doses by a strong T2* effect (64). Thus, the evaluation of for instance perfusion alterations 
could theoretically be performed with either small doses/concentrations, which shorten 
T1 relaxation times, or with higher doses, that predominantly shorten the T2 relaxation 
times. Recently reported experimental studies indicate that USPIO are well suited for the 
characterization of tumor microvessels, including abnormal macromolecular permeability 
(27, 65, 66). 
NC100150 (Feruglose, Clariscan, Nycomed Amersham, Oslo, Norway) and albumin-(Gd-
DTPA)
30
 were compared at MR imaging on sequential days in the same rats with a chemically 
induced mammary tumor (27). NC100150 consists of USPIO particles composed of single 
crystals (4-7 nm diameter core), stabilized with a carbohydrate polyethylene glycol coat. 
The fi nal diameter of the USPIO particles is approximately 20 nm. The R1 relaxivity of this 
agent is 20 mmol/L/sec, and the R2 is 35 mmol/L/sec at 37 °C and 0.5 T. The mean plasma 
half-life in rats is about 3.3 hours. The tumor vascular permeability estimated with either 
contrast agents correlated signifi cantly with the histopathologic tumor grade. Clariscan 
was administrated at a low dose of 1 mg Fe/kg. This low dose was specifi cally chosen to 
minimize the confounding T2* effects. However, one disadvantages of the low dose was 
low signal-to-noise ratio due to a low level of tumor signal enhancement. 
The value of the USPIO Clariscan in differentiating and grading of human benign and 
malignant breast tumors on the basis of microvascular characteristics has been recently 
evaluated in a multi-center clinical trial (66). In this study, a moderate and statistically 
signifi cant correlation was found between the transendothelial permeability and the 
pathologic tumor grade (r=0.496, P<0.001). The probability of breast tumor microvascular 
hyperpermeability to be associated with malignancy was 79%. Normal, non-neoplastic 
and mastopathic tissue did not enhance with Clariscan. Benign fi broadenomas could be 
accurately differentiated from high-grade carcinomas, but demonstrated a considerable 
overlap with the enhancement patterns of low-grade cancers. Another clinical study 
evaluating the role of Clariscan in grading human breast cancer (67) also demonstrated a 
statistically signifi cant correlation between the transendothelial permeability estimated 
from dynamic Clariscan-enhanced MR data and the tumor histopathologic grade.
 
A different study (65) performed in a chemically induced rodent mammary tumor model 
investigated the diagnostic potential of a different USPIO, SHU555C (Resovist S, Schering 
AG, Berlin, Germany) for quantitative tumor microvessel characterization. SHU555C is an 
USPIO with a mean core size of 3-4 nm and a hydrodynamic size of < 25 nm. The R1 of the 
agent is 22 mM-1 s-1 of Fe, and the R2 is 65 mM-1 s-1 of Fe (at 20 MHz and 37 °C). The mean 
plasma half-life in rats is about 1 hour. SHU555C was injected at a dose of 5 mg Fe/kg. The 
tumor microvascular characteristics estimated with SHU555C were compared to albumin-
(Gd-DTPA)
30
. The transendothelial permeability KPS correlated signifi cantly with the tumor 
malignancy grade for the USPIO as well as for the albumin-(Gd-DTPA)
30
. The higher dose of 
5 mg Fe/kg provided increased T2* effects, that probably were responsible for the observed 
lower correlation (r=0.36, P<0.05) of the KPS value with the tumor histopathologic grade, 
compared to the lower dose of 1 mg Fe/kg (r=0.82, P<0.001) used in the study reported by 
Turetschek (27).  The potential of dynamic MRI enhanced with USPIO (SHU555C) to monitor 
the therapeutic effects of an anti-VEGF antibody on microvascular characteristics has also 
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recently been demonstrated using a human breast cancer xenograft (33). The kinetic analysis 
of dynamic MRI enhanced with SHU555C revealed a statistically signifi cant difference in 
permeability and fractional plasma volume between examinations performed prior to- 
and after treatment with anti-VEGF antibody. 
Conclusion
Experimental and some early clinical studies have shown the potential of MMCM-
enhanced MRI for characterizing tumor angiogenesis, based on the ability to assay 
microvessel permeability and fractional plasma volume. Several xenograft studies have 
suggested that MMCM enhanced MRI can monitor antiangiogenesis cancer therapies 
including direct inhibitors of VEGF, antagonists of VEGF receptors, and inhibitors of matrix 
metalloproteases. The immediate challenge is to design a contrast agent with a suffi ciently 
high molecular weight and size that is tolerated in humans, interacts minimally with 
tissue, and is stable in vivo and completely cleared from the body. Intermediate size 
MMCM and low molecular weight agents with reversible binding to plasma proteins have 
the advantage of providing images with a good signal to noise ratio in a relatively short 
imaging time. These contrast agents can be succesfully applied in DCE-MRI monitoring of 
the effects of antiangiogenic therapies, as indicated in several experimental studies (what 
may be sacrifi ced by their use is the specifi city for cancer/diseased microvessels.) MMCM, 
currently in various stages of development, offer considerable promise for quantitative, 
physiologically based imaging evaluation of the tumor microvessels and antiangiogenesis 
therapy. The anticipated availability of a MMCM approved for human use should allow the 
future translation of these noninvasive MRI monitoring techniques from experimental to 
wide scale clinical implementation.
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Abstract
Objectives
To determine if MR estimates of quantitative tissue microvascular characteristics from 
regions of interest (ROI) limited to the tumor periphery provided a better correlation with 
tumor histologic grade than ROI defi ned for the whole tumor in cross-section. 
Methods
A meta-analysis was based upon 98 quantitative MRI breast tumor characterizations, 
acquired in three separate experimental studies using identical methods for tumor 
induction and contrast enhancement.
Results
The endothelial transfer coeffi cient (KPS) of albumin- (Gd-DTPA)
30
 from the tumor periphery 
correlated (r=0.784) signifi cantly more strongly (p < 0.001) with the pathologic tumor 
grad than KPS derived from the whole tumor (r=0.604). KPS estimates, either from the tumor 
periphery or from the whole tumor correlated signifi cantly more strongly with histologic 
grade (p < 0.01) than MRI estimates of fractional plasma volume (fPV) from either tumor 
periphery (r=0.368) or whole tumor (r=0.323).
Conclusions
KPS estimates from the tumor periphery were the best of these measurable MRI microvascular 
characteristics for predicting the histologic grade.
Key words
Magnetic resonance imaging, region of interest, tumor microvascular characteristics, breast 
tumor.
Introduction
Dynamic contrast-enhanced magnetic resonance imaging has become an increasingly 
used method for evaluating breast masses. Different methods have been proposed for 
analysis of dynamic contrast-enhanced MR data in order to characterize breast tumors and 
to improve the specifi city of diagnosis. Several approaches involve the analysis of dynamic 
MR contrast-enhanced data within the context of mathematical models (1-4). Using a 
two compartment bi directional model in conjunction with a macromolecular contrast 
medium, albumin- (Gd-DTPA)
30
, our group has shown the potential to successfully predict 
tumor histologic grade based on the MRI microvascular characteristics (5).
The choice of region of interest (ROI) to be analyzed within the tumor margins may have a 
substantial effect on accuracy of MRI predictions of tumor status. At present, there is no 
standardized method for ROI assignment in dynamic breast MRI. A large ROI encompassing 
the entire cross-section of the tumor at its maximum diameter (henceforth termed the 
“whole tumor”) can be drawn, from which mean signal intensity pixel values can be 
extracted at each time point. A large ROI has the advantage of “averaging out” random 
C h a p t e r  3
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noise contributions within and among individual pixels. However, reasonable concerns 
have arisen that a large ROI covering the whole tumor, particularly if the tumor is 
heterogeneous may yield misleading results. Such large ROI may include zones of necrosis, 
cysts, poor vascularization and areas subject to elevated interstitial pressures, any of 
which could distort the tumor contrast-enhancement profi le. Our group and others have 
intuitively proposed a selective ROI, limited to the tumor periphery or strongest enhancing 
sub-region, defi ned by an operator, in an attempt to improve the quality of the analysis 
(5-7). However, to our knowledge no group has stematically and impartially compared the 
correlations differing ROI with a quantitative non imaging tumor characteristic such as 
histologic grade.
The purpose of this study was to determine if the correlations between the tumor histologic 
grade and MRI microvascular characteristics obtained from the kinetic analysis of dynamic 
macromolecular contrast-enhanced image data from the whole tumor is signifi cantly 
different from that when only the tumor periphery is analyzed. The specifi c MRI-derived 
microvascular measures for comparison to histologic grade were the tumor fractional 
plasma volume (fPV) and the endothelial transfer coeffi cient (KPS), refl ecting the endothelial 
leakiness of the tumor vessels.
Materials and Methods
This study is based on a retrospective meta-analysis of dynamic macromolecular contrast-
enhanced MR data sets from three separate studies, already published, involving a total of 
98 chemically induced breast tumors in rodents (5, 8, 9).
A spectrum of mammary tumors, ranging from benign (fi broadenomas) to highly malignant 
(anaplastic adenocarcinomas) was induced in Sprague-Dawley rats by intraperitoneal 
injection of N-ethyl-N-nitrosourea (ENU) (10). All tumors, both benign and malignant, were 
graded using the Scarf-Bloom-Richardson (SBR) histopathologic method (11). The details of 
animal handling, MR imaging and microscopic grading have been reported previously (5, 
8 ,9).
Briefl y, MR imaging was performed on a Bruker Omega CSI-II System (Bruker Instruments, 
Fremont, CA) operating at 2 Tesla. Axial Tl-weighted three-dimensional (3D)-spoiled gradient 
recalled (SPGR) sequences were acquired prior to and following contrast agent administration 
using the following settings: echo time (TE) 1.4 ms, one acquisition, fi eld-of-view 60x60x48 
mm, matrix 128x128x16 and an effective slice thickness of 3 mm. Postcontrast images 
were acquired over a period of at least 40 minutes with an acquisition time of 1 minute 42 
seconds per volume of 16 slices. The contrast medium used in all 98 subjects was albumin- 
(Gd-DTPA)
30
, 0.03 mmol Gd/kg, a prototype macromolecular contrast medium formulated 
for blood-pool and permeability-sensitive MR imaging having a molecular weight of 92 
kDa (12).
Signal intensity values (SI) for each time point were obtained from regions of interest placed 
over the inferior vena cava, the whole tumor and the tumor periphery. For the tumor whole 
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and tumor periphery ROIs, three separate ROIs from contiguous sections were averaged 
and this average was used in subsequent analyses. Based on visual inspection of late post-
contrast images, the tumor periphery was defi ned as the peripheral strongly enhancing 
zone, typically with a thickness of 1-2 mm (See Figure 1 for a series of tumor enhancement 
images with a peripheral ROI drawn on the late post-contrast image). Tumors ranged in 
diameter from 1.0 to 1.5 cm. SI values from three regions of interest (each with a minimum 
of 30 pixels), obtained from the whole tumor and regions of peripheral tumor enhancement 
were averaged at each time point and the mean SI was used for calculating longitudinal 
relaxation rates (R1=1/T1). The SI data were converted to ∆R1values as previously described 
(5). The difference between the postcontrast R1 value at any time point and the precontrast 
R1, ∆R1(t) was assumed to be directly proportional to the gadolinium concentration of 
the tissue. The ∆R1 data from blood and tumor were used for kinetic analysis to estimate 
the endothelial transfer coeffi cient, KPS (ml min-1 100 cc-1 of tissue), and fractional plasma 
volume fPV (ml cc-1 of tissue), employing a two compartment bi-directional model for tumor 
tissue (5). The model describes the kinetic behavior of contrast agent in tumor tissue and 
is composed of equilibrating pools of plasma and interstitial water spaces (the exchange 
between the compartments is assumed to be based on passive diffusion). In this model, a 
bi-exponential function fi tted to the ∆R1 data from blood was used as an input function for 
the plasma response in the tumor tissue, after scaling for fractional plasma volume.
Nonparametric Spearman correlation analyses were performed, comparing the estimated 
MR-derived parameters (KPS and fPV) based upon kinetic analysis of data from the tumor 
periphery and from the whole tumor with the quantitative histologic tumor grade (SBR 
score). The SBR score was defi ned pathologically based on whole tumor microscopic 
interrogation for gland formation, anaplasia and mitoses in the most mitotically active 
areas, corresponding to the MR slices. All tumors were sectioned in the plane of the MR 
images. Each of these three morphologic features is score by assigning 1 to 3 points and an 
overall score is obtained by summation of the scores in each category. The lowest SBR score 
is 3 (even for a benign tumor), the highest is 9; the higher the SBR score, the more poorly 
differentiated and malignant the tumor. The SBR score and the pathologic diagnosis of 
Figure 1.  Tl -weighted SPGR image of a mammary adenocarcinoma before and 2, 10 and 60 
minutes after administration of albumin-(Gd-DTPA)30 (0.03 mmol/kg). A ROI was placed in the 
periphery of tumor.
43
C h a p t e r  3
malignancy are somewhat independent variables and subject to the judgment of a 
pathologist. The statistical signifi cance of the differences in correlations was assessed by 
calculating bias-corrected, accelerated bootstrap confi dence intervals for each difference 
(13), using 2000 bootstrap iterations. The p-value was defi ned as one minus the largest 
confi dence level for which the corresponding interval still excluded zero (no difference), 
and was reported as p < 0.001 if zero was excluded no matter what level was chosen.
Results
Figure 2.  Bar graphs depict median (height of the 
box) and the 25th and the 75th quartiles of MRI-
estimated endothelial transfer coefficient in tumor 
periphery, KPS -tumor periphery (ml min-1 100 cc-1 
of tissue) as a function histopatologic tumor grade, 
assayed using Scarff-Bloom-Richardson (SBR) 
score.
Figure 3.  Bar graphs depict median (height of the 
box) and the 25th and the 75th quartiles of MRI-
estimated endothelial transfer coefficient in tumor 
whole, KPS -tumor whole (ml min-1 100 cc-1 of 
tissue) as a function histopatologic tumor grade, 
assayed using Scarff-Bloom-Richardson (SBR) 
score.
Figure 4.  Bar graphs depict median (height of the 
box) and the 25th and the 75th quartiles of MRI-
estimated fractional plasma volume in tumor 
periphery, fPV-tumor periphery (ml cc-1 of tissue) 
as a function histopatologic tumor grade, assayed 
using Scarff-Bloom-Richardson (SBR) score.
Figure 5.  Bar graphs depict median (height of 
the box) and the 25th and the 75th quartiles of 
MRI-estimated fractional plasma volume in whole 
tumor, fPV-tumor whole (ml cc-1 of tissue) as a 
function histopatologic tumor grade, assayed 
using Scarff-Bloom-Richardson (SBR) score.
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The tumor KPS and fPV values from the tumor periphery and whole tumor for each SBR 
score are shown in Figures 2 to 5. The Spearman correlation coeffi cients between histologic 
tumor grade, quantitatively refl ected in the SBR score, and the MRI-derived microvascular 
assays of KPS and fPV from the whole tumor and from the tumor periphery are presented in 
Table 1. The differences between the correlation coeffi cients are shown in Table 2. Assays of 
microvascular permeability (KPS) derived from the tumor periphery correlated signifi cantly 
more strongly (r=0.784, p < 0.001) with the tumor histologic SBR score than did KPS estimates 
derived from the whole tumor (r=0.604). Fractional plasma volume (fPV) estimated from 
the dynamic enhancement response correlated weakly but signifi cantly with the tumor 
grade, either from regions of interest in the periphery (r=0.368, p < 0.001) or from the whole 
tumor (r=0.323, p=0.001); these fPV correlation coeffi cients did not differ signifi cantly from 
each other (p=0.32). Both correlation coeffi cients between the KPS and SBR score derived 
from the tumor periphery and from the whole tumor were signifi cantly greater than either 
correlation coeffi cients of the fPV with the SBR score (p < 0.01).
Discussion
The summed experience from 98 MRI experiments gathered from three separate 
studies shows that MRI derived estimates of endothelial transfer coeffi cient (KPS) provide 
signifi cantly stronger correlations with histologic tumor grade than do assays of fractional 
plasma volume. Furthermore, KPS-based correlation coeffi cients are improved signifi cantly 
if the region of interest chosen for analysis is limited to the tumor periphery. Accordingly, 
MRI-based microvascular characterizations might preferentially consider data from the 
Table 1. Correlation with the histologic tumor grade (SBR score) of MRI-derived 
endothelial transfer coefficient (KPS ) and fractional plasma volume (fPV) based on 
analysis of the whole tumor (Tw) or the tumor periphery (Tp).
Table 2. The Differences Between Correlation Coefficients.
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tumor periphery, particularly for estimating tumor grade. Other investigators have cited 
a preference for analysis of the tumor periphery in their efforts to characterize pathology 
or drug effects, but this preference has been largely based on intuition and the qualitative 
observation that the rim enhances more strongly than the core of tumors. But this is the fi rst 
quantitative demonstration that analysis of the tumor periphery provides a measurably 
superior correlation with a quantitative ex-vivo tumor property, namely, Scarff-Bloom-
Richardson histologic grade. Pham and coworkers observed a larger decline in apparent 
permeability in the tumor periphery than in the tumor whole in xenograft human 
breast cancers treated with an angiogenesis inhibitor, but this observation was based on 
comparisons in less than 10 tumors (14). Ma and coworkers (7), in their analysis of clinical 
musculoskeletal masses observed that the rates of rim-to-center differential enhancement 
were higher in malignant than in benign lesions. However, the current study is the fi rst to 
our knowledge to directly address the issue of whether any defi nable portion of a tumor 
provides an advantage for quantitative tumor characterization.
Multiple factors likely contribute to the superior correlation of KPS from tumor periphery with 
histologic grade. The tumor enhancement pattern varies with the degree of necrosis, cell 
density, interstitial pressure and blood fl ow. Lacking good lymphatic drainage, malignant 
tumors consistently show a marked central elevation in the interstitial pressure, much 
higher than in the periphery, “where it drops precipitously” according to Jain (15). Thus, 
accordingly to physiological principles, the diffusion (movement of molecules from an area 
of high concentration to an area of lower concentration) of water and solutes through the 
vessel endothelial barrier into the interstitium is inhibited in the center of the tumor. Jain 
stated that in the inner zone of tumors, the interstitial pressure is elevated and about equal 
to that in the blood vessels; hence convection (transport of molecules by a stream of fl owing 
fl uid from areas of high pressure to areas of low pressure) virtually ceases. By contrast, 
the contribution to transendothelial transport of diffusion is not directly infl uenced by 
pressure considerations. Jain reported that the interstitial pressure in the normal breast 
tissue is about 0.0 mm Hg, while the mean in eight breast carcinomas was 15 mm Hg (15). 
Even if the volume of blood in the tumor core is not substantially different from that in 
the tumor rim, as suggested by our results, the transendothelial convection-driven leak of 
macromolecular contrast medium should be less in the center due to the higher interstitial 
pressure. The advancing margin of the tumor, the periphery, is also the front-line site of 
angiogenesis; where vessels from the host tissue, under the infl uence of tumor secreted 
angiogenic factors, sprout new vascular buds leading to an augumented vascular supply 
for the tumor. This zone of most active growth and angiogenic activity, and consequently 
vessel immaturity, may thus display the greatest leak of contrast medium. 
Although the spectrum of breast tumor pathology induced by ENU is generally parallel to 
the pathology spectrum of human breast tumors (10), the results from an experimental 
subcutaneous rat breast tumor model may not translate completely to human tumors. 
Another limitation derives from the subjectivity and potential variability of a user-defi ned 
ROI as employed in this study for the tumor periphery. Although in the selection of ROI 
special care was taken to select the zone of contrast enhancement in the tumor periphery, 
a certain degree of observer-dependent variability can not be completely excluded. 
The report of Liney and coworkers (16) suggests that a semi-automated method for ROI 
46
defi nition might be less subject to variability. In their study, a user-defi ned ROI was used 
to subsequently analyze the selected region on a pixel-by pixel basis to establish two
additional automated ROIs (one by determining pixels within 10% of the maximum pixel 
intensity, the other by selecting the area of greatest enhancement using a 9-pixel square 
mask). Yet, another approach that could be used is the interrogation of tumors on a pixel-
by-pixel basis.
Quantitatively analyzed MR data obtained from ROI limited to the tumor periphery 
correlated signifi cantly better with the tumor histologic grade than did analysis from ROI 
covering the whole tumor cross-section. Correlations were stronger using KPS than using fPV. 
Based on these results, future efforts to characterize tumor grade based on MRI analysis 
should focus on ROI confi ned to the tumor periphery, at least as a major component in a 
more complete analysis.
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Abstract
The diagnostic potential of a new rapid clearance blood pool contrast medium (P792; 
MW = 6.47 kDa) for the MR assessment of microvessel characteristics was assessed in 42 
chemically-induced breast tumors, with comparisons to albumin-(Gd-DTPA). Microvessel 
characteristics, including the transendothelial permeability (KPS) and the fractional blood 
volume (fPV), were estimated by using dynamic MR data fi t to a bidirectional two-
compartment model. The MR-derived estimates for KPS and fPV using each contrast agent 
were compared, and assays using each contrast agent were correlated to the histologic 
tumor grade (SBR score) and the microvascular density (MVD) counts. Using P792-enhanced 
data, neither KPS nor fPV showed a statistically signifi cant correlation with the tumor 
grade or the MVD (P > .05). Conversely, using albumin-(GdDTPA)
30
, KPS values correlated 
signifi cantly with the histologic tumor grade (r = .55; P < .0005) and the MVD (r = .34, P 
< .05), whereas no correla tion was established for fPV. In conclusion, based on P792 data 
no correlation between tumor microvascular characteristics and histologic markers (SBR 
score or MVD) was found in this breast tumor model. Our analysis suggests that contrast 
media of relatively large (on the order of 90 kDa) molecular size, such as albumin-(GdDTPA)
30
, 
are more accurate for the characterization of tumor microvessels. 
Key words
Magnetic resonance imaging; breast neoplasm; contrast media; histologic tumor grade; 
microvascular permeability
Introduction
MRI is becoming a dominant imaging method for characterizing tumors both 
morphologically and functionally. Kinetic analyses of dynamic contrast-enhanced MRI 
data within the context of a physiologically-based mathematical model of endothelial 
permeability provide valuable information about tumor microvessel properties, includ-
ing a measure of transendothelial permeability (KPS) and fractional plasma volume (fPV). 
Estimates of KPS and fPV serve to define the status of tumor microvasculature and 
quantitatively refl ect the state of tumor angiogenesis (1-5), and thus offer the potential for 
delineation of the individual biological characteristics of any given tumor. New strategies 
in cancer therapy already include the inhibition of tumor angiogenesis; therefore, 
reliably defi ning tumor microvessels by contrast-enhanced MRI could represent a major 
improvement for the management of tumor patients. Defi nition of tumor biological 
characteristics could also have an impact on cancer therapy, particularly for treatments 
directed against angiogenesis. The form of therapy may hinge upon knowledge of tumor 
properties, and ther apy response may be well refl ected in MRI-defi ned char acteristics. 
The defi nition and choice of well-designed contrast media for MRI tumor characterization 
remains an area of intense investigation.
Tumor microvessels consistently demonstrate impaired endothelial barrier integrity and 
are  “leaky”  to macromolecular solutes, including macromolecular contrast media (MMCM) 
(5-8). The capacity of MMCM-enhanced MRI to assess microvascular characteristics has 
C h a p t e r  4
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been demonstrated in a variety of disease models and tumor types (1,9-13). In several 
studies, albumin-(GdDTPA)
30
 has been used successfully as a prototype MMCM, but its 
potential immunologic properties and its prolonged retention limits its potential for 
development as a clinical MRI contrast medium (14). Accordingly, there remains an un-
fulfi lled goal for a safe MMCM capable of fulfi lling pharmacologic and enhancement 
requirements. Some of the MR compounds now under development have potential as 
MRI probes for assaying endothelial permeability and plasma volume.
P792, which is representative of a rapid clearance blood pool agent (RCBPA), was tested 
in this study to defi ne its potential to characterize tumor microvessels (15,16). Results 
were correlated with histopathology, notably tumor grade and microvascular density 
(MVD) counts. These cor relations were then compared to results achieved in the same 
tumors with albumin-(GdDTPA)
30
, which was used as a reference but is larger than most 
MMCMs.
Methods
Animal Model
The study was conducted under the guidelines of the Committee of Animal Care 
according to regulations in the Guide for the Care and Use of Laboratory Animals, DHHS 
Publication NIH 86-23, 1985, and the Instructions to Use Vertebrate Animals in Research 
(7/1/92).
Forty-two female Sprague Dawley rats, 4 - 6 weeks old, weighing 160-360 g, were purchased 
from Harlan (Indianapolis, IN). Breast tumors were induced chemically by intraperitoneal 
(ip) injection of N-ethyl-N-nitrosurea (ENU) (Isopack, St. Louis, MO) (17,18) under ether 
anesthesia using doses ranging from 45-250 mg/kg (45 mg: N = 1; 90 mg: N = 2; 180 mg: 
N = 9; and 250 mg: N = 30).
Rats were inspected daily for tumor growth and general appearance. Animals were 
examined by MRI when the tumors reached a size of 1.5-2 cm. Before MRI, animals were 
anesthetized with an ip injection of 50 mg/kg BW pentobarbital. A 23-gauge butterfl y 
(Abbott Laboratories, Chicago, IL) was inserted into the tail vein for contrast media 
injection. Animals were placed supine on a heated water pad within the imaging coil; 
body temperature dur ing imaging was monitored for stability with a rectal ther mometer. 
Immediately after imaging, 2 ml of saline was injected subcutaneously to prevent 
dehydration effects.
MRI
Imaging was performed using a CSI-II Omega spectrometer operating at 2.0 T (Bruker 
Instruments, Fremont, CA) and equipped with Acustar S-150 self-shielded gradient coils 
(±20 G/cm, 15-cm inner diameter). Rats were placed su pine in a birdcage radiofrequency 
coil with a length of 7.6 cm and an inner diameter of 4.5 cm. A phantom fi lled with 
diluted 0.01 mmol/L gadopentetate dimeglumine was positioned in the fi eld of view 
(FOV) to correct for potential spectrometer variation. Precontrast T1-weighted spoiled 
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gradient-recalled (SPGR) images were obtained for calculation of the T
1
 relaxation times 
with the following parameters: TR = 100 ms, TE = 1.4 ms, 1 scan average, matrix = 128 X 128 
X 16, FOV = 60 X 60 X 48, 3-mm slice thickness. Four different fl ip angles (α = 10°, 30°, 60°, and 
90°) were used, and T1 was determined by curve fi tting to the following:
SI = kM
0
 (1 - exp-TR/T1)sin(α)/(1 - cos(α)exp-TR/T1)
where SI is the signal intensity, α the fl ip angle, TR the sequence repeat time, and kM
0
 
a constant related to magnetization density (19). Dynamic contrast-enhanced MRI was 
performed using a T1-weighted 3D-SPGR sequence with a keyhole technique  consisting 
of three initial precontrast and 17 dynamic postcontrast images with the following 
parameters: TR = 50 ms, TE = 1.4 ms, α = 90°, one signal acquired, matrix = 64 x 64 x 8, FOV = 
60 X 60 X 48, 3-mm slice thickness, and an acquisition time of 6 s per image. These “keyhole”-
acquired images were reconstructed to high resolution us ing the baseline k-space data 
acquired in the precontrast images described above. The high temporal resolution key-
hole images were immediately followed by 20 dynamic 3D-SPGR postcontrast images 
with a higher spatial resolu tion (128 x 128 x 16 matrix), acquisition time = 1 min 42 
s/sequence. The total examination time was 45 min.
MR Contrast Media
P792 (research product; Fig. 1), is formulated to contain a single gadolinium ion in a four-
armed organic chelate. P792 has a molecular weight of 6.47 kDa, a plasma half-life in rats 
of about 20 min, and an R1 relaxivity of 39 s–1mM–1, at 20 MHz and 37°C (20). The volume of 
distribution is 101 ml.kg–1.
P792 is well tolerated in animals (LD
50
 in rats >1.88 mmol/kg, maximal injected volume) 
and is eliminated by glomerular fi ltration in the kidney. P792 (Guerbet Labora tories, 
Roissy, France) was administered intravenously at a dose of 15 µmol Gd/kg based on 
enhancement of tumors and blood evaluated in pilot studies.
[1]
Fig. 1: Representative axial T1-weighted (TR = 50 ms, TE = 1.4 ms) SPGR images of a subcutaneous 
malignant mammary tumor (a) before and (b) 30 min after administration of P792 (15 µmol Gd/kg) 
showing a typical rim enhancement on the postcontrast image (arrow) (b). A phantom was placed in the 
FOV (arrowhead) to serve as an intensity reference.
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One day following P792 administration, repeat MRI enhanced with albumin-(GdDTPA)
30
 
was performed. Albumin-(GdDTPA)
30
, a prototype MMCM with a molecular weight 
of 92000 Daltons, was administered at a dose of 0.03 mmol Gd/kg. It demonstrates a 
volume of distribution that closely approximates plasma volume, 0.05 L/kg, and plasma 
half-life is approximately 3 hr, yielding nearly constant enhancement of blood and 
normal tissues for 30 min or longer after injection (14,21,22). Albumin-(GdDTPA)
30
 has 
an R1 relaxivity of 19.6 s–1mM–1/Gd at 2 T and 37°C (21).
MRI Data and Kinetic Analysis
Imaging data were transferred, processed, and analyzed on a Sun Sparc 10 workstation 
(Sun Microsystems, Mountain View, CA) using an image analysis program (The MR-
Vision Co, Menlo Park, CA). Signal intensity values at each time point were obtained from 
regions of interest (ROIs) placed in the phantom, in the inferior vena cava (IVC), and in 
the tumor periphery. Signal intensities (SI) from the tumor and the IVC blood were 
corrected for potential spectrometer variation over time by dividing the SI at each time 
point by the SI of the phantom. SIs from three ROIs taken when feasible from different 
sections of each tissue of interest were averaged, and the mean SI was used as a basis for 
further calculations. Postcontrast R
1
 values were calculated based on the measured SI and 
knowledge of precontrast R
1
 values according to:
R
1post
 = -1/TRlog[1 - S
post
/S
pre
(1 - exp(-TR R
1pre
) ) ]
which is an approximation that ignores T2* effects since we used a short TE (23). Differences 
between the precontrast and postcontrast R
1
 values (∆R
1
) at all time points were assumed 
to be directly proportional to the gadolinium concentration in the tissue of interest, as 
predicted by the Solomon-Bloembergen equations and shown in several experimental 
studies (24,25).
The ∆R
1
 data from blood and tumor were used for kinetic analysis to estimate the 
coeffi cient of transendothelial permeability, KPS (ml min–1100 cc–1 of tissue), and the fractional 
plasma volume, fPV (ml cc–1 of tissue) employing a two-compartment bidirectional model 
for tumor tis sue (2). In this model a monoexponential function fi tted to the ∆R
1
 data 
from blood (suffi cient to describe the blood disappearance for each contrast agent for 45 
min following intravenous bolus injection) was used as a forcing function for the plasma 
response in the tumor, after scaling for fractional plasma volume. In the analysis of the 
albumin (GdDTPA)
30
 data, the refl ux rate constant of the model was not resolvable, and 
was therefore set to zero. All data fi tting was performed using the SAAM II program 
(SAAM Institute, Seattle, WA) employing a weighted, nonlinear least-squares parameter 
estimation algorithm. Measurement errors were assumed to be independent and 
Gaussian with zero mean and standard deviation known with a scale factor determined 
from the data. Weights were chosen optimally, i.e., equal to the inverse of the variance of 
the measurement error. The uncertainty of our estimates of fPV and KPS were determined 
from the covariance matrix of the least-squares fi t. For convenience of presentation, the 
KPS values determined from the model were multiplied by 100 for both contrast agents.
[2]
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Histologic Analysis
Immediately after the second MRI session, animals were killed by an intravenous 
overdose of pentobarbital and bilateral thoracotomies. Tumors were resected, fixed 
in 10% buffered formalin (Poly Scientifi c Research & Development Corp., Bay Shore, NY), 
processed routinely into paraffi n, sectioned in the plane of the MR images at 4 µm, and 
stained with hematoxylin and eosin for diagnosis and grading. Additional sections were 
immunostained for von Willebrand Factor/Factor VIII using an avidin-biotin peroxidase 
technique (Sigma rabbit antihuman polyclonal, F-3520; Vector ABC kit, PK-6100) and 
sent to the pathologist for further analyses. Tumors were graded according to the Scarff-
Bloom-Richardson  (SBR)  method  (26-29). This grading system has been used extensively 
for invasive breast adenocarcinomas by evaluating the ductoglandular formation, 
nuclear pleomorphism, and mitotic activity. Each of these three morphological features 
is scored by assigning one, two, or three points. An overall score is then obtained by 
summation of the individual characteristic scores. SBR scores range from 3 to 9 points; the 
higher the score, the more malignant and more poorly differentiated is the tumor. For 
microvascular count determination, all discrete, positively immunostained endothelial 
(brown-staining) clusters with lumina were counted in 20 400x fi elds (Olympus Vanox 
AH-2 microscope) sampled from two sections of each tumor preparation. Where possible, 
fi elds were chosen in areas of highest MVD. Stromal microvessels were included in 
the counts, but capsular and preexisting host small-to-medium vessels were excluded. 
MVD is reported as the number of vessels per 20 high-powered fi elds. MVD and SBR
scoring were per formed by the same pathologist, without knowledge of MRI fi ndings.
Statistics
Mean values for KPS and fPV ± SD for a given contrast agent were compared between 
fi broadenomas and carcinomas using unpaired t-tests. Nonparametric Spearman cor-
relation analyses were performed comparing the estimated MRI-derived parameters (KPS 
and fPV) with the histologic tumor grade (SBR score). Pearson correlation analyses were 
performed comparing the albumin-(GdDTPA)
30
- and P792-derived values for KPS and fPV, 
and for correlating these values to the MVD. A P value < .05 was considered statistically 
signifi cant.
Results
Forty-two animals developed subcutaneous tumors within our study period: nine benign 
(fibroadenomas) and 32 tumors (31 adenocarcinomas, and one sarcoma arising in a 
fi broadenoma). After administration of ENU tumors appeared in the mammary fat pad as 
early as 59 days, with a mean latency of 176 ± 121 days. Benign tumors had a signifi cantly 
(P < .05) longer latency than malignant tu mors (292 ± 113 vs. 145 ± 104 days, respectively). 
There was a weak but statistically signifi cant correlation between the dose of ENU and 
the tumor grade, as refl ected in the SBR score (r = .13, P < .05). Less differentiated tumors 
(higher SBR score) tended to develop with larger ENU doses; however, fi broadenomas 
having the lowest SBR scores possible, score 3, were observed after a range of ENU doses 
from 45 to 250 mg/kg.
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MRI examinations enhanced with both contrast agents were completed successfully in 40 
animals. For two ani mals, only P792 data were available, but these data were still included 
in the analyses. The kinetic model fi t the data well in all experiments, with typical fi ts to 
albumin-(GdDTPA)
30
 and P792 data shown in Fig. 2a and b, respec tively. All parameter values 
were obtained with good precision. The mean coeffi cients of variation (CV) for fPV and KPS 
were 10% and 24%, respectively, for albumin-(GdDTPA)
30
, and 6% and 10%, respectively, for 
P792. Small   KPS  values  for  albumin-(GdDTPA)
30
 with  CVs greater than 100% were assumed 
to be not resolvable from the data, and were set equal to 0.
The tumor KPS and fPV values derived using P792 and albumin-(GdDTPA)
30
 with the 
corresponding SBR and MVD scores are shown in Table 1.
Using P792, no signifi cant difference was found between the mean KPS values for the 
carcinomas and fi broadenomas (.539 ± .354 vs. .535 ± .271, P = .97). Making the parallel 
comparison for fractional plasma volumes assayed with P792, the difference between 
malignant and benign tumors 
was not signifi cant (.040 ± 
.024 vs. .024 ± .009, P = .07). 
However, in the same tumors 
evaluated using albumin-
(GdDTPA)
30
, mean KPS values 
were signifi cantly higher in 
the carcinomas compared to 
the fi broadenomas (.014 ± .011 
vs. 0 ± .001, P < .005). Making 
the parallel comparison using 
fPV obtained with albumin-
(GdDTPA)
30
, the difference 
between carcinomas and
fi broadenomas was not
signifi cant (.038 ± .019 vs. 
.030 ±  .013, P = .33).
As shown in Table 2, fPV 
values assayed with P792 for 
both benign and malignant 
tumors taken together did 
not correlate signifi cantly 
with the histologic tumor 
grade (r = .25, P = .09) or with 
the MVD (r = .20, P = .20).
Fig. 2: Typical fits (solid lines) of dynamic mathematical model to delta R1 data from (0) blood and ( ) 
tumor using (a) P792 and (b) albumin-(GdDTPA)30 contrast media.
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Similarly, KPS values based on P792 data did not correlate with the SBR scores (r = .09, P = 
.46) or the MVD (r = .03, P = .86). However, values for KPS derived using albumin-(GdDTPA)
30
 
correlated signifi cantly with the SBR score (r = 0.55, P < .0005) and the MVD (r = .34, P < 
.05). No significant correlations were found between albumin-(GdDTPA)
30
-derived fPV 
estimates and the SBR score (r = .08, P = .50) or MVD (r = .28, P = .08). As expected, histologic 
MVD counts were signifi cantly lower in the benign than in the malignant tumors (171.3 
± 112.7 vs. 341.1 ± 130, P < .001). There was no signifi cant correlation between the grade of 
malignant tumors, as refl ected in the SBR score and tumor angiogenesis, as reflected by 
the MVD (r = -.29, P = .18).
Discussion
P792, a monomeric 6.47 kDa gadolinium-based contrast medium in clinical development 
as a rapid clearance blood pool enhancer was not shown in this experimental breast 
tumor model to be effective for the differentiation of benign from malignant tumors, or 
for tumor grading. MRI-derived microvascular characteristics (KPS and fPV) estimated 
from P792-enhanced MRI data did not correlate signifi cantly with pathologic tumor 
grade or with MVD counts, a surrogate of angiogenesis. In the same group of tumors, 
the previously shown utility of albumin-(Gd-DTPA)
30
, 92 kDa, for tumor microvascular 
grading and characterization was reconfi rmed.
Methods to better characterize tumors by noninvasive MRI are being developed on 
the premise that noninvasive imaging methods can be used effectively to discriminate 
between tumors of varying biology. Also, tumor imaging characteristics should be useful 
for guiding the choice of therapy as well as for better evaluating the effects of various 
therapeutic interventions. Although many character istics of tumors might reasonably 
be evaluated by imaging, tumor microvascular properties are of particular interest, 
and may be uniquely well suited for defi ning tumor biol ogy and following the effects of 
therapy. Tumor angiogen esis, the recruitment of new vessels into the tumor, is essential 
for unrestricted tumor growth and metastases (30,31). In this study we assayed two 
tumor microvascular properties-specifi cally, the richness of tumor vascularity expressed 
quantitatively as the fractional plasma volume (fPV), and the leakiness or permeability 
of the tumor ves sels expressed as the coeffi cient of endothelial permeabil ity (KPS). The 
methods and rationale for our KPS and fPV assays have been described previously in detail 
(2,32). Inherent in the microvascular analytical approach for tumor characterization is 
the hypothesis that biologically more aggressive tumors, having more active angiogenesis, 
will have relatively more blood (fPV) and relatively greater microvascular permeability 
to macromolecules (KPS) than benign or less aggressive tumors. These hypotheses are 
supported by numerous imaging and invasive studies conducted in a spectrum of tumor 
types (1,33-35). In fact, the hyperpermeability of malignant tumors to macromolecular 
solutes has been a reliable and consistent characteristic of neoplastic vessels (7). It is this 
special property, macromo lecular hyperpermeability, that we intend to exploit in our 
contrast-enhanced MRI method.
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Currently, a major challenge for contrast-enhanced MRI is to identify one or more MMCM 
that can safely be used clinically. The sought-after compounds must be well tolerated, 
have appropriate pharmacologic properties, and be effi cacious for tumor vessel 
characterization. Albumin-(GdDTPA)
30
 is a prototype molecule that was previously shown 
to be effective for tumor microvascular characterizations, but which was never intended 
for clinical use. It has a relatively high and long retention within the body, and there 
is also a potential for immunologic reactivity (21). New MMCM candidates must be 
examined for their diagnostic potential.
Table 1.  Tumor Pathology and MRI-Derived Microvessel Characteristics Arranged by Ascending  SBR
  Score.
C h a p t e r  4
60
P792 is a new monodispersed contrast media with a molecular weight of 6.47 kDa, 
which allows for a relatively rapid blood clearance by glomerular fi ltration. This rapid 
clearance from the plasma is refl ected in the blood enhancement curve shown in Fig. 
2a. Although blood clear ance is more rapid and complete than for albumin-(GdDTPA)
30
, 
we hypothesized that the P792 macromolecular confi guration (approximately 10 times 
heavier than a molecule of GdDTPA; MW = 557) would prove useful for tumor  microvascular 
characterization.   The   results   obtained in this model did not support this hypothesis, and 
no signifi cant correlations with SBR and MVD were found using P792. However, fractional 
plasma volumes using albumin-(GdDTPA)
30
 and P792 were not signifi cantly dif ferent, 
suggesting that this microvascular property can be monitored with equal success with 
either contrast agent. P792 may still prove diagnostically useful for certain enhancement 
applications, such as angiography or evaluations of non-neoplastic lesions. First-pass 
kinetic analysis using this compound may also have clinical utility. For assessment of 
tumor microvessel hyperpermeability, our analysis shows a mean KPS value for P792 in 
malignant tumors that is approximately 39 times greater than the mean KPS values 
observed in the same tumors for the albumin-based contrast agent. This notably greater 
perme ability of P792 is likely due to its smaller molecular weight and size.
Since P792 is now under clinical investigation, comparison of these experimental data 
with the results obtained in patients for tumor characterization will be interesting to 
assess, taking into account that the pharmacokinetics are likely different between rat 
and human.
The potential clinical utility of assaying microvascular characteristics with an MMCM, 
specifically albumin-(GdDTPA)
30
, has been demonstrated for multiple disease processes 
(neoplasia, infl ammation, myocardial and renal ischemia, and reperfusion injury (11-13,36)) 
as well as for numerous tumor types (prostate, ovary, brain, and breast (1,34—36)). The 
same ENU-induced tumor model used for this study has been evaluated previously with 
dynamic albumin-(GdDTPA)
30
-enhanced MRI (1,36). In all cases, a signifi cant correlation 
was shown between permeability (KPS) and tumor histologic features, both with MVD 
counts and SBR scores. The degree of correlation (r value) varies among groups of tumors 
but has always been statistically significant. In the current study, the observed r value 
of .55 is less than the .86 value shown in the Daldrup study (1). This difference in degree 
of correlation may be explained by the respective proportions of low-, medium-, and 
high-grade tumors. In the current study, there were relatively few high-grade tumors 
(SBR score 7-9) compared to previously studied groups of tumors. This variation in tumor 
SBR scores is attributed to simple biological variation in the ENU response in different 
animals.
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There is no single “gold standard” for the biological characterization of a tumor. For this 
study, the SBR scoring system was selected as an appropriate measure of tumor cell 
morphology. SBR has been used in numerous previous studies as a breast cancer grading 
system. It is based upon three elements of tumor cell morphology, each scored separately 
(26,27). Angiogenesis is considered a distinct and independent prognostic factor from 
tumor cell morphology. MVD counts were selected for this study as the surrogate of 
angiogenesis, and have been used widely for this purpose (37-40).
Conclusions
Conclusions from this study are limited in that only one tumor type (breast) was 
examined, and these tumors were induced chemically in rodents. Alternative doses of 
P792 might have been tried, but the single dose chosen produced enhancement of 
the blood comparable to that achieved with albumin-(GdDTPA)
30
. This study did not 
adequately examine the potential of P792 enhancement to monitor changes in tumor 
microvascular characteristics that might result from tumor treatment—for instance, 
with antiangiogenic chemotherapy. We did not evaluate the angiography properties of 
this contrast agent.
In summary, kinetic analysis of dynamic P792-enhanced MRI data (using a physiologically-
based compartmental model of microvessel permeability) in a rodent breast tu mor model 
showed a lack of feasibility for the differentiation of benign from malignant tumors, and 
for the image-based grading of tumors corresponding to either tumor cell morphology or 
microvascular counts. Yet, the feasibility of individually characterizing the microvessels 
of tumors and for tumor differentiation was confi rmed in the same tumors using a 
larger prototype MMCM. Clinical investigations will be helpful in better defi ning the level 
of selectivity needed for tumor characterization.
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Table 2: Correlations Between MRI-Estimated Coefficients of Tumor Endothelial Permeability (KPS) and 
Fractional Plasma Volume (fPV) With Pathologic Scarff-Bloom-Richardson (SBR) Tumor Grades and 
Microvascular Density Counts (MVD).
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Abstract
Carboxymethyldextran-A2-Gd-DOTA, a slow clearance blood pool contrast agent with a 
molecular weight of 52.1 kDa, designed to have intravascular residence for more than one 
hour, was evaluated for its potential to characterize and differentiate the microvessels of 
malignant and benign breast tumors.  
Precontrast single-slice inversion recovery (IR) snapshot FLASH and dynamic contrast 
enhanced-MR imaging using an axial T1-weighted three-dimensional (3D)-spoiled gradient 
recalled (SPGR) sequence was performed in 30 Sprague-Dawley rats with chemically 
induced breast tumors. Endothelial transfer coeffi cient (KPS) and fractional plasma 
volume (fPV) of the breast tumors were estimated from MRI data acquired with CMD-A2-
Gd-DOTA enhancement, injected at a dose of 0.1mmol Gd/kg body weight, using a two-
compartment bidirectional model of the tumor tissue. The MRI microvessel characteristics 
were correlated with the histopathologic tumor grade using the Scarff-Bloom-Richardson 
(SBR) method. Using CMD-A2-Gd-DOTA, no signifi cant correlations were found between 
the MR-estimated endothelial transfer coeffi cient (r= 0.09, P= 0.47) or plasma volumes (r= 
0.19, P= 0.22) with the histologic tumor grade. Analysis of CMD-A2-Gd-DOTA-enhanced 
MR kinetic data failed to demonstrate feasibility for the differentiation of benign from 
malignant tumors or for image-based tumor grading. 
Keywords
Magnetic resonance imaging, contrast media, carboxymethyldextran-A2-Gd-DOTA, breast 
neoplasms, dynamic contrast enhancement
Introduction
Dynamic contrast-enhanced MRI has become an increasingly employed noninvasive 
imaging method for assessing the morphological and functional properties of tumor tissue. 
The importance of defi ning the physiological characteristics of tumors and their microvessels 
is central to imaging evaluations of therapeutic interventions. The pharmacological 
inhibition of tumor angiogenesis represents only one possible option for using contrast-
enhanced MRI to monitor treatment [1,2]. Quantitative MRI assays of tumor microvessel 
characteristics could also be applied to estimate tumor grade and prognosis [3,5].
Using kinetic analysis of dynamic contrast-enhanced MR data in the context of a tissue 
compartmental model, transendothelial permeability estimated as the endothelial 
transfer coeffi cient (KPS) and the fractional plasma volume (fPV) of the tumor tissue can 
be evaluated quantitatively. Numerous studies have demonstrated that the microvessels 
of malignant tumors have an increased permeability for macromolecular solutes, 
including prototype macromolecular contrast media (MMCM), attributed to tumor-related 
morphologic alterations of vascular endothelial lining [3, 6-8]. The clinically currently 
available small molecular gadolinium chelates have a limited potential in the quantitative 
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assessment of blood volume or abnormal permeability outside the central nervous system 
due to their non-selective leak through the endothelium of both normal and pathologic 
blood vessels. The ability of dynamic MRI enhanced with macromolecular contrast agents 
to quantitatively defi ne the leakiness of tumor microvessels has been shown in several 
experimental models [3,6,7]. However, the reference contrast medium used in these 
studies, albumin-(Gd-DTPA)
30
, is considered unsuitable for clinical use due to its potential 
immunogenicity and its incomplete clearance from the body [9,10].
The search for clinically applicable MR contrast agents has been expanded in recent years, 
with the goal to allow improved assessment of regional blood fl ow and tissue perfusion. 
Recently, several MR contrast media were studied with respect to their potential for 
quantitative description of tissue microvessels. These contrast media include blood pool 
agents such as P792 (Vistarem, Guerbet, Aulnay Sous Bois, France) [11], small molecular 
gadolinium chelates such as MS-325, characterized by reversible binding to human serum 
albumin (Angiomark, Schering AG, Berlin, Germany) [12], ultrasmall superparamagnetic 
iron oxide particles (USPIO) such as NC100150 (Clariscan, Nycomed Amersham, Oslo, 
Norway) [13] and SHU 555C (Resovist, Schering AG, Berlin, Germany) [14].
Meglumine-carboxymethyldextran-ethylenediamino-gadoterate (CMD-A2-Gd-DOTA), a 
product of Guerbet Group  (Guerbet Laboratories, Aulnay Sous Bois, France), is a new slow 
clearance blood pool agent with a high paramagnetic effi cacy, approximately 3 times higher 
than that of extracellular gadolinium-based compounds such as Gd-DOTA, and a good 
tolerability [15]. In previous studies CMD -A2-Gd-DOTA has been shown to be useful for MRI 
in demonstrating tracer kinetics for in vivo assessment of myocardial perfusion [16].   
The objective of the current study was to determine if MRI assays of microvascular 
characteristics might provide a non-invasive insight into the biological characteristics of 
the tumor as refl ected in the histopathologic tumor grade, specifi cally the Scarff-Bloom-
Richardson grade. The reasons for testing this hypothesis include the previous successful 
demonstration of this potential application of MRI for the assay of tumor biology using a 
different and larger contrast agent (3) and the generally recognized connection between 
the degree to which a tumor can acquire a rich vascular supply and the biological 
aggressiveness of the tumor, as might be refl ected in its histopathologic properties. 
Microvascular characteristics endothelial transfer coeffi cient and fractional plasma 
volume derived from the kinetic data analysis of dynamic MRI enhanced with CMD-A2-
Gd-DOTA were correlated with results of pathologic analysis, namely quantitative tumor 
histopathologic grade.
Material and methods
Animal Model
The study has been conducted with the approval of our Committee for Animal Research, 
and conformed to the guidelines of the National Institutes of Health for the care and use of 
the laboratory animals. Mammary tumors were induced in Sprague-Dawley rats (Charles 
River Laboratories) by intraperitoneal injection of N-ethyl-N-nitrosurea (ENU) (ENU Isopack, 
C h a p t e r  5
70
Sigma Chemicals, St. Louis, MO). ENU is an alkylating agent and a potent carcinogen that 
induces tumors of varying grade and location in rats, depending on the dose, the site of 
injection, the age and the sex of the rats [17-19]. Mammary cells are the primary target cells 
when ENU is administrated intraperitoneally into the female rats [18,19]. For our study, 
ENU, purchased as a crystalline substance, was dissolved shortly before administration 
in 0.9% sterile saline to a solution with a concentration of 10mg/ml. ENU was injected at 
different doses: 90 mg/kg (n=8), 180 mg/kg (n=10) and 250 mg/kg (n= 12). The animals 
were checked for tumor growth every second day. The tumors were imaged when they 
reached a size of 1 to 1.5 cm.
Experimental procedure
Before the MRI imaging, the animals were anesthetized by intraperitoneal administration 
of pentobarbital sodium, 50mg/kg body weight. Analgesia was achieved by intraperitoneal 
injection of 0.03mg/kg buprenorphine hydrochloride (Buprenex￦, Reckitt & Colman 
Products, Hull, UK), an opiate. A 23-gauge butterfl y canula (Abbott Laboratories, North 
Chicago, ILL. USA) was inserted into a tail vein for contrast medium injection. Immediately 
after the MR imaging, 0.32 mg Naloxone (Abbot Laboratories, North Chicago, ILL) was 
injected intraperitoneally to reverse opioid effects. In addition, 2.0 ml of saline was injected 
intravenously to avoid dehydration as might occur after anesthesia.
Magnetic resonance imaging
MR imaging was performed on a Bruker Omega CSI-II System (Bruker Instruments, 
Fremont, CA) operating at 2 Tesla.  This system is equipped with Acustar S-150 (Bruker 
Instruments, Fremont, CA) self-shielded gradient coils (20 G/cm, 15cm inner diameter). 
Animals were placed supine in a birdcage radio-frequency coil with a length of 7.6 cm and 
an inner diameter of 4.5 cm. A phantom fi lled with diluted gadopentetate dimeglumine 
(0.01 mmol/liter) was included in the fi eld of view, close to each animal, to allow correction 
for potential spectrometer variation.
Precontrast images were acquired using an single-slice inversion recovery (IR) snapshot 
FLASH sequence [20] with the following parameters: TR 3ms, TE 1.5 ms, one acquisition, 
fi eld of view 55x55 mm, matrix 64x64, slice thickness 3 mm and a fl ip angle of 5 degrees. 
Per slice, nine images at nine different inversion recovery times TI =100, 400, 700, 1000, 
1300, 1600, 1900, 2200 and 2500 ms were acquired. A total of eight slices were obtained. 
After the inversion recovery time TI, the data were acquired using a snapshot FLASH 
readout scheme with centric reordering to maintain the appropriate T1 contrast for the 
center of the k space. This sequence was used to calculate baseline longitudinal relaxation 
rates (R1=1/T1) for tumor by curve fi tting [21].
Dynamic contrast enhanced MR imaging was performed using an axial T1-weighted three-
dimensional (3D)-spoiled gradient recalled (SPGR) sequence with the following parameters: 
TR 30ms, TE 4.83 ms, one acquisition, fi eld-of-view 55x55x48mm, matrix 128x128x16, an 
effective slice thickness of 3.6mm and fl ip angle of 90 degrees. To monitor enhancement 
response 3 initial precontrast images and 30 dynamic postcontrast images were acquired 
serially with an acquisition time of 1 minute 1 second per volume of 16 slices.
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Magnetic Resonance Contrast Media
CMD-A2-Gd-DOTA, a slow-clearance blood pool agent (Fig.1), is a MMCM under develop-
ment (Guerbet Laboratories, Aulnay Sous Bois, France). CMD-A2-Gd-DOTA consists of a 
carboxymethyldextran polymer bound to the paramagnetic macrocyclic complex Gd-DOTA 
using an amino spacer. The polymer is formed of 22% Gd-DOTA, 39% of carboxyl group and 
39% of glucose group. The mean molecular weight of CMD-A2-Gd-DOTA is 52.1 kDa and 
the polydispersity index of 1.79. The r1 relaxivity of the agent is 10.6 mmol-1sec-1 and the 
r2 relaxivity is 11.1 mmol-1sec-1 (measured in water at 37°C and 20 MHz). The plasma half-
life in rabbits is >180 minutes. CMD-A2-Gd-DOTA is mainly excreted by the kidneys and 
in a small amount by fecal elimination after hepatocyte metabolism [15]. It has a good 
tolerance in animals (LD50 in mice > 5mmol Gd/kg body weight at injection rate of 2ml/
min). CMD-A2-Gd-DOTA was injected at a dose of 0.1mmol Gd/kg body weight.
Kinetic analysis of dynamic MRI data
The MR images were transferred, processed and analyzed using a Sun SPARC 10 workstation 
(Sun Microsystems, Mountain View, CA) and an image analysis program (MRVision Co., 
Standford, CA). Signal intensity values (SI) for each time point were obtained from multiple 
(three to six) operator-defi ned regions of interest (ROIs). Signal intensities for the blood 
within the inferior vena cava (IVC), the phantom, and the tumor periphery were measured 
in the central section of the imaging volume. The tumor periphery was defi ned as the 
peripheral zone of strong contrast enhancement, usually 1-2 mm thick. Corresponding ROI 
measurements were made in each of three adjacent images, each containing a minimum 
of 30 pixels, and were averaged. The mean signal intensities (SI) from the tumors and the 
blood in the vena cava were corrected for potential spectrometer variation over time by 
dividing the SI of each ROI by the SI from the phantom. Kinetic analysis was limited to 
the tumor periphery that represents the least necrotic and also the most vascularized 
region of the tumor [22, 23]. Precontrast longitudinal relaxation rates R1 (1/T1) estimates 
for tumors were obtained by curve fi tting based on one set of inversion recovery snapshot 
FLASH images. The precontrast R1 value for IVC blood was assumed to be 0.724 s-1 (1/1.38) 
on the basis of numerous previous measurements in rat blood [21]. Postcontrast R1 values 
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Fig. 1: Representative axial T1-weighted (TR= 30ms, TE =4.83 ms) SPGR images of a subcutaneous 
malignant mammary tumor (a) before and (b) 30 min after administration of CMD-A2-Gd-DOTA (0.1mmol 
Gd/kg). A phantom was placed in the fi eld of view (arrowhead) to serve as an intensity reference.
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were calculated based on the observed signal intensities and knowledge of precontrast R1 
values [21]. The difference between the postcontrast R1 value at any time point and the 
precontrast R1, ∆R1 (t) is assumed to be directly proportional to the concentration of the 
contrast medium, either in the blood or in the tissue [24, 25]. The ∆R1 data from blood and 
tumor (Fig 2 and Fig 3) were used for kinetic analysis to estimate leakiness expressed as the 
endothelial transfer coeffi cient (KPS, µl min –1 100 cc–1 of tissue) and the fractional plasma 
volume of the tumor tissue (fPV, µl cc–1 of tissue), using previously reported methods [3]. 
Briefl y, a compartmental model of microvascular permeability is fi tted to the ∆R1 (t) data 
from tumor and IVC after correction for hematocrit. The ∆R1 (t) from the IVC, fi tted by a 
monoexponential function, serves as a forcing function for the tumor tissue model that has 
a two-compartment structure corresponding to blood plasma and tumor interstitial water 
spaces. The model was fi tted to both IVC and tumor tissue at the same time using the SAAM 
II software (SAAM Institute, Seattle, WA) that employs a standard non-linear regression. 
The uncertainty of the estimates of fPV and KPS were derived from the covariance matrix 
at the least-squares fi t assuming a data weighting scheme characterized by a coeffi cient of 
variation of 10 % for each point.
Histologic Analysis
After completing the second MR examination, all animals were sacrifi ced by an intravenous 
overdose of 0.3ml pentobarbital. Post-mortem, all tumors were removed, immediately fi xed 
for 18-24 hours in 10 % buffered formalin (Poly Scientifi c Research & Development Corp., 
Bay Shore, NY, USA), embedded in paraffi n, sectioned in the same plane as the MR images 
at 4 µ, and stained with hematoxylin and eosin for diagnosis and grading. All tumors, both 
benign and malignant, were graded using the Scarff-Bloom-Richardson (SBR) method [26, 
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Fig 2. Representative ∆R1-vs-time curves of blood and a malignant breast tumor following intravenous 
administration of carboxymethyldextran-A2-Gd-DOTA (0.1mmol Gd/kg)
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27], that has been used extensively in the clinical evaluation of invasive human breast 
adenocarcinoma. This histopathologic grading system evaluates the ducto-glandular 
formation and nuclear characteristics including pleomorphism and mitotic activity. Each 
of these three morphological features is scored by assigning one to three points and an 
overall score is obtained by summation of the individual characteristic scores. The lowest 
SBR score possible, even for a benign tumor, is 3. The highest SBR score is 9 and it indicates 
a poorly differentiated tumor. The SBR score determination were performed by a single 
pathologist without knowledge of MR imaging fi ndings.
Statistics
Mean values for KPS and fPV were compared between fi broadenomas and carcinomas 
using unpaired t tests. Non-parametric Spearman correlation analyses were performed, 
comparing the histologic tumor grade (SBR score) with the estimated MR-derived 
parameters (KPS and fPV). A P value of < 0.05 was considered statistically signifi cant.
Results
Following the single intraperitoneal administration of ENU, 30 rats developed mammary 
tumors within our study period. Eight tumors were benign fi broadenomas and twenty-
two were malignant adenocarcinomas. The overall assignment of a tumor to the benign or 
malignant group by the pathologist was independent of the SBR score. 
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Fig 3. Representative ∆R1-vs-time curves of blood and a benign breast tumor following intravenous 
administration of carboxymethyldextran-A2-Gd-DOTA (0.1mmol Gd/kg)
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CMD-A2-Gd-DOTA-enhanced dynamic images were acquired successfully in all 30 
animals. The kinetic model fi t the data well in all the experiments. All parameter values 
were obtained with good precision. The mean coeffi cients of variation (CV) for fPV and KPS 
were 31% and 5%, respectively. Small KPS values with CV greater than 100% were assumed 
not to be resolvable from the data and were set equal to 0.  The KPS and fPV values in all 
fi broadenomas and carcinomas, with their respective SBR scores for each tumor, are shown 
in Table 1. 
SBR scores Tumor type fPV KPS
Benign
3 Fibroadenoma   22 30
3 Fibroadenoma   10   9
3 Fibroadenoma   43 27
3 Fibroadenoma 129 70
3 Fibroadenoma   38 44
3 Fibroadenoma   19 19
3 Fibroadenoma   75   0
4 Fibroadenoma   52 40
Mean   49 30
SD   39 22
Malignant
4 Carcinoma   42 42
4 Carcinoma 101 69
5 Carcinoma   33 36
5 Carcinoma   51 20
5 Carcinoma   90 63
5 Carcinoma   34 12
6 Carcinoma   69 33
6 Carcinoma   85 88
6 Carcinoma   76 31
6 Carcinoma   33 57
6 Carcinoma   19 28
6 Carcinoma   44 41
6 Carcinoma   32 30
6 Carcinoma 101 82
6 Carcinoma   61 65
6 Carcinoma   71 39
6 Carcinoma   67 40
6 Carcinoma   33 17
6 Carcinoma   56 91
8 Carcinoma   47 22
8 Carcinoma 104 30
9 Carcinoma   39 13
Mean   59 43
SD   26 24
Table 1: Tumor Pathology and MRI-derived Microvessel Characteristics by Ascending SBR score
SBR, Scarff Bloom Richardson score; fPV, fractional plasma volume (µl cc-1 of tissue); KPS endothelial transfer 
coeffi cient (µl min –1 100 cc-1 of tissue)
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The mean values for KPS in carcinomas (43±24 µl min–1 100 cc–1 of tissue) were not 
signifi cantly different (P= 0.18) from the mean KPS values in the fi broadenomas (30±22 µl 
min–1 100 cc–1 of tissue). The mean values for fPV in carcinomas (59±26 µl cc–1 of tissue) did 
not differ signifi cantly (P= 0.41) from the mean fPV values in fi broadenomas (49±39 µl cc–1 
of tissue).  No signifi cant correlation was found between KPS and SBR score (r= 0.09, P= 0.47). 
Also estimates of fPV did not correlate signifi cantly with SBR scores (r= 0.19, P= 0.22).
Discussion
In this experimental breast tumor model, CMD-A2-Gd-DOTA, a slow clearance blood pool 
contrast agent was not shown to be effective for differentiation of benign from malignant 
tumors, nor for tumor grading. KPS and fPV, the MRI-derived characteristics estimated 
from CMD-A2-Gd-DOTA-enhanced MR data, did not correlate signifi cantly with histologic 
measures of tumor grade (SBR score). 
The measurement of functional parameters of tumor tissue such as transendothelial 
leakiness and plasma volume can be achieved by contrast-enhanced MRI, analyzing 
the distribution kinetics of the contrast agent in the tissue. Several studies have 
demonstrated that the tumors with an aggressive behavior have relatively greater 
transendothelial leakiness to macromolecules (KPS) and relatively more blood (fPV) than 
benign or biologically less aggressive tumors [3,7,28,29].  The quantitative assessment of 
these tumor properties thus makes possible an accurate noninvasive description of the 
microcirculation of individual tumors. Such imaging assays can be effectively used in 
differentiation between tumors of variable biological behavior. In addition, the follow-up 
of the MRI-derived estimates of microvessels properties could provide a tool for in vivo 
monitoring of the tumor response to therapy. These microvascular characteristics can be 
estimated, based on kinetic analysis of dynamic enhancement data using simple models of 
the tumor tissue as a compartmentalized system [30-32]. Two-compartment tissue models 
that represent the blood plasma and the extracellular extravascular space are typically 
used. The concentration of the contrast agent can be derived from signal intensity data, 
assuming that changes in longitudinal relaxation rates R1 (1/T1) after administration of 
the contrast medium are proportional with contrast agent concentration. Thus the increase 
in enhancement can be translated to contrast agent concentration and quantifi ed using 
kinetic modeling, fi nally providing estimates of microvascular characteristics. 
The search for a contrast agent suitable for characterization of the vessels of tumors in 
a clinical setting has been enthusiastic. The ideal contrast medium must be retained 
within the circulating plasma for at least one our after administration, show effi cacy 
for characterization of tumor microvessels and have an appropriate pharmacokinetic 
behavior. In addition, the compound should be well tolerated over a wide dose range, be 
completely excreted form the body and immunologically inactive. In recent years, the 
feasibility of several candidate contrast media to quantitatively assess the properties 
of tumor microvessels has been evaluated [33]. Ultrasmall superparamagnetic iron 
oxide (USPIO) particles such as SHU 555C (Schering AG, Berlin, Germany) and NC100150 
(Clariscan, Nycomed Amersham, Oslo, Norway) have been shown feasible for defi ning 
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the tumor microvasculature in the same chemically induced breast tumor model used for 
this study [13, 14]. However, one limitation in the use of USPIO for tumor microvessels 
characterization is the negative enhancement induced by the T2* shortening, that is 
competitive with the positive signal enhancement caused by the T1 shortening [34]. 
CMD-A2-Gd-DOTA is a new paramagnetic macromolecular polymer with a mean molecular 
weight of 52.1 kDa, potentially large enough to differentiate the macromolecular hyper-
permeability of cancer microvessels. Recent investigations have shown its potential 
for applications in MRI myocardial perfusion studies, due to the high relaxivity and its 
prolonged intravascular residence time [16]. Also CMD-A2-Gd-DOTA proved to be useful 
in depiction of myocardial infarction during fi rst pass studies and in evaluating the 
enhancement of the infarcted zone on delayed MR imaging [35]. Another potential clinical 
application includes MR angiography. [36-38]. Following its intravenous administration 
at a dose of 0.05 mmol Gd/kg body weight in an experimental rabbit model, CMD-A2-Gd-
DOTA demonstrated signifi cant signal enhancement of abdominal organs and pelvic bone 
marrow, partial storage in the liver and return to baseline signal intensities after 10 days 
post-injection [39]. To our knowledge, CMD-A2-Gd-DOTA has not been previously tested 
for its potential to characterize tumor microvessels. 
Urinary excretion of 45% in 24h [15] indicates that its molecular weight of 52.1 kDa may 
be below the threshold of urinary excretion. Since the prototype macromolecular contrast 
agent albumin-(Gd-DTPA)
30 
, with a molecular weight of 92kDa, seems to be unsuitable for 
clinical use, because its renal excretion is incomplete and slow, CMD-A2-Gd-DOTA may 
offer a compromise between the required renal elimination and the blood pool properties. 
The reported prolonged retention [15, 39] of CMD-A2-Gd-DOTA in the liver could indicate 
also a minor component of hepatic metabolism and fecal excretion. CMD-A2-Gd-DOTA 
was well tolerated in all anesthetized rats. This observation is in agreement with previous 
studies [15, 34, 39] that showed no toxic effects at a dose of 0.05 mmol. The hypothesis of 
this present study was that CMD-A2-Gd-DOTA could be used for characterization of tumor 
microvessels. The results obtained in this rodent model of chemically induced mammary 
tumors did not support this theory. 
One factor that could have infl uenced the lack of correlation of the microvascular 
characteristics with the histologic tumor grade is the distribution of SBR scores in the 
investigated group. There were relatively few high-grade tumors (SBR score 7-9). Of the 
thirty tumors, seven were fi broadenoma with a SBR score of 3, while the most of the 
remainder of the tumors had  SBR scores of 5 and 6. Only one tumor had the maximum 
SBR of 9 and two tumors were classifi ed as SBR score of 8. This variation in the distribution 
of the tumors is subject to statistical variation, cannot be controlled and can be attributed 
to different biological responses to ENU administration in different animals. 
Conclusions from our data are limited in several ways. The tumors investigated in this 
study were chemically induced in rats. Results from this rodent tumor model may not apply 
directly to human neoplasms. Tumors were imaged at only a single time point in their 
growth, at a diameter of approximately 1 to 1.5 cm, while microvascular characteristics KPS 
and fPV may differ as a function of time and tumor size. In addition, only a single tumor type 
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(breast tumor) was investigated. The current study did not examine the potential of CMD-
A2-Gd-DOTA enhancement to monitor the changes in the tumor microvascular assays that 
could result from tumor therapy. Also the “gold standard” used in this study, the histologic 
tumor grading by SBR score, could be subject to inter-individual variations [40]. In order to 
minimize the potential of bias in correlations of MR characteristics with the histology, the 
MR data analysis was performed completely independently of histopathologic evaluation, 
by a different investigator. The pathologist had no knowledge of the results of kinetic 
analysis and the image analyzer was blinded to the histopathologic score.  
As is generally the case for a negative study, the failure to prove the hypothesis may be due 
to the particular model studied or to the precise methods employed and thus the negative 
conclusions are not necessarily generalizable to all tumors or analysis methods. Additional 
negative observations under different conditions would be required to confi rm the results 
of this study.  CMD-A2-Gd-DOTA, the contrast agent examined for this protocol, may yet 
have many and varied useful applications in the area of MRI tumor characterization.
In conclusion, kinetic analysis of dynamic CMD-A2-Gd-DOTA-enhanced MRI data in the 
context of a compartmental model of capillary permeability in a rodent breast tumor model 
failed in differentiation between benign and malignant tumors and in grading of tumors. 
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Abstract
The diagnostic potential of ultrasmall superparamagnetic iron oxide particles (USPIO) for 
quantitative tumor microvessel characterization was assessed by kinetic analysis of dy-
namic magnetic resonance imaging (MRI) in a rodent breast cancer model. Microvascular 
characteristics (transendothelial permeability (KPS) and fractional plasma volume (fPV)) were 
estimated in 32 female Sprague Dawley rats, bearing breast tumors of varying malignancy. 
These values were compared to a prototype macromolecular contrast medium standard, 
albumin-(GdDTPA)
30
. Transendothelial permeabil ity (KPS) correlated signifi cantly (P < 0.05) 
with the tumor grade (Scarff-Bloom-Richardson (SBR) score) for the USPIO (r = 0.36), as well 
as for the reference macromolecule, albumin-(GdDTPA)
30
 (r = 0.54). Estimates for the fPV did 
not show a statistically significant correlation with the tumor grade for either contrast 
medium. In conclusion, USPIO-enhanced MRI data were capable to characterize tumor mi-
crovessel properties in this breast cancer model: microvas cular permeability (determined 
using USPIO) correlated significantly with tumor grade. Thus, quantitative estimation of 
microvascular characteristics in tumors could provide a surrogate of new vessel formation 
(angiogenesis) and thus a further important clinical indication for USPIO, in addition to 
MR angiography. 
Key words
Magnetic resonance imaging; breast neoplasms; contrast media; microvascular density; 
histologic tumor grade
Introduction
Accurate characterization of individual tu mors is critical for patient management, 
prognosis, and long-term survival, as well as selection of appropriate therapy (1). Tumor 
growth, as well as tumor aggressiveness/grade and the potential of setting distant met-
astatic sites, has shown a direct relationship to tumor neovascularization (2,3). Thus, 
any morphological and/or functional assessment focused on tumor microvessels might 
provide important additional information on the biological potential of a tumor.
Cancer microvessel characteristics, in particular fractional plasma volume (fPV) and 
transendothelial permeability (KPS), have been assessed by dynamic contrast-enhanced 
magnetic resonance imaging (MRI) us ing macromolecular contrast media (MMCM) and 
appropriate kinetic modeling (4-6) and have been compared to histopathologic tumor 
parameters in a number of animal models. Differences in MR-estimated microvessel 
properties represented a pathophysiological basis for differentiating between benign and 
malignant tumors, and even between various tumor grades (4,7). Albumin-(GdDTPA)
30
 has 
been the reference con trast medium for characterizing tumor vessel proper ties in several 
studies (7-9), but its prolonged elimination and its immunologic potential impede its 
clinical use. Recently, ultrasmall superparamagnetic iron oxide particles (USPIO), which 
also demonstrate positive enhancement on T1-weighted imaging, have been tested and 
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compared to albumin-(GdDTPA)
30
 for tumor mi crovessel characterization (7). The correlation 
coeffi  cient between these two media for defi ning transendo thelial permeability was high (r 
= 0.81, P < 0.0001), and correlations between both contrast media and the histopathological 
tumor grade were statistically signifi cant (P < 0.05). Thus, assuming their approval for 
clinical use, USPIO are likely to be the fi rst large-size contrast medium on the market that 
are capable of characterizing tumor microvessels.
However, one major limitation reported in this study was the minimal enhancement of 
the tumors after intravenous injection of low-dose USPIO; contrast differ ences compared 
to precontrast images were barely detectable. The most likely and obvious reason for 
this minimal enhancement effect was the dose chosen in that study, 1 mg of Fe/kg of 
body weight. Thus, the goal of this study was to use in the same tumor model a different 
USPIO with a higher dose (in this case, 5 mg of Fe/kg) to improve conspicuity of tumor 
enhancement, to test the reproducibility of previous results, and to assess and discuss 
possible dose dependencies of US PIO for tumor microvessel characterization. MR-derived 
estimates (fPV and KPS) were correlated to histopathological tumor grade and microvascular 
density (MVD) counts.
Materials and methods 
Animal Model
The study was performed with the approval of the Institutional Committee for Animal 
Research and in accordance with the guidelines of the National Institutes of Health for the 
care and use of laboratory animals.
Breast tumors were induced in 32 4- to 6-week-old female Sprague Dawley rats, weighing 
210-340 g, by intraperitoneal injection of the carcinogen N-ethyl-N-nitrosurea (ENU) (ENU 
Isopack, Sigma Chemicals, St. Louis, MO) (10,11). The rats were sedated with ether, and ENU 
was injected at different doses (90-250 mg); tumors appeared as early as 61 days thereafter. 
Ani mals were visually checked for tumor growth every second day. Tumors were imaged 
as soon as they reached a size of 2 cm.
Before MRI, anesthesia was induced by intraperito neal injection of 50 mg/kg of sodium 
pentobarbital. A 23-gauge butterfl y catheter (Abbott Laboratories, North Chicago, IL) was 
inserted into the tail vein for contrast media injection. Immediately after the MRI examina-
tion, 2 mL of saline was injected subcutaneously to avoid dehydration effects.
MRI
MRI was performed on animals using a 2 Tesla Omega CSI-II superconducting system 
(Bruker Instruments, Fremont, CA). This system is equipped with Acustar S-150 self-
shielded gradient coils (±20 G/cm, 15-cm inner diameter). The rats were placed supine 
within a birdcage radio-frequency coil (inner diameter, 4.5 cm; length, 7.6 cm). A phantom 
fi lled with diluted gadopentetate dimeglumine (0.01 mmol/liter) was positioned in the 
fi eld of view to correct for potential spectrometer variation.
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Dynamic contrast-enhanced MRI was performed us ing an axial T1-weighted 3D spoiled 
gradient-recalled (SPGR) sequence with the following parameters: TR = 50 msec, TE = 1.4 
msec, 1 NEX, 128 X 128 X 16 matrix, 60 X 60 X 48-mm fi eld of view, 3-mm slice thickness, 
and an acquisition time of 1 minute, 42 seconds. That such a temporal resolution can be 
considered dynamic refl ects the low extraction rate of the larger contrast media, and is 
based on considerable prior experience with protein-sized macromolecules and ultrasmall 
particles (4,7,9). Precontrast T1-weighted images with varying fl ip angles (α = 10°, 30°, 60°, 
and 90°) were obtained to calculate baseline relaxation rates (R1 = 1/T1) for blood and 
tumor by curve fi tting (12). Twenty-fi ve dynamic postcontrast 3D image sets were acquired 
serially at 2-minute intervals for 50 minutes with the parameters described above, except 
TR was fi xed at 50 msec with the fl ip angle, α, fi xed at 90°.
MR Contrast Media
Albumin-(GdDTPA)
30
 is a 92-kDa prototype of a water-soluble MMCM with a 6-nm diameter, 
synthesized in our laboratory following the method of Ogan et al (13). Albumin-(GdDTPA)
30
 
has a distribution volume of 0.05 liters/kg (which closely approximates the blood vol ume) 
and a plasma half-life of 3 hours in rats, which produces nearly constant enhancement of 
normal tis sues for 30 minutes or longer after injection (14). Albumin-(GdDTPA)
30
 was injected 
on imaging day 1 at a dose of 0.03 mmol Gd/kg. SHU555C (Schering AG, Berlin, Germany) 
consists of USPIO with a mean core size of 3-4 nm in diameter and a hydrodynamic size of < 
25 nm. The distribution volume of SHU555C is 0.04 liters/kg, the acute tolerance (in mice, i.v.) 
is > 10 mmol/kg. The R1 (1/T1) of the agent in plasma is 22 sec -1mM -1 of Fe, and the R2 (1/T2) 
is 65 sec -1mM -1 of Fe (at 20 MHz, 37°C). The mean plasma half-life in rats is about 1 hour, and 
the particles are taken up by the mononuclear phagocyte system and distributed mainly to 
the liver and spleen. SHU555C was injected 24-30 hours after the fi rst examination at a dose 
of 5 mg of Fe/kg.
MRI Data and Kinetic Analysis
Images were transferred to, processed, qualitatively examined, and quantitatively analyzed 
on a Sun Sparc 10 workstation (Sun Microsystems, Mountain View, CA) using the MR-Vision 
Software package (MR-Vision Co., Menlo Park, CA). In each rat and at each time point, regions 
of interest were defi ned by a semiautomated threshold-based method, in which the strongly 
contrast-enhancing pixels on a late postcontrast image were selected to represent the tumor 
periphery. Regions of interest (ROIs) were also drawn in the phantom and in the inferior vena 
cava (IVC). The dynamic signal responses were corrected for potential temporal spectrometer 
variation by dividing by the signal intensity (SI) of the phantom. Postcontrast R1 values were 
calculated based on the SI and knowledge of precontrast values for each ROI (12). Differences 
between the pre contrast and postcontrast R1 values at any time (∆R1) were assumed to be 
proportional to the concentration of the contrast medium, either in the blood or in the tissue 
of interest (12,15). This method of ∆R1 determination is limited by the inherent assumption 
that the fully re laxed SI did not vary signifi cantly on pre- and postcon trast SPGR images. The 
∆R1 data from the blood and tumor were used for kinetic analysis to estimate the coeffi cient 
of endothelial permeability, KPS (mL min -1 100 cc -1 of tissue), and the fPV (mL cc -1 of tissue) 
using a two compartment, bidirectional model for tumor tissue as previously described in 
detail (4,16). In this model, a monoexponential function fi tted to the ∆R1 data from 
the blood was used as a forcing function (input function) for the plasma response in the 
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tumor after correction for hematocrit and after scaling for the fPV. The KPS values determined 
from the model were multiplied by 100, thereby scaling our permeability measure for 100 
cc of tissue. All data fi tting was performed with the commercially available SAAM II com-
puter program (SAAM Institute, Seattle, WA), which employs standard variance-weighted 
nonlinear regression. The uncertainty of the estimates of the model parameters was 
determined from the covariance matrix at the least-squares fi t.
Histologic Analysis
All animals were sacrifi ced after the second MR examination by an intravenous overdose 
of 0.3 mL of pentobarbital. Tumors were excised, immediately fi xed for 18-24 hours in 10% 
buffered formalin (Poly Scientifi c Research & Development Corp., Bay Shore, NY), processed 
routinely into paraffi n, sectioned approximately in the plane of the MR images at 4 µm, 
and stained with hematoxylin and eosin for diagnosis and grading. Additional sections 
were immunostained for von Willebrand Factor and Factor VIII using an avidin-biotin 
peroxidase technique (Sigma rabbit anti-human poly-clonal, F-3520; Vector ABC kit, PK-6100, 
Sigma Chem icals, St. Louis, MO).
The Scarff-Bloom-Richardson (SBR) method was applied for tumor grading (17,18). This 
grading system evaluates (i) the ductoglandular formation and the nuclear characteristics, 
including (ii) pleomorphism and (iii) the mitotic activity of the tumors. Each of these 
three morphological features is scored by assigning one to three points; an overall score is 
obtained then by summation of the individual characteristic scores. SBR scores range from 
3 to 9 points; the higher the score, the more malignant and more poorly differentiated is 
the tumor. For MVD count determination, all discrete, positively immunostained endothelial 
(brown-staining) clusters with lumina were counted in 20 400 X fi elds (Olympus Vanox 
AH-2 microscope) sampled from two sections of each tumor. Where possible, fi elds were cho-
sen in areas of highest MVD. Stromal microvessels were included in the counts, but capsular 
and preexisting host small-to-medium vessels were excluded.
MVD is reported as the number of vessels per high-power fi eld. MVD and SBR scoring were 
performed by the same pathologist without knowledge of MRI fi ndings.
Statistics
Mean values for KPS and fPV for a given contrast agent were compared between fi broadenomas 
and carcinomas using unpaired t-tests. The paired two-tailed Student’s t-test was used to 
compare mean values of KPS and fPV in the same tumors between albumin-(Gd-DTPA)
30
 
and USPIO. Spearman correlation analyses were performed comparing the estimated MRI-
derived parameters (KPS and fPV) with the histologic tumor grade (SBR score) and the MVD. 
Pearson correlation analyses were performed, comparing the albumin-(Gd-DTPA)
30
- and the 
USPIO-derived values for KPS and fPV in the same tumors. A P value of < .05 was considered 
statistically signifi cant.
Results
Thirty-two rats developed mammary tumors as early as 61 days and within 430 
days after ENU injection with a mean latent period of 177 ± 114 days. In general, 
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the latent period for benign tumors was signifi cantly longer (mean, 309 ± 108 days) than 
for malignant tumors (mean, 143 ± 94 days). Six tumors were benign fi bro adenomas, and 
26 were malignant tumors (24 adenocarcinomas, 1 sarcoma arising in a fi broadenoma) 
showing a clear trend toward 
higher SBR scores with a higher 
injected ENU dose. However, 
fi broadenomas were found 
after injection of 90 (N = 2), 180 
(N = 2), and 250 (N = 2) mg of 
ENU/kg. All six fi broadenomas 
had the lowest possible SBR 
score, 3; the malignant tumors 
spanned a range from 3 to 7; 
none of the malignant tumors 
in this study had the highest 
SBR score possi ble (8 or 9). 
(Table 1).
There was a statistical signi- 
fi cant difference between the 
MVD counts in the benign 
fi broadenomas (187.0 ± 154.5), 
compared to the malignant 
tumors (355.8 ± 128.9, P < 0.05). 
No statistically signifi cant 
correlation between the SBR 
score and the MVD was found 
(r = 0.13, P= 0.41).  
Both albumin-(GdDTPA)30 and 
USPIO-enhanced MR exa-
minations could be completed 
successfully in all 32 animals. 
The kinetic model fi t the data 
well in all experiments. In none 
of the experiments was a refl ux 
rate constant resolvable from 
the data using our bidirec-
tional model. Consequently, 
each data set was refi t subject 
to the constraint that the refl ux 
rate constant was zero. Under 
Table 1. Histopathologic Results and
MR-derived Microvessel Characte-
ristics (fPV, KPS) Sorted by Ascending 
SBR Score
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these conditions all coeffi cients of variation for the estimated parameter values were accept 
able, being less than 50%. A tabulation of KPS and fPV values for albumin-(GdDTPA)
30
 and 
USPIO in the fi bro adenomas and carcinomas with their respective SBR and MVD scores for 
each experiment is shown in Table 1. 
The mean values for KPS were signifi cantly larger in the carcinomas than in the 
fi broadenomas for both albumin-(GdDTPA)
30
 (0.017 ± 0.012 vs. 0, P < 0.05) and USPIO (0.014 
± 0.020 vs. 0, P < 0.05). Making the same comparisons for fPV, no signifi cant differences were 
found between carcinomas and fi broadenomas using albumin-(GdDTPA)
30
 (0.044 ± 0.023 vs. 
0.033 ± 0.013, P = 0.15) or USPIO (0.028 ± 0.016 vs. 0.025 ± 0.003, P = 0.39). Furthermore, no 
signifi cant differ ences were found comparing mean KPS values between albumin-(GdDTPA)
30
 
and USPIO for either fi broadeno mas (0 vs. 0) or carcinomas (0.017 ± 0.012 vs. 0.014 ± 0.020, 
respectively, P = 0.49). No signifi cant differences were found for mean values of fPV between 
albumin-(Gd-DTPA)
30
 and USPIO for fi broadenomas (0.033 ± 0.013 vs. 0.025 ± 0.03, P = 0.15). 
However, a statisti cally signifi cant difference was observed for the mean values of fPV 
in the malignant tumor group between albumin-(GdDTPA)
30
 and USPIO (0.044 ± 0.023 vs. 
0.028 ± 0.016, P< 0.05).
Nonparametric correlation values between KPS (derived with albumin-(GdDTPA)
30
 and 
USPIO) and the SBR scores were moderate (r = 0.54 and 0.36, respectively) but nonetheless 
statistically signifi cant (P < 0.05). Correlations between the fPV values and the histologic 
tumor grades were poor for both contrast media (r = 0.11 for albumin-(GdDTPA)
30
, r = -0.06 for 
USPIO) and did not reach statistical signifi cance.
Weak but still signifi cant (P < 0.05) correlations were found for KPS and fPV values between 
albumin-(Gd-DTPA)
30
 and MVD (r = 0.39 and 0.36, respectively). MR estimates of KPS and fPV 
derived with USPIO did not correlate signifi cantly with MVD (r = 0.08 and 0.15, P>0.05). Results 
of Pearson correlation analyses between albumin-(GdDTPA)
30
 and USPIO for KPS values in all 32 
tumors (fi broadenomas and carcinomas grouped together) in the same animals showed 
a strong and sig nifi cant correlation (r = 0.60, P < 0.0005). Making the same comparison for 
fPV values, correlations were weak and did not reach statistical signifi cance (r = 0.27, 
P= 0.13).
Discussion
The current study shows that USPIO are capable of differentiating various tumor grades 
by characterizing their microvascular characteristics in a rodent breast cancer model. 
The transendothelial permeability of cancer microvessels, as expressed by KPS, correlated 
signifi cantly (P < 0.05) with the histologic tumor grade (SBR score) for both contrast media, 
albumin-(Gd-DTPA)
30
 (r = 0.54) and USPIO (r = 0.36). None of the benign tumors revealed any 
measurable leak to the two MMCM; all tumors with measurable hyperpermeability were 
malignant.
These results might have important diagnostic consequences for breast cancer patients 
because USPIO, unlike albumin-(GdDTPA)
30
, are already used in clinical trials as an 
angiographic agent and their approval for clinical use is pending (19,20). 
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SHU555C, as a representative of these contrast me dia class, is an insoluble iron oxide 
particle with an average size of < 25nm. Thus, SHU555C has a considerably smaller size 
than the already clinically available SPIO (200-400nm), which is refl ected by prolonged 
plasma half-life (approximately 3 hours in rats), be cause the uptake of iron oxide particles 
by the mononuclear phagocytic system (MPS) is known to be basically a function of their 
size (21). Consequently, MR angiography has been considered to be the primary indication 
for USPIO so far; but the shown potential of USPIO to also characterize tumor microvessels 
will extend its range of clinical indications: USPIO could be used to grade noninvasively 
individual tumors and, subsequently, could guide therapeutic decisions. USPIO-enhanced 
MR estimates of tumor endothelial per meability might infl uence the choice of the optimal 
therapy (antiangiogenic, cytotoxic, radiation etc.) and, furthermore, could be used for 
monitoring these thera peutic effects.
The capability of USPIO to characterize tumor mi crovessels has recently been demonstrated 
in another animal study (7). Turetschek et al could show, using a different USPIO with slightly 
different paramagnetic properties than the one used in the current study, that USPIO-
enhanced estimates of tumor microvessel hy perpermeability are capable of differentiating 
various tumor grades (7). The reported correlations between the MR estimates and the SBR 
scores were high and sta tistically signifi cant (r = 0.88 for albumin-(GdDTPA)
30 
and r = 0.82 for 
USPIO, P < 0.05). However, one limitation of this study was the poor tumor enhancement, 
which was interpreted to be due to the low dose of USPIO (1 mg of Fe/kg). Although kinetic 
analyses of their MR data could retrieve suffi cient measurable differences between pre- and 
postcontrast images, in daily clinical routine clear postcontrast enhancement of tu mors is 
a desired morphologic feature for reading and interpreting the fi lms. For this reason, in our 
study we have chosen to use a rather high dose of USPIO (5 mg/kg), which is still considered 
to be safe and well tolerated in clinical practice and, moreover, provides an increased signal-
to-noise ratio after contrast media injection (Fig. 1).
Figure 1. Representative axial T1-weighted (TR = 50 msec, TE = 1.4 msec) SPGR images of a 
subcutaneous malignant mammary tumor before (a) and 10 minutes after (b) administration of SHU (5 
mg of Fe/kg), showing a typical rim enhancement on the postcontrast image (arrow) (b). A phantom was 
placed in the field of view (arrowhead).
a b
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An intrinsic property of USPIO is the reduction of T1 and T2* relaxation times; the magnitude 
of these effects are dose and MR parameter dependent. The key MR parameter for avoiding 
confounding T2* effects is the echo time (TE), which, in both studies, was kept as low as 
possible (1.4 msec). 
Two factors compromise the use of USPIO for quantitative descriptions of the tissue 
microvasculature, primarily, the fact that the positive signal enhancement associated 
with T1 shortening is accompanied by a negative enhancement associated with T2* 
shortening. Especially at higher doses, the T2* shortening effects can be severe and may 
even overwhelm the positive en hancement (15,22). The second is the capricious dependence 
of the T2* shortening on compartmentalization of the superparamagnetic particle—in short 
the microgeometry of the microvascular organization. In homogeneous distribution the 
T2* effects of such contrast agents are less pronounced then when compartmentalized, as 
in tissue. To a certain extent, leakage of the contrast medium reduces the heterogeneity of 
compart mentalization, further complicating the scenario. 
Our results demonstrate that, using USPIO at a dose of 5 mg/kg, the contrast-to-noise ratio 
is excellent and correlations between tumor grades and cancer microvessel permeability 
are still statistically signifi cant. However, the trade-off is a decrease in the correlation values 
(compared to the results in reference 7), which are interpreted to be caused by technical 
(higher dose of USPIO) and partly by biological factors. 
Unlike Gd-based macromolecules, such as albumin-(GdDTPA)
30
, the magnetic fi eld disruption 
and T2* shortening associated with iron oxide particles is considerable, compared to their 
positive enhancing or T1 shortening effects. Indeed, both large and small iron oxide 
particles have been considered as T2* shortening agents for studies of the liver and lymph 
nodes (primary sites of accumulation) (23-25). 
The effect of concomitant T2* shortening is a further nonlinearity in the relationship 
between signal en hancement on T1-weighted MRI and contrast agent concentration. 
As previously stated, at high concentrations or long TEs, T2* effects may overwhelm T1 
short ening and lead to paradoxical isointensity or even hypointensity. To ameliorate 
this, a short TE is critical, such that the effects of T2* shortening on SI are minimized. As 
reported by Bremerich et al, a difference in TE between 1.1 and 4.2 msec can dramatically 
reverse vessel/tissue contrast at high doses of USPIO administration (at 1.5 T). In principle, 
if changes in T2* can be related to changes in T1, as a function of tracer concen tration, 
these confounding effects could at least in theory be addressed and compensated for (22). 
However, unlike the relationship between T2 and T1, associated with a contrast medium, 
the relationship between T2* and T1 depends additionally on the compartmentaliza tion 
and microgeometry of distribution of the T2* short ening moiety. Water proton spins in the 
gradient of magnetic fi eld caused by heterogeneous iron distribu tion dephase, leading 
to signal loss. In a homogeneous distribution, this gradient vanishes and the dephasing 
mechanism is averted.
Thus, the relative error in contrast agent concentra tion determination in a reference, large 
blood vessel and the tumor tissue, cannot be determined due to the dif ferent fractional 
blood volumes and microvessel distributions. One might argue that the lower fractional 
blood volume of tissue leads to a lower pixel concentra tion of iron and thus a lesser 
T2* shortening—this would lead to a relative hyperintensity on T1-weighted images in 
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tissue compared to blood and consequent fPV overestimation. On the other hand, one 
might argue that large vessel pixels contain a homogeneous distribution of iron and 
do not suffer the confounding distribution heterogeneities that lead to pronounced T2* 
shortening in tissue voxels. This would lead to an underestimation of tissue fPV (based on 
positive enhancement). The truth must be presumed to lie somewhere between these two 
arguments, a function of the specifi c microvascular geometry and biased by the sensitivity 
of the pulse sequence, primarily the length of the TE. By choosing a short TE, we attempted 
to minimize the signifi cance of the above debate. However, the systematic, albeit small, 
underestimation of fPV using USPIO compared to albumin-(GdDTPA)
30
  forces us to conclude 
that the latter argument carries more weight and that tissue heterogeneous distribution 
of contrast media leads to a more pronounced T2* shortening effect per pixel, compared to 
a pixel containing 100% blood.
An interesting ray of light may be shone upon the above discussion by the direct comparison 
of fPV determined by albumin-(GdDTPA)
30
 and USPIO in a rat-by-rat basis.
Dividing the rats into upper and lower 50 percentiles in terms of their albumin-(GdDTPA)
30
-
based fPV (inde pendent of histopathological fi ndings) (cutoff = 3.8%) reveals that the lower 
fPV group shows no difference in fPV between albumin-(GdDTPA)
30 
and USPIO (2.7 vs. 2.7). 
Interestingly, the group defi ned by albumin-(Gd-DTPA)
30
 as having higher fPV (3.9%-11.9%; 
mean, 5.6%) has a mean USPIO-derived fPV of 2.8%, no dif ferent for the other 50 percentile 
group. That is to say that differences between albumin-(GdDTPA)
30
- and US PIO-derived fPV 
determination differ only when the albumin-(GdDTPA)
30
-derived values are high (in this 
case, > 3.8%). Does this mean that in some cases albumin-(GdDTPA)
30
 overestimates fPV, or 
does it suggest that at high fPVs the underestimation of fPV associated with the T2* shortening 
effects of USPIO becomes signifi cant?
Hypothesizing why albumin-based fPV estimates are too high in the more vascular group 
might introduce arguments about temporal resolution and the leakage of contrast media 
before the fi rst postcontrast imaging point. In particular, in aggressive tumors with higher 
permeabilities, this might have some impact.
On the other hand, arguments for the underestima tion of USPIO-derived fPV have been made 
based on the heterogeneous distribution of the agent. Which of these positions is correct is 
not yet clear. Arguing for albumin-(GdDTPA)
30
-based accuracy of fPV is the correlation with 
the MVD (which was absent in the USPIO-derived fPV calculations).
On the other hand, arguing in favor of USPIO, one might expect the larger particle to better 
remain intravascular (even in malignant hyperpermeable tumor vessels) and not suffer 
the leak before the fi rst postcon trast imaging time point.
In general, pursuit of yet shorter TEs will render the confounding effects of T2* shortening 
decreasingly rel evant.
The SBR score has been used as our pathologic gold standard for assessing different tumor 
grades. This grading method evaluates tumor cell morphology, and each tumor is assigned 
a score between 3 and 9. It has been shown in previous studies that SBR scores correlate 
strongly with tumor hyperpermeability to macromolecules (4,5). From a statistical point 
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of view, the scores of the graded tumors should ideally be distributed equally to the 
different groups in order to ensure maximal statistical power. This, unfortunately, cannot 
be determined a priori. Any inhomogeneous distribu tion of tumor grades (i.e., in our study 
we did not have the highest possible grades, 8 and 9) will infl uence the results in terms of 
lower correlation values. We see this as a major explanation for the different correlation val-
ues in this study, compared to previously reported values.
Another commonly used biomarker to evaluate tumor microvessels quantitatively is the 
MVD count. MVD determines quantitatively the vascular status of a given tissue and has 
been shown to be a marker for patient prognosis and outcome. High MVDs are considered 
to be linked to the degree of tumor malignancy; the higher the MVD, usually the more 
malignant or less differentiated a tumor is (26). In this study, using albumin-(GdDTPA)
30
, 
we observed a statistical signifi cance (P < 0.05) between MVD and KPS and fPV. In our current 
tumor model, higher counts of tumor microvessels correlated with higher permeability 
values and a higher fPV. However, no statistical signifi cant correlation was found between 
these microvascular characteristics (KPS and fPV) and MVD using USPIO. We interpret these 
particular results to be the consequence of the higher USPIO dose used in this study 
because the apparent T2* effects obviously lead to an underestimation of fPV and KPS 
values.
In summary, our study shows that USPIO can be used for quantitative characterization of 
tumor microvessels. Estimates of transendothelial permeability, as expressed by KPS, correlate 
with histologic tumor grade and therefore seem to be better indicators than fPV for assessing 
cancer microvessel characteristics. Furthermore, we have demonstrated that quantitative 
MR estimates of mi crovessels are infl uenced by intrinsic properties of USPIO, requiring careful 
considerations of the dose and MR pa rameters used in any clinical study.
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Abstract 
The aim of this study was to evaluate the potential of dynamic magnetic resonance imaging 
(MRI) enhanced by macromolecular contrast agents to monitor noninvasively the therapeutic 
effect of an anti-angiogenesis VEGF receptor kinase inhibitor in an experimental cancer 
model. MDA-MB-435, a poorly differentiated human breast cancer cell line, was implanted 
into the mammary fat pad in 20 female homozygous athymic rats. Animals were assigned 
randomly to a control (n=10) or drug treatment group (n=10). Baseline dynamic MRI was 
performed on sequential days using albumin-(GdDTPA)
30
 (6.0 nm diameter) and ultrasmall 
superparamagnetic iron oxide (USPIO) particles (~30 nm di ameter). Subjects were treated 
either with PTK787/ZK 222584, a VEGF receptor tyrosine kinase inhibitor, or saline given 
orally twice daily for 1 week followed by repeat MRI examinations serially using each 
contrast agent. Employing a unidirectional kinetic model comprising the plasma and 
interstitial water compartments, tumor microvessel characteristics including fractional 
plasma volume and transendothelial permeability (KPS) were estimated for each contrast 
medium. Tumor growth and the microvascular density, a histologic surrogate of angiogenesis, 
were also measured. Control tumors signifi cantly increased (P<0.05) in size and in microvascu-
lar permeability (KPS) based on MRI assays using both macromolecular contrast media. In 
contrast, tumor growth was signifi cantly reduced (P<0.05) in rats treated with PTK787/ZK 
222584 and KPS values declined slightly. Estimated values for the fractional plasma vol ume 
did   not  differ  signifi cantly  between   treatment groups or contrast agents. Microvascular 
density counts correlated fairly with the tumor growth rate (r=0.64) and were statistically 
signifi cant higher (P<0.05) in the con trol than in the drug-treated group. MRI measurements 
of tumor microvascular response, particularly transendo thelial permeability (KPS), using either 
of two macromo lecular contrast media, were able to detect effects of treatment with a VEGF 
receptor tyrosine kinase inhibitor on tumor vascular permeability. In a clinical setting such 
quantitative MRI measurements could be used to moni tor tumor anti-angiogenesis therapy.
Keywords
Magnetic resonance imaging - Breast cancer - Vascular endothelial growth factor receptor 
tyrosine ki nase - Contrast media
Introduction
Neovascularization by angiogenesis is crucial for tumor development, growth, and metastasis 
[1]. A high level of vascularization, considered a negative prognostic mark er, is associated with 
higher tumor aggressiveness and increased potential for metastasis [2, 3, 4]. Thus, inhibi tion 
of tumor angiogenesis has become a primary target of numerous therapeutic anticancer 
schemes [5, 6, 7, 8, 9, 10, 11].
Tumor cells and/or tumor-associated infl ammatory cells produce a range of growth 
factors that have become targets for suppression as a therapeutic approach to slow, stop, 
or even reverse tumor growth [5, 6, 7, 8, 9, 10, 11]. One of these growth factors, vascular 
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endothelial growth factor (VEGF), also termed vascular permeability factor (VPF), is a well-
studied multifunctional cytokine considered to play a pivotal role in the induction of tumor 
angiogenesis. Expression of VEGF and its receptors correlates with the degree of tumor 
vascularization and has been proposed as a prognostic factor for assessing pa tient survival 
[12]. Current approaches to inhibit tumor neovascularization by attacking the VEGF pathway 
include (a) a direct inhibition of VEGF itself, (b) blockade of VEGF receptors, (c) blockade of the 
intracellular mo lecular cascade triggered by the VEGF-receptor com plex, and (d) blockade 
of VEGF-receptor associated adhesion molecules [13, 14, 15]. In the current study, an orally 
administered inhibitor of VEGF receptor tyrosine kinase (PTK787/ZK 222584, Novartis, 
Basel, Switzerland) was used to block the intracellular receptor phosphorylation and signal 
transduction triggered by the VEGF-receptor complex.
Dynamic magnetic resonance imaging (MRI) enhanced by macromolecular contrast media 
(MMCM) combined with kinetic modeling has shown a potential for the detection of drug-
induced (IL-2 and anti-VEGF antibodies) [16, 17] changes in tumor microvascular sta tus, 
particularly transendothelial permeability [16, 18]. However, the prototype MMCM used in 
these previous studies, albumin-(GdDTPA)
30
, is considered ill-suited for clinical development 
based on potential immunologic responses and incomplete, prolonged elimination of ga-
dolinium [19, 20]. As alternative MMCM, like ultrasmall superparamagnetic iron oxide (USPIO), 
are identifi ed as having potential for clinical use [21], these should be evaluated in tumor 
models as probes for the defi nition of microvascular characteristics with the fi nal goal of trans-
lation to clinical practice.
Thus, in the current study, two macromolecular con trast media, USPIO particles (~30 nm 
diameter) and albumin-(GdDTPA)
30
 (~6 nm diameter), were compared in the MRI assessments 
of tumor microvessel status in an experimental human breast cancer model. Furthermore, 
the potential use of each contrast medium to detect and measure hypothesized changes in the 
tumor microvasculature, as well as accompanying changes in fractional plasma volume (fPV) 
and permeability to the macromolecules, was evaluated 1 week after initiation of anti-angio-
genesis therapy with PTK787/ZK 222584. Measures of the dynamic MRI data, including fPV 
and transendotheli al permeability (KPS), obtained with each contrast medi um were compared 
and correlated to tumor growth and to microvascular density, a biomarker of angiogenesis.
Materials and methods
Animal model
The study was performed with the approval of the institutional Committee for Animal 
Research and in accordance with the guidelines of the National Institutes of Health for 
the care and use of laboratory animals.
Twenty 4-week-old female homozygous athymic rats (Harlan, Indianapolis, Ind.) were 
implanted in mammary fat pad with 5x106 human breast cancer cells, MDA-MB-435 
(Cell Culture Facility of the University of California, San Francisco), suspended in a total 
volume of 0.3 ml (1:1 mixed with Matrigel), using a 25G needle. This cell line represents 
a poorly differentiated adenocarcinoma with high expression of VEGF. Animals were 
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visually checked for tumor growth every second day. Tumors were imaged the fi rst time 
when they reached a diameter of 1.0-1.5 cm. Before MRI, anesthesia was induced by 
intraperitoneal injection of 50 mg/kg sodium pentobarbital. A 25-gauge butterfl y 
catheter (Abbott Laboratories, North Chicago, Ill.) was inserted into the tail vein for 
contrast medium injection. Rats were placed on a heated water pad to keep the body 
temperature at physiological levels. Immediately after the MRI examination, 2 ml saline 
was injected subcutaneously to avoid potential dehydration.
MR imaging
MRI was performed on animals using a 2-Tesla Omega CSI-II superconducting system 
(Bruker Instruments; Fremont, Calif.). This system is equipped with Acustar S-150 self-
shielded gradient coils (±20 G/cm, 15 cm inner diameter). The rats were placed supine 
within a birdcage radiofrequency coil (inner diameter 4.5 cm, length 7.6 cm). A 
phantom filled with diluted 0.01 mmol/l gadopentetate dimeglumine was positioned 
in the fi eld of view to correct for temporal spectrometer variation. A series of precontrast 
images were acquired using an axial T1-weighted 3D-SPGR (spoiled gradient-recalled) 
sequence with varying repetition times between 30 and 1,000 ms. Other parameters 
were: TE 1.4 ms, one NEX (number of excitations), 128x128x16 matrix, 60x60x48 mm, 3 
mm slice thickness, fl ip angle (α) =900. These sequences were used to calculate baseline 
relaxation rates (R1=1/T1) for blood and tumor by monoexponential curve fi tting. 
Subsequently dynamic images (precontrast, n=3; postcontrast, n=20) were acquired 
serially at 2-min intervals for 46 min with the parameters described above, except TR 
was fi xed at 30 ms.
MR contrast media
Albumin-(GdDTPA)
30
. Albumin-(GdDTPA)
30
 is a 92-kDa proto type of a water-soluble 
macromolecular contrast medium with 6 nm hydrodynamic diameter, synthesized in 
our laboratory following the method of Ogan [22]. Albumin-(GdDTPA)
30
 has a distribution 
volume of 0.05 l/kg (which closely approximates the blood volume) and a plasma half-
life of approximately 3 h in rats, which produces nearly constant enhancement of normal 
tissues for 30 min or longer after injection. Albumin-(GdDTPA)
30
 was inject ed on imaging 
day 1 at a dose of 0.03 mmol Gd/kg.
SHU555C. SHU555C (Schering AG, Berlin, Germany) consists of USPIO particles with a 
mean core size of 3-4 nm diameter and a total hydrodynamic diameter of ~30 nm. The 
distribution volume of SHU555C is 0.04 l/kg, and the acute tolerance (in mice, i.v.) is >10 
mmol/kg. The R1 (=1/T1) of the agent in plasma is 22 s–1 mM–1 Fe, and the R2 (=1/T2) 
is 65 s–1 mM–1 Fe (at 20 MHz, 37°C). The mean plasma half-life in rats is about 1 h, and the 
par ticles are ultimately degraded by the mononuclear phagocyte system. SHU555C was 
injected on day 2, 24 h after the albumin-(GdDTPA)
30
 injection at a dose of 2.5 mg Fe/kg. 
At the time the SHU555C was injected, the tumor signal, potentially infl uenced by the 
previous day’s injection of albumin (Gd-DTPA)
30
, had returned to baseline values.
Tumor volumes were calculated by summation of the measured tumor area on each 
slice, adjusted by the slice thickness (3 mm).
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Experimental protocol
After the baseline MR examinations, animals were randomly assigned to either the drug 
treatment or the control group. The control group was fed by gavage with saline; the 
drug group was treated, also by gavage, with a novel tyrosine kinase inhibitor drug, 
PTK787/ZK 222584.
PTK787/ZK 222584 is a potent VEGF receptor tyrosine kinase inhibitor [23] that has not 
been observed to have harmful effects on physiological neovascularization such as wound 
healing. PTK787/ZK 222584 suppresses VEGF-mediated endothelial cell proliferation, 
migration, and cell survival. PTK787/ZK 222584 was prepared as follows for oral 
administration: the succinate salt was suspended in a vehicle containing 5% DMSO and 
1% Tween 80 in distilled water. PTK787/ZK 222584 was administered orally by gavage 
twice daily (morning and evening) at a dose of 50 mg/kg per feeding.
On the day following the seventh day of gavage treatment, all animals were imaged a 
second time using the identical protocol applied for pretreatment assessment.
MRI data and kinetic analysis
Images were transferred to, processed, qualitatively examined and quantitatively analyzed 
on a Sun Spark 10 workstation (Sun Mi crosystems, Mountain View, Calif.) using the MR-
Vision Software package (The MR-Vision Co, Menlo Park, Calif.). In each rat and at each 
time point, regions of interest were defi ned by a semiautomated threshold-based method 
in which the strongly contrast-enhancing pixels on a late postcontrast image were 
selected to re present the tumor periphery. Regions of interest (ROIs) were also drawn in the 
phantom and in the inferior vena cava (IVC). The dynamic signal responses were corrected 
for potential temporal spectrometer variation by dividing by the signal intensity (SI) of 
the phantom. Postcontrast R1 values were calculated based on the SI and knowledge of 
precontrast R1 values for each ROI as previously described [24]. Differences between the 
precontrast and post contrast R1 values at any time (∆R1) were assumed to be proportional 
to the concentration of the contrast medium, either in the blood or in the tissue of interest 
[25, 26, 27]. This method of ∆R1 determination is limited by the inherent assumption that 
the fully relaxed SI did not vary significantly on pre- and postcontrast SPGR images 
[27]. The ∆R1 data from blood and tumor were used for kinetic analysis to estimate the 
coeffi cient of endothelial permeability, KPS (µl min–1 100 cc–1 of tissue), and the fractional 
plasma volume, fPV (µl cc–1 of tissue) using a two-compartment, unidirectional model for 
tumor tissue as previously described in detail [18, 24]. In this model, a monoexponential 
function fi tted to the ∆R1 data from blood was used as a forcing function for the plasma 
response in the tumor after correction for hematocrit and after scaling for fractional 
plasma volume. The KPS values determined from the model were multiplied by 100, thereby 
scaling our permeability measure for 100 cc of tissue. All data fi tting was performed with 
the commercially available SAAM II computer pro gram (SAAM Institute, Seattle, Wash.), 
which employs standard variance-weighted nonlinear regression. The uncertainty of the 
estimates of the model parameters was determined from the covariance matrix at the 
least squares fi t.
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Histologic analysis
All animals were sacrifi ced after the second, post-treatment MR examination by an 
intravenous overdose of pentobarbital and thoracotomy. Tumors were excised, immediately 
fi xed in 70% ethanol and stored at 4°C for 24 h. Tumor sections were processed routine-
ly into paraffi n, sectioned in the plane of the MR images at 4 µm, and immunostained 
with anti-CD31 antibodies for microvascular density (MVD) counts. All discrete, positively 
immunostained en dothelial clusters were counted in twenty 200X fi elds (Olympus Vanox 
AH-2 microscope). Areas containing the highest number of stained vessels were chosen. 
Stromal microvessels were included in the counts, but capsular and preexisting host 
small-to-medium vessels were excluded. MVD is reported as the number of vessels per 
high-power fi eld. The same pathologist, without knowledge of MRI fi ndings, performed all 
MVD counting.
Statistics
The paired two-tailed Student’s t test was used to compare mean values of KPS and fPV 
values in the same tumors pre and post intervention (drug or control) for each contrast 
medium. This statistical test was also used to compare changes in tumor volume over time 
in each rat. The unpaired two-tailed Student’s t test was used to compare mean values for 
KPS and fPV between the control and the treated group. Pearson correlation analyses were 
performed comparing the KPS and fPV values for each contrast agent to MVD for both 
control and treatment studies. A P value <0.05 was considered statistically signifi cant.
Results
Tumors grew in all implanted animals and obtained a di ameter of approximately 1.5 cm within 
14 days (Fig. 1). MR imaging was completed successfully in 23 animals; however, MR-derived 
data from three rats (all assigned to the control group) were excluded from group analysis 
because of unacceptably high noise, attributable to sub ject motion during data acquisition. 
Thus, the fi nal study population consisted of 20 animals (ten controls and ten treated).
There was no signifi cant difference (P=0.52) between groups with respect to tumor volume 
at baseline: 1,701 ±957 mm3 (mean±SD) in the drug treatment group and 1,813±769 mm3 
in the control group. At the second MRI examination following 7 days of treatment, mean 
tumor volume had increased signifi cantly in both groups (P<0.005), to 3,444±2,321 mm3 in the 
PTK787/ZK 222584-treated group and to 5,610±1,604 mm3 in the control group. The calculated 
tumor volume growth ratio between baseline and follow-up examinations was sig nifi cantly 
higher (P<0.01) in the control group (3.5±1.4) than in the drug-treated (2.1 ±0.9) group.
The model provided good fi ts to the data from all four studies (one baseline and one perturbed 
experiment for each contrast agent) for each rat. The uncertainty esti mates (coeffi cient of 
variation in %) for all model measures were within acceptable limits (<50% with means of 
7% and 30% for fPV and KPS, respectively). The mean values for fPV and KPS obtained from the 
model in the pre- and postdrug studies for each contrast agent are shown in Table 1.
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Using albumin-(GdDTPA)
30
, the mean KPS values at baseline were 19±15 µl min–1 100 cc–1 tissue for 
the drug group and 20±12 µl min–1 100 cc–1 tissue for the control group (P=0.89). At the follow-
up examination, the mean KPS values decreased modestly but not signifi cantly (P=0.16) in the 
drug group to 9±11 µl min-1 100 cc–1 tis sue but increased significantly in the control group, 
to 33±12 µl min–1 100 cc–1 (P<0.05) when compared with baseline values. In addition, KPS 
post values were significantly greater in the control group (33±12 µl min–1 100 cc–1 
tissue) than in the drug-treated group (9±11 µl min–1 100 cc–1; P<0.05). 
Making the same comparisons 
for USPIO-generated microvas-
cular assays, mean KPS values 
at baseline were 36±36 µl 
min–1 100 cc–1 tissue in the 
drug group and 20±18 µl min–1 
100 cc–1 tissue in the control 
group (P=0.24). At the follow-
up examination, KPS values 
in the PTK787/ZK 222584 
group had decreased modestly 
(24±39 µl min–1 100 cc–1; P=0.31) 
while they had increased 
significantly in the control 
group to 43±25 µl min–1100 
cc–1 tissue (P<0.05) (Fig. 1).
Mean fPV values for both 
contrast agents were not 
signifi cantly different at 
baseline, nor was there any 
evidence of signifi cant change 
with either drug or placebo 
treatment.
The mean MVD counts in the 
drug-treated group (120±37) 
were statistically signifi cant 
lower (P<0.05) than in the 
control group (171±57 vessels 
per high-pow-er fi eld) (Fig. 2). 
MVD counts correlated fairly 
strongly with the tumor growth 
rate (r=0.64), moderately with 
permeability estimates (KPS) 
(r=0.46), and rather poorly 
with fractional blood volume 
estimates (r=-0.07).
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Fig. 1. Transendothelial permeability (KPS in µl min–1  100 cc 
tissue) at baseline and follow-up examinations after saline 
(= con trol) or PTK787 treatment based on enhancement with 
either albumin-(GdDTPA)30 (a) or USPIO (b). *, Statistically 
significantly different from baseline (P<0.05)
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Discussion
MRI-assayed MDA-MB-435 
breast tumor microvascular 
permeabilities (KPS) and 
tumor volumes increased 
signifi cantly (P<0.05) in 
the saline-treated controls. 
Although PTK787/ZK 222 
584-treated tumors also 
grew over 7 days (Fig. 3), 
they grew signifi cantly 
(P<0.05) more slowly as 
measured by the tumor 
volume growth ratio. Also, 
while the microvascular 
permeability in control tu-
mors increased signifi cantly, 
there was a decline, albeit nonsignifi cant, in KPS for the PTK787/ZK 222584-treat ed tumors 
over 1 week.
Inter-subject variability in KPS determination refl ecting underlying biological differences 
across times in fact partially shrouds the signifi cance of the individual progression or 
response data. This is evident in the rath er large standard deviations observed in the 
within-group KPS values. In fact a decline in KPS was observed in eight of ten (80%) drug-
treated animals but only one of ten (10%) animals in the contrast group. This re sponse 
difference was statistically signifi cant (chi test: P<0.01) and refl ects the general tendency 
of KPS re sponse in the absence of therapy and reduction in re sponse to drug (Fig. 4). That 
a small fraction [2/10 (20%)] nonetheless showed elevated KPS post drug treatment may in 
fact highlight the very clinical scenar io that we hope to address, i.e., identifi cation of nonre-
sponders. It may also refl ect insuffi cient amount or duration of drug exposure.
Fig. 2. Human breast carcinoma xenografts showing endothelium immunostained for CD31. 
The microvascular density of the control tumor (A) is greater than that of the treated tumor (B). 
The treated tumor also has an area of necrosis (arrowhead)
Table 1. MRI estimates of fractional plasma volume (fPV) and 
transendothelial permeability (KPS) for PTK787/ZK222584-treated 
and control groups.
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These results indicate that MMCM-
enhanced MRI as analyzed here can 
be used to evaluate tumor response to 
an angiogenesis inhibitor, PTK787/ZK 
222584, at least for the circumstances of 
this study. Not only can MRI be used to 
measure tumor growth response but data 
also show its potential to detect a useful 
differentiated physiologic response in 
transendothelial permeability. Changes in 
fractional plasma volume were not useful 
or sensitive to treatment but perhaps 
this parameter might become more 
sensitive after longer periods of drug treat-
ment. The more responsive nature and 
higher sensitivity of KPS to anti-angiogenic 
treatment is consistent with the results of 
Pham et al. [16], who also observed sharp 
inhibition of KPS and no change in fPV 
following 1 week of anti-VEGF antibody 
treatment using the same tumor model 
enhanced with albumin-(GdDTPA)
30
 as MR 
con trast agent.
PTK787/ZK 222584 is representative of 
a VEGF tyrosine kinase inhibitor which 
blocks the intracellular mo lecular cascade 
at the receptor phosphorylation step of 
VEGF-mediated angiogenesis. VEGF and 
its receptors are upregulated especially in the early phases of tumor neovascularization. 
VEGF stimulates endothelial cell proliferation and cell migration; any inhibition of VEGF, its 
receptors, or its intracellular molecular cascade mechanism is expected to be associated with 
morphological and/or functional changes in the tumor microvascularization. Indeed, as shown 
in this study and in recent literature reports, using various anti-VEGF drugs, tumor growth 
is slowed signifi cantly [13, 23, 28]. However, tu mor growth is not reported to completely halt or 
to be reversed; cancers treated with VEGF and angiogenesis inhibitors, in general, continue to 
grow slowly, indicating that other factors are also involved. As well as VEGF, other cytokines 
such as basic fi broblast growth factor (bFGF), epidermal growth factor (EGF), and platelet-
derived growth factor (PDGF) stimulate tumor growth and might even play a compensatory 
agonist role when VEGF is inhibited [29]. This compensatory mechanism may be the cause 
for continued tumor growth as ob-served in the present study. Thus, for more complete tu mor 
growth inhibition, a combination of multiple growth factor inhibitors and/or a combination 
with cytotoxic drugs (to suppress the stimulatory effect of tumor cells and tumor-associated 
infl ammatory cells for growth fac tor production) might be necessary.
Fig. 3. T1-weighted axial images after i.v. administration 
of albumin(GdDTPA)30 showing the implanted breast 
cancer (small arrows) pre (a) and post (b) 7 days of 
treatment with PTK787/ZK 222584. A phantom was 
placed in the field of view to correct for temporal 
spectrometer variation (thick arrow)
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VEGF is a multifunctional cytokine. In addition to endothelial cell proliferation, migration, 
and cell surviv al, VEGF has a strong effect on vascular permeability, particularly to 
macromolecular solutes. VEGF is thought to possibly open endothelial pores by loosening 
intercellular junctions or by induction of endothelial fenestrations [30]. The VEGF-induced 
macromolecular hyperpermeability of tumors leads to extravasation of plasma proteins and 
the formation of a gel-like matrix that is considered favorable for new blood vessel growth 
[12]. Thus, a successful inhibition of VEGF or the VEGF-receptor complex should generate a 
decreased microvascular permeability to macromolecules. Yano et al. [28] have shown in an 
experimental lung cancer model that PTK787/ZK 222584 reduces pleural effusions as a func-
tion of reducing the tumor-associated vascular hyperpermeability.
In this study transendothelial macromolecular perme ability (as estimated by KPS assayed 
with dynamic contrast-enhanced MRI within the context of a simple mathematical model) 
decreased slightly in the PTK787/ZK 222584-treated group while a signifi cant increase 
(P<0.05) in permeability values was observed in the control group using either of two 
MMCM. Albumin-(GdDTPA)
30
 has been used successfully as a prototype MMCM to defi ne 
microvascular characteristics in several experimental studies. These include different physio-
logical and pathological conditions such as tumors [24, 31, 32], infl ammation [33, 34], 
myocardial ischemic states [35], and toxin exposure [36]. Aicher et al. [37] demonstrated in 
a mouse fi brosarcoma model that the enhancement of tumors with albumin(GdDTPA)
30
 corre-
sponds to the amount of Evans blue staining with the obvious advantage that the use of this 
MMCM does not require sacrifi ce of the animal. However, the incomplete elimination of the 
gadolinium component of this compound from the body and its potential immunologic re-
sponse discourage its clinical development. USPIO particles, which have been shown to have 
the potential to de fi ne tumor microvessel characteristics [21], are now being tested in human 
clinical trials as an angiographic agent [38, 39] and for the assessment of the reticuloen-
dothelial system [40, 41]. Assuming the regulatory approval of USPIO for clinical use, the 
potential for tumor microvascular characterization might expand their clini cal indications 
and usefulness. USPIO in combination with dynamic MRI and kinetic modeling might prove 
useful for clinical monitoring of tumor therapy, in particular when anti-angiogenic drugs are 
used.
As with all contrast-enhanced MRI (and unlike with computed tomography or nuclear medicine 
methods), ac curate quantitation of tracer concentration is potentially limited by the indirect 
nature of the measured response. In essence we use local water T1 changes to report on 
the contrast agent concentration. The underlying assumption is that water access to the 
tracer moiety does not vary in different tissue settings or compartments, i.e., the effective 
relaxivity of the tracer is contrast. Indeed, given a compartmentalized tracer restricted mostly 
to the intravascular space, the assumption of fast water exchange (i.e., access of all tissue 
water to the tracer), seems likely to be inappropriate. Our group and others have previously 
addressed this issue [26, 27, 42, 43] -the practical conclusion has been to adopt a short TR 
gradient echo sequence, where fPV overestimates are minimized. Thus we adopted such an 
image strategy for the purposes of our investigations, for both candidate tracers.
In conclusion, dynamic MRI enhanced with MMCM and analyzed within the context of a 
simple two-compartment mathematical model of tumor tissue has been applied successfully 
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to monitor effects of an anti-angio genic therapy with a VEGF-receptor tyrosine kinase in-
hibitor. In a clinical setting, transendothelial permeabili ty, estimated here as KPS using MMCM-
enhanced MRI and a simple kinetic model, might serve as a functional vascular parameter to 
follow anti-angiogenesis therapy.
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Abstract
Purpose
To test magnetic resonance (MR) contrast media of different molecular weights 
(MWs) for their potential to characterize noninvasively microvascular changes in an 
experimental tumor treatment model.
Materials and Methods
MD-MBA-435, a poorly differentiated human breast cancer cell line, was implanted into 
31 female homozygous athymic rats. Animals were assigned randomly to a control 
(saline) or drug treatment (monoclonal antibody vascular endothelial growth 
factor (Mab-VEGF) antibody) group. In both groups, dynamic MR imaging (MRI) was 
performed in each animal using up to three different contrast media on sequential 
days at baseline and follow-up examination. The MWs of the contrast media used 
ranged from 557 Da to 92 kDa. Using a bidirectional kinetic model, tumor microvessel 
characteristics, including the fractional plasma volume (fPV) and transendothelial 
permeability (KPS), were estimated for each contrast me dium. These microvascular 
characteristics were compared between drug and control groups and between 
contrast media of different MWs.
Results
Tumors grew significantly slower (P < 0.0005) in the drug treatment group than in 
the control group. Mean KPS and fPV values decreased signifi cantly (P < 0.05) in the 
Mab-VEGF antibody-treated group compared to baseline values using intermediate 
or macromolecular contrast me dia (MMCM), but did not change significantly using 
small molecular contrast media (SMCM). In the control groups, mean KPS and mean 
fPV values did not reach statistical significance for any of the contrast media used.
Conclusion
Therapeutic effects of a Mab-VEGF antibody on tumor microvessel characteristics can 
be monitored by dynamic MRI. Intermediate-size agents, such as Gadomer-17, offer a 
substantial dynamic range and are less limited by imaging precision and therefore 
should be considered a practical alternative to monitor antiangiogenesis treatment 
effects in a clinical setting.
Key Words
magnetic resonance imaging; angiogenesis; vascular endothelial growth factor; 
contrast media; perme ability
Introduction
Tumor neovascularization is crucial for cancer growth and therefore directly infl uences 
patient prognosis. The close relationship between tumor angiogen esis, the metastatic 
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potential of malignant tumors, and, fi nally, patient survival has already been shown in 
numerous studies (1-5). Recent advances in the development of angiogenesis inhibitors 
have led to new forms of tumor treatment. Many drugs are currently under pre-clinical 
investigation to test their individual potential to stop, reverse, or at least slow down 
tumor growth (6-10). Although different drugs target tumor angiogenesis at different 
molecular levels, all of them have in common various morphological changes of the tumor 
microvasculature: these include apoptosis (11,12), changing the microvascular permeability 
by loosening endothelial tight junctions (13), increasing the number of transcellular 
channels or vesiculovacuolar organelles (VVOs) (14), and more.
Dynamic magnetic resonance imaging (MRI), used in combination with macromolecular 
contrast media (MMCM) and kinetic modeling, has shown the potential to monitor changes 
in the tumor microvasculature following antiangiogenic therapy by determination of mi-
crovessel parameters, such as transendothelial perme ability (KPS) or fractional plasma 
volume (fPV) (15-17). In these studies small molecular contrast media (SMCM), i.e., 
gadopentetate (GdDTPA), failed to differentiate reliably between pre- and post-drug-
induced changes of microvessel characteristics (17). Thus, the widely used contrast medium 
GdDTPA does not seem to be promising for the purpose of quantitatively monitoring 
permeability changes in the microvasculature. On the other hand, because the more 
promising prototype MMCM, albumin-(GdDTPA)
30
, is not suited for human use, several 
new MR contrast media are under vigorous development. Despite these research efforts, so 
far it is not known which size or molecular weight (MW) of a particular contrast medium 
would be best suited for tumor microvessel characterization. In particular, an ideal agent 
must show sensitivity to disease progression and responsiveness to interventional therapy, 
of fering a wide dynamic range of target parameters such as permeability, and be amenable 
to clear-cut demonstrations of both positive and negative effects (change to noise ratio). 
Furthermore, for clinical applicability, such clear-cut resolution of permeability changes 
should ideally be derived from only a few minutes of dynamic imaging.
Therefore, the purpose of this study was to investigate different MR contrast media of 
various sizes/MWs in order to defi ne the cutoff size that would be best suited to enable 
a reliable, quick, and precise tumor microvessel characterization, sensitive to changes 
associated with disease progression and therapeutic re sponse. For this purpose, an 
established model of suppressing tumor angiogenesis was used: tumor neovascularization 
was blocked by means of an anti-vascular endothelial growth factor (VEGF) antibody in an 
experimental human breast cancer.
Materials and methods 
Animal Model
The study was performed with the approval of the Institutional Committee for 
Animal Research and in accordance with the guidelines of the National Institutes of 
Health for the care and use of laboratory animals.
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MD-MBA-435, a poorly differentiated human breast cancer cell line with high 
expression of VEGF, was implanted into 31 four-week-old female homozygous athymic 
rats (Harlan, Indianapolis, IN). Approximately 5 X 106 human breast cancer cells, MDA-
MB-435 (Cell Cul ture Facility of the University of California, San Francisco), suspended 
in a total volume of 0.3 mL (1:1 mixed with Matrigel®; Collaborative Biomedical 
Products, Bedford, MA), were implanted in the mammary fat pad using a 25-Gauge 
needle (Abbott Laboratories, North Chicago, Ill). All animals were observed daily at 
the test facility for general appearance, behavior, and tumor growth. Baseline MRI 
was performed when tumors reached a size of 10-15 mm. Before MRI animals were 
anesthetized by intraperitoneal injection of 50 mg/kg sodium pentobarbital. A 25-
Gauge butterfly catheter (Abbott Laboratories, North Chicago, IL) was inserted into the 
tail vein for contrast media injection. Rats were placed on a heated water pad to keep 
the body temperature at physiological levels. Immediately after the MRI examination 
2 mL of saline was injected subcutaneously to avoid dehydration effects.
MRI
Table 1. Contrast Agents Administered (With Molecular Weights 
and Doses)
MRI was performed on animals using an Omega CSI-II superconducting  system  (Bruker 
Instruments,   Fremont, CA) operating at 2 Tesla and equipped with Acustar S-150 self-
shielded gradient coils. The rats were placed supine within a birdcage radio frequency 
coil (inner diameter = 4.5 cm, length = 7.6 cm). A phantom fi lled with diluted 0.01 mmol/
liter gadopentetate dimeglumine was positioned in the fi eld of view (FOV) to correct 
for potential spectrometer variation in each experiment. A series of precontrast images 
were acquired using an axial T1-weighted three-dimensional spoiled gradient-recalled 
(3D-SPGR) sequence with varying repetition times between 30 and 1000 msec; other 
parameters were TE =1.4 msec, one excitation, matrix = 128 X 128 X 16, FOV = 50 X 50 
X 48 mm, slice thickness = 3 mm, and fl ip angle (α) = 90°. These sequences were used 
to calculate baseline relaxation rates (R1 = 1/T1) for blood and tumor by curve fi tting. 
Dynamic contrast-enhanced MRI was performed using a T1-weighted 3D-SPGR sequence 
with a keyhole technique consisting of three initial precontrast and dynamic postcontrast 
images. When small- and medium-size MR contrast media (GdDTPA, ZK159560, ZK181220, 
Gadomer-17) were used, 37 postcontrast images were acquired with high temporal 
resolution using a keyhole technique with the following parame ters: TR = 50 msec, 
TE =1.4 msec, one signal acquired, matrix = 128 X 64 X 8, FOV = 50 X 50 X 48 mm, slice 
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thickness = 3 mm, and acquisition time = 6 seconds per image. When MMCM (albumin-
(GdDTPA)
30
 or SHU555C) were used precontrast images were immedi ately followed by 30 
dynamic 3D-SPGR postcontrast images with a high spatial resolution (matrix = 128 X 128 
X 16, otherwise identical parameters, acquisition time = 1 minute 42 seconds/sequence).
MR Contrast Media
Six different media of different sizes and/or MW have been used in this study (Table 1).
GdDTPA has an MW of 547 and was injected on day 1 at a dose of 0.1 mmol/kg. GdDTPA has 
a distribution volume approximating the extracellular volume, its plasma disappearance 
is rapid and multiexponential, and its elimination occurred exclusively via the kidneys 
(18).
ZK159560 and ZK181220 are prototype MR contrast media developed by Schering AG 
(Berlin, Germany) and differ only by their MWs (ZK159560, 8.7 kDa; ZK181220, 25.9 kDa). 
Both ZK159560 and ZK181220 were injected at a dose of 0.1 mmol/kg.
Gadomer-17 is a prototype MR contrast medium from Schering AG (Berlin, Germany) with 
an MW of 17 kDa (19). Gadomer-17 has 24 Gd complexes bound to each molecule; the 
distribution volume is 0.11 liter/kg. It is eliminated by the kidneys with only 4% remaining 
at 24 hours (19). The toxicity is low with an LD
50
 (lethal dose in 50% of the population) of 
more than 30 mmol/kg in the rat. Gadomer-17 was injected at a dose of 0.1 mmol/kg.
Albumin-(GdDTPA)
30
 is a 92-kDa prototype of a water-soluble MMCM with 6 nm diameter, 
synthesized in our laboratory following the method of Ogan et al (20). Albumin-(GdDTPA)
30
 
has a distribution volume of 0.05 liter/kg (which closely approximates the blood volume) 
and a plasma half-life of three hours in rats, which produces nearly constant enhancement 
of normal tis sues for 30 minutes or longer after injection. Albumin-(GdDTPA)
30
 was injected 
on imaging day 1 at a dose of 0.03 mmol Gd/kg. 
SHU555C (Schering AG, Berlin, Germany) consists of ultrasmall superparamagnetic iron 
oxide (USPIO) particles with a mean core size of 3-4 nm diameter and a total hydrodynamic 
diameter of ~30 nm. The distribu tion volume of SHU555C is 0.04 liter/kg and the acute 
tolerance (in mice, i.v.) is >10 mmol/kg. The R1 (= 1 /T1) of the agent in plasma is 22 second–
1mM–1 Fe and the R2 (= 1/T2) is 65 second–1mM–1Fe (at 20 MHz, 37°C). The mean plasma 
half-life in rats is about one hour, and the particles are taken up by the mononuclear 
phagocyte system. SHU555C was injected 24 hours after the albumin-(GdDTPA)
30
 injection 
at a dose of 2.5 mg Fe/kg.
Experimental Protocol
After the baseline MR examinations, animals were randomly assigned to the drug treat-
ment or control group. Each rat was then imaged with one of the two smaller agents, one 
of the two intermediate agents, and one of the two larger agents (day 0, intermediate; day 
1, small, followed after at least two hours by large). Because of the lack of availability of 
ZK159560 and SHU555C compared to GdDTPA and albumin-GdDTPA, and the prototypical 
nature of the latter two, more animals were imaged with these better-characterized agents 
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than their analogs of similar size category. Physiological sa line (0.2 mL) was injected i.p. 
in rats belonging to the control group; the drug group was treated with an i.p. injection 
of 0.2 mL of monoclonal antibody (Mab)-VEGF antibody (Genentech, South San Francisco, 
CA). The i.p. injections were done on days 1, 4, and 7. The day following the seventh day of 
drug/saline treatment all animals were imaged a second time using the identical protocol 
applied for pretreatment assessment. All ani mals were killed after the second post-
treatment MR examination by an intravenous overdose of 0.3 mL of pentobarbital.
MRI Data and Kinetic Analysis
Images were transferred to, processed, qualitatively examined, and quantitatively analyzed 
on a Sun Sparc Ultra-10 workstation (Sun Microsystems, Mountain View, CA) using the 
MR-Vision Software package (The MR-Vision Co., Menlo Park, CA). In each rat and at each 
time point, regions of interest (ROIs) were defi ned by a semiautomated threshold-based 
method in which the strongly contrast-enhancing pixels on a late postcontrast image 
were selected to represent the tumor periphery. ROIs were also drawn in the phantom and 
in the inferior vena cava (IVC). The dynamic signal responses were corrected for potential 
temporal spectrometer variation by dividing by the signal intensity (SI) of the phantom. 
Postcontrast R1 values were calculated based on the SI and knowledge of precontrast R1 
values for each ROI. Differences between the precon trast and postcontrast R1 values at any 
time (∆R1) were assumed to be proportional to the concentration of the contrast medium, 
either in the blood or in the tissue of interest (21-23). This method of ∆R1 determination is 
limited by the inherent assumption that the fully re laxed SI did not vary signifi cantly on 
pre- and postcon trast SPGR images (23). The ∆R1 data from blood and tumor were used for 
kinetic analysis to estimate the coeffi cient of KPS (mL minute–1 100 cc–1 of tissue) and the 
fPV (mL cc–1 of tissue). In brief, while the initial enhancement of relaxation in a voxel of 
tissue relates to the fractional blood volume, progressive tissue relax ation enhancement 
relates to contrast agent leak from the intravascular to the extravascular compartment. 
Constructing the ratio of tissue relaxation enhance ment to reference vascular relaxation 
enhancement (from the IVC) allows approximate graphical visualization of fPV and 
permeability from the intercept and slope of the plot against time, respectively. Accurate 
estimations incorporating consideration of plasma tracer disappearance and bidirectional 
tracer transport between intra- and extravascular compartments are obtained from two-
compartment bidirectional kinetic modeling.
All data fi tting was performed using a nonlinear least squares numerical approach, 
implemented in Kaleidagraph 3.5 (Synergy Software, Reading, PA). Fit param eters fPV and 
KPS are converted to units of mL/cc tissue (equivalent to the fraction given by the intercept 
of the plot of the ratio of tissue to vascular relaxation en hancement) and mL/100 g/minute 
(manageable units of volume transport per mass of tissue, derived by scaling fi t units of 
tissue to vascular relaxation enhance ment ratio, or fraction, per second, assuming a tissue 
density of 1 g/cc and rescaling from seconds to min utes).
Tumor volumes were calculated by approximate numerical integration: summation of the 
measured tu mor area on each slice, multiplied by the slice thickness (3 mm).
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Statistics
The paired two-tailed Student’s t-test was used to compare mean KPS and fPV values in the 
same tumors pre- and postintervention (drug or control) for each contrast medium. The 
two-tailed paired Student’s t-test was used to calculate differences in the tumor volume 
over time in each rat. P < 0.05 was considered statistically signifi cant.
Results
Table 2. Study Sample Sizes for Each Contrast Agent and Treatment Arm
Implanted tumors grew to a size of approximately 1.5 cm within 14 days. The fi nal study 
population consisted of 31 rats, which were randomly assigned to control or drug-treated 
groups (Table 2).
Taking all animals together, tumor volumes at base line examination were not signifi cantly 
different (P = 0.49) between the drug-treated (1076 ± 763 mm3) and control (777 ± 240 mm3) 
groups. Tumors continued growing in both animal groups, from 777 ± 240 to 2594 ± 1121 
in the control group, and from 1076 ± 763 to 1830 ± 1408 in the drug-treated group. Hence, 
tu mors grew signifi cantly faster (P < 0.0005) in the con trol group (calculated tumor growth 
ratio = 3.3 ± 1.0) than in the drug-treated group (tumor growth ratio = 1.79 ± 0.7).
Mean KPS and fPV values at baseline and at the follow-up examination using all contrast 
media are listed in Table 3 for both groups, drug-treated and control animals. In the Mab-
VEGF antibody-treated group, mean KPS and fPV values decreased signifi cantly (P < 0.05) 
from baseline values using any of the four intermediate or larger-size agent: albumin-
(GdDTPA)
30
, SHU555C, Gadomer-17, or ZK181220. Using smaller agents, ZK159560 and 
GdDTPA, mean KPS and fPV values between pre- and post-treatment exam did not reach 
statistical signifi cance (P > 0.05). In the control groups, mean KPS and fPV values did not 
reach statis tical signifi cance for any of the contrast media used.
Discussion
This study shows that suppression of tumor neoangiogenesis leads to a considerable 
slowdown in tumor growth within one week of treatment. Although the implanted human 
breast cancers continued to grow in both groups, no matter if the animals were treated 
with saline (control group) or a Mab-VEGF antibody (drug group), the tumor growth ratio 
was statistically signifi  cantly (P < 0.0005) smaller in the drug-treated group than in the 
control group.
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VEGF is considered to be one of the most important promoters of tumor neoangiogenesis 
(24-27). VEGF and its receptors are upregulated in early phases of tumor neovascularization, 
thereby stimulating endothelial cell proliferation and migration. Also, VEGF has crucial 
effects on the endothelial wall integrity, gaps and channels within endothelial cells 
are numerically increased, and tight junctions between the cells are loosened. Indeed, 
VEGF, also known as vascular per meability factor (VPF), induces vessel hyperpermeability, 
which leads to an extravasation of plasma proteins and the formation of a matrix that 
is favorable for blood vessel growth (28,29). Thus, inhibition of VEGF is accompanied 
by a decrease in microvascular permeability to proteins and macromolecules and a 
suppression of neoangiogenesis, both facts nicely demonstrated in the present study.
It is clear, however, that the property of microvascu lar permeability must depend upon 
the physical characteristics (size) of the tracer solutes. Whereas SMCM diffuse through 
normal and injured vessel walls, MMCM remain strongly intravascular within normal 
vessels. But as soon as the vessel wall integrity is disrupted—no matter if the underlying 
cause is neoplastic, infl ammatory, or toxic—MMCM diffuse into the interstitial space 
(30-32). Albumin-(GdDTPA)
30 
has been used successfully as a prototype MMCM (≈92 kDa) 
to defi ne microvascular characteristics in several experimental studies (15,33). These 
include different physiological and pathological conditions such as tumors (16,33-35), 
infl ammation (31), myocardial ischemic states (32), wound healing (36), and toxin exposure. 
The incomplete elimination of the gadolinium part of this compound from the body and 
its potential immunologic response, however, hinder its clinical use (20). Recently, USPIO 
particles have been shown in an animal model to have the potential for defi ning tumor 
microvessel characteristics (16). KPS and fPV generated with USPIO correlated strongly 
and statistically signifi cantly (P< 0.01) with albumin-(GdDTPA)
30
-derived KPS and fPV 
values using dynamic MRI and a bidirectional kinetic model (16). However, both albumin-
(GdDTPA)
30 
and USPIO suffer from very low absolute signal en hancement due to very low 
rates of contrast media extravasation. Consequently, long scan observation periods are 
necessitated to observe signifi cant enhance ment above the image noise level.
Table 3. Mean Permeability Values (KPS) and Fractional Plasma Volume (fPV) Using Different Contrast 
Media for the Control (Saline) Drug-Treated (Mab-VEGF antibody) Groups
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Using SMCM, like GdDTPA (MW = 547) and ZK159560 (MW = 8.7 kDa), for determining KPS 
and fPV, no statis tically signifi cant correlation between pre- and post-Mab-VEGF antibody-
treated subjects was found, largely due to the very rapid and very pronounced signal 
enhancement observed, which precluded simple kinetic modeling, yielding estimates of fPV 
and KPS with high uncertainties and large within group standard deviations. In some sense, 
kinetic modeling of dynamic enhancement with such agents can be considered to be limited 
by ceiling effects, in contrast to the fl oor limits associated with albumin-Gd-DTPA and USPIO. 
Hence, the development of 
intermediate- size agents 
might facilitate conside-
rably the monitoring and 
cal- culation of effects of 
changes in KPS following anti- 
angiogenic therapy.
Indeed, using Gadomer-17, 
in comparison to GdDTPA 
and albumin-GdDTPA, Su et 
al (37) have demonstrated 
MR determination of 
microvascular permeability 
in an N-ethyl-N-nitrosourea 
(ENU) model of breast cancer 
in the rat. In their study, they 
show that the intermediate 
permeability of Gadomer-
17 was able to distinguish 
low-grade from high-grade 
cancers, but unable to resolve 
benign from low-grade, 
because of permeability 
range overlap. GdDTPA failed 
to differentiate between low- 
and high-grade malignant 
tumors. Albumin could 
differentiate both, high- 
from low-grade malignant 
tu mors and benign from 
malignant tumors, but its 
low contrast-to-noise ratio 
raised major concerns. 
This study in fact shows that 
intermediate-size con trast 
media with an MW in the 
Figure 1. a: ∆R1 ratios in tumors pre- (0) and post- (  ) Mab-VEGF 
antibody treatment over one week demonstrate sub stantial signal 
enhancement within five minutes using an intermediate agent, 
represented here by Gadomer-17. b: In contrast, using MMCM 
(i.e., albumin-(GdDTPA)30) imaging precision is limited because of 
very small signal enhancement, comparable to image noise levels.
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range of 20-30 kDa also allow tumor microvessel characterization, in a therapy model, 
in a fashion similar to that in larger macromolecules. Both medium-size contrast media, 
Gadomer-17 (MW = 17 kDa) and ZK181 (MW = 25.9 kDa), revealed a statistically signifi cant 
difference (P < 0.05) in perme ability and fPV values between pre- and post-treatment 
examinations. 
Additionally, resolution of such treatment effects was in fact facilitated using Gadomer-17 
and  ZK181220 by the greater degree of enhancement, or rate of contrast media extra-
vasation, compared to the prototype MMCM. In such a way, imaging precision did not 
appear to limit permeability estimation to the same extent as seen with the low leak 
rates and very small signal enhancement of MMCM, comparable to image noise levels. 
Consequently, for MMCM contrast media leakage over a period of up to one hour is 
generally required for unambiguous observation of progressive signal en hancement (as 
opposed to mere image noise). Intermediate agents demonstrated substantial (~ 100%) 
signal enhancement within fi ve minutes. This observation alone is of considerable 
practical utility when translating to a clinical setting (Fig. 1).
Clarity of resolution of 
treatment effects with Ga-
domer-17 and ZK181220 can 
be further documented by 
considering individual instead 
of group effects. In all seven 
rats treated with Mab-VEGF 
antibody, Gadomer-17-KPS esti- 
mates decrease over the 
treatment period (Fig. 2). While 
group comparison showed a 
signifi cant decrease in mean 
KPS for albumin-(GdDTPA)
30
, 
there was not a similar 100% 
concordance observed in the 
individual data, in which 
only 76% of cases showed a decrease in KPS. In general, as can be seen from Fig. 3, there 
is an approximately exponential decrease in KPS values with increasing MW. In fact, the 
correlation co effi cient of ln(K) vs. MW is r = -0.98, indicating a strong negative correlation 
when considering the pooled pre-treatment values from both control and treated groups. 
This can be rationalized intuitively if one considers the impediments to larger molecule 
transport, including slower diffusion (to the extent that diffusion is a mechanism), greater 
sensitivity to elevated tumor interstitial pressure (to the extent that convection is the 
transport mechanism), and reduced access to fenestrae in the vascular wall.
The intermediate agents were not, however, so leaky (compared to GdDTPA, for example) 
that documentation of progressive enhancement was rendered impractical because of 
high fi rst-pass extraction fraction (~50% for GdDTPA). However, both intermediate con trast 
media did overestimate fPV (as did the SMCM) when compared to the bigger reference 
MMCM, albumin-(GdDTPA)
30
 and SHU555C. It is possible that this overestimation can in 
part be attributed to partial fi rst-pass extravasation.
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Figure 2. Individual permeability values, KPS µL minute–1 100 
cc–1 of tissue) before and after one week of drug treatment in 
the group imaged with Gadomer-17.
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There are three possible explanations for the apparent lack of utility of permeability 
assessment using SMCM to document treatment success in this study: 1) insuffi cient image 
acquisition rates to capture the more rapid dynamics; 2) inappropriate modeling, violating 
extraction fraction assumptions; and 3) biological irrelevance, i.e., KPS to SMCM may not 
in fact be affected by Mab-VEGF antibody action. Although there have been a number of 
reports of the successful use of dynamic contrast-enhanced MRI for characterizing tumor 
microvasculature phenomena in clinical patients, most of these methodologies do not 
rely on the elucidation of a parameter with physiologically specifi c interpretation (such 
as microvascular permeability). Rather, they rely on observed or derived descriptors of 
signal change, typically sensitive to a combination of perfusion, vas cular volume, and 
microvascular permeability. Examples include the use of fi rst-pass T2*-based imaging 
(measuring the peak change in 1 /T2* observed) (38) or constructions such as the initial 
area under the curve (IAUC) (39). Both can be demonstrated to be robustly determined 
and of some clinical utility, but lack the above physiologically specifi c interpretation and, 
as such, are subject to a number of potential confounds (e.g., systemic changes in cardiac 
output or blood pres sure as well as local perfusion alterations that may be incidental to 
the mechanism of action of the drug).
In conclusion, the quantitative use of microvascular permeability estimation as an index 
of antiangiogenic therapeutic effi cacy is constrained by two limits. If the MW of the tracer 
is too small, estimates of fPV and KPS have high uncertainties and true values are usually 
overestimated considerably. If, on the other hand, the MW is too big, contrast media 
enhancement of tumors is confounded by image noise and diffi cult or even impossible to 
determine. 
Figure 3. Pooled pretreatment (precontrol) KPS values as a function of MW indicate an approximately 
exponential decrease in KPS with MW. The correlation coeffi cient between ln(K) and MW is r = 
-0.98.
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A successful compromise appears delivered by intermediate-size agents, such as Gadomer-
17, whereby a substantial dynamic range of permeability offers clear delineation of 
treatment effects, much less limited by imaging precision, and thus practically requiring 
shorter observation times to observe signifi cant en hancement. 
In summary, therapeutic effects of a Mab-VEGF antibody on tumor microvessel 
characteristics can be monitored by dynamic MRI. Intermediate-size agents, such as 
Gadomer-17, offer a substantial dynamic range and are less limited by imaging precision 
and therefore should be considered a practical alternative to monitor antiangiogenesis 
treatment effects in a clinical setting.
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Abstract
Purpose
To evaluate the diagnostic and prognostic potential of a new protein-binding contrast 
medium, B22956/1, for quantitatively characterizing tumor microvessels by MRI and 
monitoring response to antiangiogenic therapy.
Materials and Methods
Dynamic contrast-enhanced MRI (DCE-MRI) was performed in an experimental cancer 
model with the use of the novel protein-binding agent B22956/1, a low molecular contrast 
agent (ProHance™), and a macromolecular contrast medium, albumin-(Gd-DTPA). MDA-
MB-435, a human cancer cell line, was implanted in 22 athymic rats. Animals were assigned 
randomly to a control (saline) or drug-treated (Avastin™) group. MRI was performed at 
baseline and after nine days of treatment. The transendothelial permeability (KPS) and the 
fractional blood volume (fBV) were estimated from the kinetic analysis of dynamic MR 
data using a two-compartment model. Tumor growth was also measured from volumetric 
MRI.
Results
Tumors grew more slowly, although not signifi cantly (P = 0.07), in the drug-treated 
group. The KPS determined for B22956/1 decreased signifi cantly in the drug-treated group 
compared to baseline (P < 0.05), and progressed signifi cantly in the control group. However, 
no signifi cant changes were resolved with the use of ProHance or albumin-(Gd-DTPA).
Conclusion
With the use of appropriate contrast media, the therapeutic effects of an anti-VEGF 
antibody on tumor microvessels can be monitored by dynamic MRI. The dynamic range 
of permeability to B22956/1, and the sensitivity to change of this parameter suggest a 
potential application in the clinical setting. 
Key Words
magnetic resonance imaging; tumor angiogenesis; microvascular permeability; contrast 
agent; therapy  
Introduction
Angiogenesis, the process whereby new blood vessels are formed from preexisting 
vasculature, plays a pivotal role in the development, growth, and metastasis of malignant 
tumors (1,2). Several growth factors have been identifi ed as possible regulators of 
angiogenesis (3). One of these growth factors, vascular endothelial growth factor (VEGF), 
a cytokine that is present in various human tumors and a potent inducer of vascular 
permeability, is considered to play an important role in tumor angiogenesis (4-7). The 
expression of VEGF and its receptors has been demonstrated to correlate with the degree 
of tumor vascularization, and has been proposed as a prognostic factor in patient survival 
(8). The suppression of tumor angiogenesis has become a promising strategy in cancer 
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treatment. Several experimental studies have indicated that the inhibition of VEGF 
decreases tumor neovascularization and inhibits primary tumor growth and metastasis 
(5,8-17). In the current study, an intraperitoneally administered, humanized anti-VEGF 
antibody (Avastin™, rhu-MAb-VEGF; Genentech Inc., South San Francisco, CA) was used to 
directly inhibit VEGF.
Magnetic resonance imaging (MRI) offers investigators a possible means of noninvasively 
characterizing tumors. The ability of dynamic MRI enhanced with macromolecular 
contrast agents to quantitatively defi ne the permeability of tumor microvessels has 
been shown in several experimental models (18-20). The potential of MRI to monitor the 
effects of antiangiogenesis therapy with this humanized anti-VEGF antibody (Avastin) 
has also been demonstrated (21,22). However, the reference contrast medium used in 
these studies, albumin-(gadolinium (Gd)-DTPA), is considered unsuitable for clinical use 
due to its potential immunogenic properties and prolonged retention in the body (23,24). 
Additionally, long scan times have been necessary to resolve progressive extravasation 
of the albumin-(Gd-DTPA) molecule, and large population sizes have been necessary to 
demonstrate statistically signifi cant effects. 
Recently, several MR contrast media were studied with respect to their diagnostic potential 
for quantitatively describing tissue microvessels. These contrast agents include ultrasmall 
superparamagnetic iron oxide particles (USPIO) such as NC100150 (Clariscan; Nycomed 
Amersham, Oslo, Norway) (25) and SHU 555C (Resovist; Schering AG, Berlin, Germany) (26), 
and blood pool agents such as MS-325 (Angiomark; Schering AG, Berlin, Germany) (27) and 
P792 (Vistarem; Guerbet, Aulnay-sous-Bois, France) (28). However, many of these agents 
fail to resolve treatment effects, require extended imaging periods to achieve adequate 
“leak,” or offer characterization only at the expense of conspicuity.
The purpose of the current study was to evaluate the use of a novel protein-binding 
contrast agent, B22956/1 (gadocoletic acid trisodium salt), for MRI assessments of 
tumor microvascular characteristics in an experimental human breast cancer model. 
Microvascular characteristics, transendothelial permeability, and fractional blood volume 
derived from the kinetic analysis of data acquired with dynamic MRI enhanced with 
B22956/1, ProHance (a prototypical small molecular agent that has been found in many 
studies to be less amenable to physiologically-specifi c kinetic modeling and resolution 
of treatment effects), and albumin-(Gd-DTPA) (a prototypical macromolecule that has 
been demonstrated to resolve treatment effects, but only with extended (approximately 
one hour) scan times, and is unlikely to proceed clinically due to incomplete or slow 
elimination and potential immunogenicity) were compared and correlated with tumor 
growth. In particular, the microvascular permeability of the contrast agents was studied 
as a marker of disease progression and response to antiangiogenesis therapy with the 
recombinant humanized monoclonal antibody to VEGF (Avastin; Genentech Inc., South 
San Francisco). The hypothesis of this study was that permeability to B22956/1 may be 
a more sensitive measure of disease progression and/or response to antiangiogenesis 
therapy than permeability to either low-molecular-weight agents, such as ProHance, or 
covalently bound albumin-(Gd-DTPA), a prototype macromolecular contrast medium.
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Materials and methods 
Animals and Tumor Models
The study was conducted with the approval of the committee for animal research at our 
institution, and conformed with the guidelines of the National Institutes of Health for the 
care and use of laboratory animals. The human cancer cell line MDA-MB-435 (Cell Culture 
Facility, University of California-San Francisco) was used for tumor induction. This cell line 
is representative of human breast cancer, and although current debate is challenging its 
origin as a melanocyte, recent studies have continued to consider its origin as breast cancer 
(29). Of importance for the purposes of this study, this cell line is known to express VEGF. 
We implanted approximately 5 x 106 tumor cells, suspended in a total volume of 0.3 mL 
(one part sterile saline: one part Matrigel® (Collaborative Biomedical Products, Bedford, 
MA)) in the mammary fat pad of 22 4-week-old female homozygous athymic rats (Harlan, 
Indianapolis, IN), using a 25-gauge needle. The animals were inspected daily for tumor 
growth and general appearance.
MRI
MRI was performed with the use of a Bruker Omega CSI-II magnet (Bruker 
Instruments, Fremont, CA) operating at 2 Tesla. This system is equipped with Acustar 
S-150 (Bruker Instruments, Fremont, CA) self-shielded gradient coils (±20 G/cm, 15-
cm inner diameter). The animals were placed supine in a birdcage radiofrequency 
coil with a length of 7.6 cm and an inner diameter of 4.5 cm. A phantom fi lled with 
diluted 0.01 mmol/liter gadopentate dimeglumine was included in the fi eld of view 
(FOV), close to each animal, to allow correction for potential spectrometer variation.
Precontrast T1 mapping was performed by means of a single-slice inversion recovery (IR) 
snapshot fast low-angle shot (FLASH) sequence (29) with the following parameters: TR = 3 
msec, TE =1.5 msec, one acquisition, FOV = 55 x 55 mm, matrix = 64 X 64, slice thickness = 3 
mm, and fl ip angle = 5°. Per slice, nine images at nine different IR times (TI = 100, 400, 700, 
1000, 1300, 1600, 1900, 2200, and 2500 msec) were acquired. A total of eight slices were 
obtained. After the TI, the data were acquired with a snapshot FLASH read-out scheme 
with centric reordering to maintain the appropriate T1 contrast for the center of the k-
space. This sequence was used to calculate baseline longitudinal relaxation rates (R1 = 1/
T1) for the tumors by curve- fi tting (31).
We performed dynamic contrast-enhanced MRI (DCE-MRI) using an axial T1-weighted, 
three-dimensional, spoiled gradient-recalled (SPGR) sequence with a keyhole technique 
consisting of three initial precontrast and 37 dynamic postcontrast images with the 
following parameters: TR = 30 msec, TE = 4.83 msec, one acquisition, FOV = 55 x 55 x 48 mm, 
keyhole acquisition matrix =128 x 16 x 8 (the keyhole technique achieves high temporal 
resolution by only partially updating imaging data with high spatial frequencies, or 
substituting detailed structures from a slower full-matrix scan), effective slice thickness = 
3 mm, and fl ip angle = 90°. The temporal resolution was six seconds per three-dimensional 
dataset. The 40 high-temporal-resolution keyhole images were followed by 30 full-matrix, 
dynamic, three-dimensional SPGR postcontrast images (matrix = 128 x 128 x 16) with an 
acquisition time of one minute per volume of 16 slices. The total examination time was 35 
minutes.
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Experimental Protocol
MR examinations were performed over a two-day period at baseline (when the tumor 
diameter was approximately 15 mm) and again over a two-day period after nine days of 
treatment (or placebo). 
Before the MRI sessions, the animals were anesthetized by intraperitoneal administration 
of pentobarbital sodium (50 mg/kg body weight). Analgesia was achieved by intraperitoneal 
injection of 0.03 mg/kg buprenorphine hydrochloride (Buprenex®; Reckitt & Col man 
Products, Hull, UK), which is an opiate. A 25-gauge butterfl y cannula (Abbott Laboratories, 
North Chicago, IL) was inserted into a tail vein for contrast medium injection. The animals 
were placed on a heated water pad to maintain the body temperature at physiological 
levels, and 2 mL of saline were injected intravenously to avoid dehydration effects that may 
occur after anesthesia. After the baseline MR examinations, the animals were randomly 
assigned to either the drug treatment group or the control group. The drug-treatment group 
was treated with a recombinant humanized monoclonal anti-VEGF antibody (Avastin, 
rhuMAb-VEGF; Genentech Inc., South San Francisco, CA), injected intraperitoneally at a 
dose of 1 mg every third day, for a total of three doses. The control group received saline, 
also injected intraperitoneally (0.1 mL) every third day, for a total of three doses. On the 
day following the last injection of Avastin or saline, all of the animals were imaged a 
second time by the same protocol applied for the baseline assessment. After a second MR 
examination was completed on the following day, all of the animals were killed by an 
intravenous overdose of 0.3 mL pentobarbital.
MR Contrast Media
B22956/1, a novel protein-binding contrast medium (Bracco, S.p.A., Milan, Italy) (32), is a 
Gd chelate with a low molecular weight (molecular mass = 1059 Dalton). B22956/1 is the 
trisodium salt of a polyaminocarboxylate Gd complex linked to deoxycholic acid through a 
fl exible spacer (33), and it has a high affi nity for serum proteins (94% for a 0.5 mM solution 
in Seronorm® for human serum albumin, and 84% for rat serum albumin). The relaxivity 
of this contrast agent is 27 mM–1 second–1 at 20 MHz in human serum.
B22956/1 was injected on imaging day 1 at a dose of 0.1 mmol/kg. Gadoteridol (ProHance) 
was injected on day 2, 24 hours after the B22956/1 injection, at a dose of 0.1 mmol/kg. 
Albumin-(Gd-DTPA) is a prototype of a water-soluble macromolecular contrast medium 
with a molecular weight of 92,000 Dalton. It has a distribution volume of 0.05 liter/kg and 
a plasma half-life of three hours in rats, which produces nearly constant enhancement 
of normal tissues for 30 minutes or longer after injection (34). Albumin-(Gd-DTPA) was 
also injected on day 2, four hours after the injection of ProHance, at a dose of 0.1 mmol 
Gd/kg. At the time albumin-(Gd-DTPA)    was    injected,    the    tumor    signal potentially 
infl uenced by the previous administration of ProHance had returned to baseline values. 
On days 9 and 10, similar imaging was performed (B22956/1 on day 9, and Prohance and 
Albumin-GdDTPA on day 10, four hours apart).
Kinetic Analysis of Dynamic MRI Data
The MR images were transferred, processed, and analyzed with the use of a Sun SPARC 
10 workstation (Sun Microsystems, Mountain View, CA) and an image analysis program 
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(MRVision Co., Menlo Park, CA). Signal intensity (SI) values for each time point were 
obtained from multiple (three to six) regions of interest (ROIs) defi ned by a threshold-based 
semiautomated selection of strongly enhancing pixels on a late postcontrast image. SIs for 
the blood within the inferior vena cava (IVC), the phantom, and the tumor periphery were 
measured in the central section of the imaging volume. The tumor periphery was defi ned as 
the peripheral zone of strong contrast enhancement (usually 1-2 mm thick). Corresponding 
ROI measurements were made in each of three adjacent slice images, each of which 
contained a minimum of 30 pixels, and were averaged. We corrected the mean SIs from the 
tumors and the blood in the vena cava for potential spectrometer variation over time by 
dividing the SI of each ROI by the SI from the phantom. Precontrast longitudinal relaxation 
rates R1 (1/T1) estimates for tumors were obtained by curve-fi tting based on nine sets of 
IR snapshot FLASH images. The precontrast R1 value for IVC blood was assumed to be 0.724 
(1/1.38) based on numerous previous measurements in rat blood (31). Postcontrast R1 values 
were calculated based on the observed SIs and knowledge of pre contrast R1 according to:
The difference between the postcontrast R1 value at any time point and the precontrast R1, 
∆R1 (t) is assumed to be directly proportional to the concentration of the contrast medium, 
in either the blood or the tissue (31,35). Although this assumption is limited in the presence 
of intermediate or slow water exchange, previous studies (31,35) suggested that this level 
of approximation is nonetheless acceptable, provided that a short TR (30 msec in this case) 
is used.
We used the ∆R1 data from blood and tumor for kinetic analysis to estimate the 
transendothelial permeability (KPS, mL • minute–1 100 g–1 tissue) and the fractional blood 
volume of the tumor tissue (fBV,%) using a two-compartment, kinetic model (35-39). In 
this model, a biexponential function fi tted to the ∆R1 data from blood was used as an 
input function for the blood response in the tumor tissue. The ratio of ∆R1 tumor/∆Rl 
blood, plotted against a “pseudo time,” was used to fi t a straight line to the MR data. 
Pseudo-time can be calculated (39) from the integral of the contrast agent volume that has 
passed from time zero to the current time, divided by the instantaneous contrast agent 
concentration. The slope of the curve approximated the transendothelial permeability KPS, 
and the intercept represented the fractional blood volume. The pseudo-time related to the 
time required for a constant unit of intravascular contrast medium to pass. The linearity of 
this plot (determined from linear regression) implied the validity of neglecting the refl ux 
of contrast medium to the intravascular space over this time period, and justifi ed the 
use of the simpler unidirectional model. We calculated tumor volumes by summing the 
measured tumor area on each slice, multiplied by the slice thickness (3 mm).
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Table 1.
Statistics
A paired two-tailed Student’s t-test was used to compare mean values of KPS and fBV values 
in the same tumor before and after therapy (drug or control) for each contrast agent. The 
same statistical test was used to compare changes in tumor volume over time in each rat. 
An unpaired two-tailed Student’s t-test was used to compare mean values for KPS and fBV 
between the control and the treated groups. A P-value of < 0.05 was considered statistically 
signifi cant.
Results
The tumors grew in all implanted animals within 14 days. MRI was completed successfully 
in all 22 animals (11 controls and 11 drug-treated). 
There was no signifi cant difference (P = 0.11) between groups with respect to tumor 
volume at baseline: 3.24 ± 0.55 cm3 (mean ± SD) in the drug treatment group, and 4.52 
± 0.64 cm3 in the control group. At the second MRI examination following nine days of 
treatment, mean tumor volume had increased signifi cantly in both groups (P < 0.05), to 
5.86 ± 1.20 cm3 in the Avastin-treated group, and 9.84 ± 1.28 cm3 in the control group. The 
tumors grew signifi cantly more slowly (P > 0.05) in the drug-treated group, as measured 
by the difference between mean tumor volume at follow-up examination and mean 
tumor volume at baseline (2.62 ± 0.79 cm3) compared to the control group (5.32 ± 0.77 cm3). 
However, the tumor volume ratio between baseline and follow-up examinations in the 
drug-treated group (1.76 ± 0.17) did not reach a statistically signifi cant difference (P = 0.07) 
from the control group (2.27 ± 0.24). This minor disparity is probably attributable to the 
extra uncertainty introduced in the “ratio” construction, in combination with a relatively 
small sample size. The mean values for KPS and fBV obtained in the pre-and post-therapy 
studies for each contrast agent are shown in Table 1. Using B22956/1, the mean KPS values 
at baseline were for the drug group 0.131 ± 0.026 mL • minute–1 100 g–1, and 0.148 ± 0.020 
mL • minute–1 100 g–1 for the control group (P = 0.59). At the follow-up examination, the 
mean KPS values decreased signifi  cantly (P < 0.05) in the anti-VEGF-treated group (0.076 
± 0.025 mL • minute–1 100 g–1) compared to baseline, and increased signifi cantly in the 
control group to 0.236 ± 0.040 mL • minute–1 100 g–1 (P < 0.05). In addition, KPS post values 
were signifi cantly greater in the control group (0.236 ± 0.040 mL • minute–1 100 g–1) than 
in the drug-treated group (0.076 ± 0.025 mL • minute–1 100 g–1, P < 0.05) (Figs. 1 and 2). 
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Making the same comparison for 
ProHance, the mean KPS values at 
baseline were 2.434 ± 1.214 mL • 
minute–1 100 g–1 in the drug group, 
and 1.211 ± 0.408 mL • minute–1 
100 g–1 in the control group (P = 
0.33). It is important to note the 
increased coeffi cient of variation 
in the Prohance data compared 
to B22956/1. At the follow-up 
examination, KPS assessments 
with Prohance did not change 
signifi cantly in the drug-treated 
(2.749 ± 1.081 mL • minute–1 100 
g–1) (P > 0.8) or con trol (1.987 ± 
0.736 mL • minute– 100 g–1) (P > 
0.3) groups (Fig. 3). The difference 
in order of magnitude of the Kps 
between Prohance and albumin-
GdDTPA can largely be attributed 
to their molecular size (500 Da vs. 
92 kDa). Previous studies have 
shown that Kps decrease with 
MW. 
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Figure 1. Dynamic enhancement using 
B22956/1. a: Baseline. Six images 
obtained before and after B22956/1 
injection (pre, + 10 seconds, 
+5 minutes, +10 minutes, +20 
minutes, and +35 minutes). b: Nine 
days after treatment with Avastin. 
Signal enhancement from the rim 
region of the tumor (arrows) plotted 
as a function of plasma-clearance-
corrected “pseudo-time.” (c) Before 
and (d) after Avastin treatment. 
Progressive enhancement is clearly 
reduced post-Avastin treatment.
c
d
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With albumin-(Gd-DTPA), the mean KPS values at baseline were 0.007 ± 0.004 mL • minute–1 
100 g–1 in the drug group, and 0.008 ± 0.003 mL • minute–1 100 g–1 in the control group (P 
= 0.88). Albumin-(Gd-DTPA) also failed to demonstrate a signifi cant reduction in KPS as a 
consequence of Avastin therapy (0.008 ± 0.003 vs. 0.007 ± 0.004 mL • minute–1 100 g–1, P > 
0.8), although KPS tended (P = 0.18) to be lower than in the control group (0.014 ± 0.004 mL 
• minute–1 100 g–1) (Fig. 4). Again, the limitation of effect resolution with albumin might be 
expected from the large coeffi cients of variation.
The mean fBV values (between groups) for all three contrast agents were not signifi cantly 
different at baseline, nor was there any evidence of signifi cant change with either drug or 
placebo treatment. However, con sistent with previous studies using a similar methodology, 
we found that small molecules such as Prohance lead to overestimation of fBV and can 
better be interpreted in terms of a distribution volume that includes extravascular space. It 
appears that the unbound form of B22956/1 also undergoes a certain rapid extravasation 
leading to overestimation of fBV compared to albumin-GdDTPA, which more faithfully 
represents the vascular fraction.
Discussion
With DCE-MRI, one can quantitatively assess certain properties of tumor tissue, such as 
capillary permeability and blood volume, and analyze the kinetics of the distribution 
of the contrast medium in the tissue. These microvascular characteristics are estimated 
from kinetic analyses of dynamic 
enhancement data, with simple 
models of the tissue represented 
as a compartmentalized system
(36-39).  Usually, two compart-
ment tissue models (representing 
the blood plasma and the extra-
vascular extracellular space) 
are used. The contrast agent 
concentration, modeled as a 
function of time, can be derived 
from MR SI data, assuming 
that changes in longitudinal 
relaxation rates R1 (1/T1) after 
administration of the contrast 
medium are proportional to the 
contrast agent concentration, 
according to:
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Figure 2. Transendothelial permeability (KPS in ml • minute–1 
100 g–1 tissue) at baseline and follow-up examination after 
saline (control) or Avastin treatment, based on enhancement 
with B22956/1.
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where C
t
 is the tissue concentration of the contrast agent, and r1 is a constant of 
proportionality, known as the relaxivity (mM–1 second–1). Based on the observed MR SIs, 
these changes in R1 are calculated accordingly to Eq. [1]. Thus, the increased enhancement 
can be translated to contrast agent concentration and quantifi ed by kinetic modeling to 
yield estimates of microvascular characteristics. By measuring these functional parameters, 
one can obtain an accurate, noninvasive, quantitative description of the microcirculation 
of individual tumors. Following up the MRI-derived estimates of the microvascular 
characteristics provides a tool for in vivo monitoring of tumor response to therapy.
Although the tumors treated 
with anti-VEGF antibody 
also grew over nine days of 
treatment, they grew more 
slowly (P = 0.07), as indicated 
by the tumor growth rates. 
The difference between mean 
tumor volume at follow-
up examination and mean 
tumor volume at baseline was 
signifi cantly (P < 0.05) higher 
in the control group compared 
to the drug-treated group, but 
it lost its signifi cance after it 
was normalized to the mean 
tumor volume at baseline. The 
relatively small (N = 11) number 
of experiments (as well as the 
extra uncertainty introduced 
by the mathematical pro-
cess of normalization, or 
division) probably explains 
the lack of signifi cance of 
the difference in tumor growth rates. This result is in agreement with several other 
studies that indicated that treatment with various anti-VEGF drugs is associated 
with a signifi cant reduction in tumor growth rate (5,9-12,14-17,21). However, tumor 
growth has not been reported to be completely stopped or reversed. Malignant tumors 
treated with angiogenesis inhibitors continue to grow slowly, indicating that other 
factors are probably involved. Cytokines such as basic fi broblastic growth factor (bFGF), 
epidermal growth factor (EGF), and platelet-derived growth factor (PDGF) also play a 
role in stimulating tumor growth, and may be responsible for the observed continued 
tumor progression by a compensatory agonist mechanism when VEGF is inhibited (40).
Data from this study indicate that the effects of antiangiogenesis treatment can be 
successfully monitored by MRI. Dynamic MRI enhanced with B22956/1 defi ned signifi cant 
declines in the microvascular permeability of experimental human breast cancer as a result 
of a nine-day therapy with an anti-VEGF antibody. The tumor microvascular permeability 
to B22956/1 decreased signifi cantly (P < 0.05) compared to baseline in the animal group 
Figure 3. Transendothelial permeability (KPS in ml • minute–1 
100 g–1 tissue) at baseline and follow-up examination after saline 
(control) or Avastin treatment, based on enhancement with 
Prohance.
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treated with anti-VEGF antibody. A decline of KPS was observed in eight of 11 (73%) drug-
treated animals, but in only two of 11 (18%) animals in the placebo group. This difference 
in response was statistically signifi cant (chi test: P < 0.05). Conversely, only three of 11 of 
the drug-treated animals demonstrated an increase in KPS, compared to nine of 11 control 
animals. The fact that a small fraction (27%) (three of 11 animals) showed an increase in KPS 
values after drug therapy may play a role in a clinical setting, allowing the identifi cation and 
assessment of nonresponders to therapy (and thus candidates for alternative treatment). 
It may also refl ect a sampling error in comparing ROIs nine days apart, or an insuffi cient 
amount or duration of drug 
therapy. Dynamic imaging 
with Prohance, a low mole-
cular weight contrast medium, 
did not resolve any signifi cant 
changes in the microvascular 
characteristics in either the 
drug-treated or the control 
group. Furthermore, with 
albumin-(Gd-DTPA), proto-
type macromolecular con-
trast medium, no signi-
fi cant declines in micro- 
vascular permeability were 
demonstrated following the 
antiangiogenesis therapy.
Our results are in general 
agreement with previous 
studies (18,41). This suggests 
that small molecular contrast 
media are not appropriate for 
detecting abnormal micro-
vessel permeability outside the central nervous system, because such con trast agents diffuse 
unrestrictedly from the blood to the extravascular space through the endothelium of both 
normal vessels and tumor vessels (42-44). However, unlike previous experiments by our group, 
using the same tumor model as in the current study (21) or an intraperitoneally-growing ovarian 
tumor (22), no signifi cant reduction of microvascular permeability to albumin-(Gd-DTPA) was 
resolved as a result of rhuMab-VEGF treatment. This may be attributed to the smaller sample 
size, or, more likely, the shorter scan times (35 minutes) used in the current study, which did 
not permit adequate contrast agent extravasation for robust permeability determination. This 
discrepancy highlights a potential diffi culty of using a large (92,000 Dalton) tracer in such a 
model—namely, the demands on imaging precision and examination duration (to achieve an 
adequate “effect-to-noise ratio”)—when trying to distinguish between low permeability values 
(this can be considered a “fl oor” effect of near-zero permeability values). In any case, it is clear 
that individualized decision-making will require more sensitive determinations of physiologic 
parameters than can be achieved with conventional or prototypical macromolecular contrast 
media. B22956/1 offers one potentially clinically viable alternative.
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B22956/1, a research product of Bracco S.p.A., is a new Gd-based blood-pool contrast 
medium with a high affi nity for serum proteins. Its potential for angiographic imaging 
and three-dimensional MR pulmonary perfusion was recently demonstrated in an 
experimental model of pulmonary embolism (33). To our knowledge, B22956/1 has not 
been previously tested for its ability to characterize tumor microvessels. The behavior of 
the relatively low-molecular-weight agent B22956/1 as a blood-pool contrast medium 
can be explained by its binding with serum proteins. B22956/1 bound to serum albumin, 
similar to macromolecular contrast media (as used as prototypical references in this study), 
will selectively leak through the endothelium of malignant tumors into the extravascular 
extracellular fl uid. In this study, B22956/1 demonstrated a number of favorable 
imaging characteristics. In a short examination time, substantial (but, importantly, not 
overwhelming) progressive enhancement was observed, allowing clear visualization 
of the effects of vascular permeability and changes thereof. Furthermore, over a 5-10-
minute period, bidirectional kinetic modeling was reduced to the simpler special case of 
unidirectional transport (revealed by the linearity of the ∆R1 ratio vs. pseudo-time plots). 
This is of considerable advantage in pixel-wise mapping, where computation essentially 
reduces to the analytic linear regression (in contradistinction to typical nonlinear least 
squares approaches). Finally, the dynamic range of permeability changes observed spanned 
a wide range, rendering observation of progressive disease and the permeability-reducing 
effects of successful antiangiogenic therapy readily resolved.
The relative roles of free and bound B22956/1 in the observed signal and relaxation rate 
enhancement dynamics cannot be fi nally assessed at this point. In rat plasma, in contrast 
to human plasma, a sizable proportion of B22956/1 is in the free state. One might expect 
this free fraction to diffuse readily across the endothelium and to bind again to serum 
albumin in the interstitial space of the tumor, gaining again high relaxivity in the process. 
On the vascular side, equilibrium levels of the free ion would quickly be reestablished 
by dissociation of the chelate-albumin complex. The net effect of this would have to be 
an observed signal enhancement in tumor tissue, as well as an enhanced relaxation rate 
ratio, both peaking soon after administration of B22956/1, refl ecting concentration of 
extravasated con trast agent and interstitial albumin in tumor tissue. However, our results 
show that this is clearly not the case. Thus, to explain the results, we have to hypothesize 
that transendothelial diffusion and/or mixing in the interstitium of the free gadocoletic 
acid ion is restricted by some specifi c interaction of the free ion with interstitial moieties. 
This is not unlikely given the binding affi nity of the free B22956/1 moiety. As a consequence, 
the concentration gradient driving the fl ux across the microvessel wall would be only 
slowly restored, limiting the clearance and thus release of the unbound B22956/1 moiety 
from its intravascular bound form. Evidence in support of this hypothesis comes from the 
overestimation of fBV, which may be accounted for by a rapid early-phase distribution 
of agent just beyond the vessel wall (on the interstitial side). This hypothesis must be 
explored in further studies.
Changes in fractional blood volume did not show any evidence of signifi cant change as a 
result of therapy. The higher sensitivity of KPS (permeability) to antiangiogenic therapy is 
consistent with results from other studies, which demonstrated no changes in fractional 
plasma volume of the tumor tissue following one week of anti-VEGF antibody treatment 
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(21) or a VEGF receptor tyrosine kinase inhibitor treatment (45) using the same tumor 
model enhanced with albumin-(Gd-DTPA) (21,45) and SHU555C (45) as contrast agents. It 
is both possible and likely that different treatment durations will lead to different relative 
impacts of fBV and KPS.
The search for a contrast agent suitable for characterizing the vessels of tumors in a 
clinical setting has been extensive. Since the prototype macromolecular contrast medium 
albumin-(Gd-DTPA) is not appropriate for human use, the feasibility of several other 
contrast media for quantitatively assessing the properties of tumor microvessels has 
been recently evaluated. USPIO such as NC100150 (Clariscan; Nycomed Amersham, Oslo, 
Norway) and SHU 555C (Schering AG, Berlin, Germany) could be used successfully to defi ne 
the tumor microvasculature in a chemically induced rodent breast cancer model (25,26). 
However, one limitation of using USPIO for characterizing tumor microvessels is the fact 
that the positive signal enhancement associated with T1 shortening is associated with 
negative enhancement induced by the T2* shortening (35,46). Especially when higher 
doses of USPIO are used, the positive enhancement caused by the T1 shortening can be 
overwhelmed by the T2* effects. A second factor that can negatively infl uence the use of 
USPIO for quantitatively estimating microvessel properties is the dependence of the T2* 
effects on the compartmentalization of the iron particles in the tissue (26). These limiting 
factors associated with USPIO can be avoided with the use of B22956/1. Because of the low 
r2/r1 ratio (~1) of B22956/1, the T2* shortening effect is less pronounced (33).
VEGF has been demonstrated to both stimulate endothelial cell proliferation and increase 
the vascular permeability. The observed reduction in tumor microvascular permeability 
in the current study as a result of therapy with anti-VEGF antibody refl ects the successful 
suppression of VEGF-induced hyperpermeability, and is in agreement with previous 
reports (47).
One limitation of the current study was that the tumors were implanted in athymic rats, 
which exhibit a pattern of immune response different from that in humans. Nevertheless, 
this is the regime in which antiangiogenic agents are fi rst to be evaluated. Indeed, clinical 
imaging protocols may not differ from the experimental imaging approaches discussed 
above, since experimental imaging is performed at the clinically-relevant fi eld strength 
of 2T.
The data in this study support the hypothesis that estimates of transendothelial 
permeability to B22956/1 are an appropriate measure of tumor response to therapy, and 
are superior in resolution and responsiveness (dynamic range) to either low-molecular-
weight or macromolecular contrast agents.
In conclusion, dynamic MRI enhanced with the new contrast medium B22956/1 has 
shown potential for measuring the effects of antiangiogenesis therapy with an anti-VEGF 
antibody in an experimental rat model. Quantitative microvascular characterization of 
tumors with dynamic MRI using such a contrast agent could prove to be clinically useful 
in monitoring the results of antiangiogenesis treatment, and serve to provide an early and 
physiologically-specifi c indicator of the biological activity of such therapeutics. It may also 
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provide a useful selection criterion for inclusion of patients into clinical trials to evaluate 
putative antiangiogenic agents. Importantly, with the use of an agent such as B22956/1, it 
appears that a straightforward resolution of the effects of antiangiogenic treatments can 
be revealed within very reasonable scan times of 5-10 minutes (i.e., without the need for 
the 30 full-matrix images acquired after the initial 40 keyhole images (approximately six 
minutes), since inclusion of these data added no precision. This offers a straightforward 
translation from an experimental to a clinical implementation.
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Abstract
The objective of this study was to evaluate the potential of dynamic contrast-enhanced MRI 
for quantitative characterization of tumor microvessels and to assess the microvascular 
changes in response to isolated limb perfusion with TNF-α ￦ and melphalan. Dynamic 
contrast-enhanced MRI was performed in an experimental cancer model, using a 
macromolecular contrast medium, albumin-(Gd-DTPA)
45
. Small fragments of BN 175, a 
soft-tissue sarcoma, were implanted in 11 brown Norway (BN) rats. Animals were assigned 
randomly to a control (Haemaccel) or drug-treated group (TNF-α ￦/melphalan). MRI was 
performed at baseline and 24 h after ILP. The transendothelial permeability (KPS) and the 
fractional plasma volume (fPV) were estimated from the kinetic analysis of MR data using 
a two-compartment bi-directional model. KPS and fPV decreased signifi cantly in the drug-
treated group compared to baseline (p < 0.05). In addition, KPS post therapy was signifi cantly 
lower (p < 0.05) in the drug-treated group than in the control group. There was no signifi cant 
difference in fPV between the drug-treated and the control group after therapy. Tumor 
microvascular changes in response to isolated limb perfusion can be determined after 24 h 
by dynamic contrast-enhanced MRI. The data obtained in this experimental model suggest 
possible applications in the clinical setting, using the appropriate MR contrast agents.
Keywords 
Magnetic resonance imaging · Isolated limb perfusion · Tumor angiogenesis · Microvascular 
permeability · Soft-tissue sarcoma
Introduction
Low concentration of anti-tumor agents can be the cause of failure of tumor treatment. 
In isolated limb perfusion (ILP) local drug concentrations are increased while systemic 
exposure to the drug is minimal. Tumor necrosis factor alpha (TNF-α ￦), a cytokine with 
known anti-tumor activity, cannot be used systemically in dosages high enough to obtain 
tumor response. However, in ILP with TNF-α ￦, tumors are exposed to concentrations up to 
15-20 times higher than those reached after systemic administration of the maximum 
tolerated dose without major side effects [1]. TNF-α ￦ is directly cytotoxic for tumor cells 
[2] and has indirect toxicity by affecting endothelial cells and tumor vascularization [3-
5]. By combining TNF-α ￦ and a cytostatic drug like melphalan, a synergistic effect on the 
tumor activity can be obtained, because of an immediate TNF-α mediated tumor-selective 
enhanced drug uptake of the cytostatic agent [6, 7], dependent on the vascularity of the 
tumor [8], followed by a tumor-selective eradication of the tumor-associated vasculature 
[9]. In the clinical setting the combination of TNF-α ￦, interferon-γ￦ and melphalan in 
isolated limb perfusion has lead to a limb salvage rate of 90% in isolated limb perfusion 
for irresectable melanomas and sarcomas [9-11].
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Magnetic resonance imaging (MRI) offers the possibility to noninvasively characterize 
tumors. The ability of dynamic MRI enhanced with macromolecular contrast agents to 
quantitatively defi ne the permeability of tumor microvessels has been shown in several 
experimental models [12-14].
The purpose of the current study was to evaluate whether blood-pool enhanced MRI could 
identify and monitor the effect of a combined treatment with TNF-α and melphalan. 
Microvascular characteristics, such as transendothelial permeability and fractional plasma 
volume, derived from the kinetic analysis of data acquired with dynamic MRI enhanced 
with albumin-(Gd-DTPA)
45
, were studied as a marker of disease progression and response 
to anti-tumor therapy by isolated limb perfusion with TNF-α ￦ and melphalan. Although 
hemorrhagic necrosis and destruction of the endothelial cells will develop in time after 
TNF-α administration, the hypothesis of this study was that the synergistic anti-tumor 
effects could be demonstrated 24 h after initiation of ILP.
Material and methods
Animal and tumor model
The study was conducted with the approval of the Committee for Animal Research at our 
institution. Male inbred BN strain rats weighing 250-300 g were used (Harlan-CPB, Austerlitz, 
The Netherlands). Small fragments (3-5 mm) of the syngenic BN 175 soft-tissue sarcoma were 
implanted subcutaneously in the right hind limb just above the ankle. BN 175 sarcoma is a 
rapidly growing and metastasizing tumor. The animals were inspected daily for tumor growth 
and general appearance. The tumors were imaged when they reached 15 mm in diameter. 
Before the MR imaging, the animals were anesthetized by administration of Hypnorm 
(Janssen Pharmaceutica, Beerse, Belgium). Analgesia was achieved by intraperitoneal injection 
of ketamine (Alfasan, Woerden, The Netherlands). A 25-gauge butterfl y canula was inserted 
into a tail vein for contrast medium injection.
Magnetic resonance imaging
Magnetic resonance imaging was performed using a MR Signa CV/i scanner (General Electric 
Medical Systems, Milwaukee, WI, USA) operating at 1.5 T. A single-loop (custom-made) surface 
coil with an internal diameter of 1.7 cm was constructed specifi cally to create a high signal-to-
noise ratio. A phantom fi lled with corn oil was positioned in the fi eld of view as a T1 reference. 
Pre-contrast T1 mapping was performed using a three-dimensional spoiled gradient-recalled 
sequence (3D-SPGR) with the following parameters: TR 17 ms, TE 4 ms, slice thickness 3 mm, 
matrix 256 × 224 × 80, FOV 4.0 × 4.0 × 3.2 cm, and varying fl ip angles of 5˚, 15˚, 30˚, 45˚ and 
60˚. Data from this sequence was used to calculate baseline longitudinal relaxation rates 
(R1 = 1/T1) for tumor by curve fi tting [15]. Subsequently dynamic images (pre-contrast n = 2, 
post-contrast n = 10) were acquired serially at three-minute intervals with the parameters 
described above, except the fl ip angle was fi xed at 60˚.
Magnetic resonance contrast media
Albumin-(Gd-DTPA)
45
 is a prototype of a water-soluble macromolecular contrast medium with 
a molecular weight of 92,000 Da, synthesized following the method of Ogan [16] (Center of 
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Pharmaceutical and Molecular Imaging, Department of Radiology, University of California San 
Francisco, CA, USA). It has a distribution volume of 0.05 l/kg and a plasma half-life of 3 h in rats, 
which produces nearly constant enhancement for 30 min or longer after injection. Albumin-
(Gd-DTPA)
45
 was injected at a dose of 0.03 mmol Gd/kg.
Experimental protocol
Magnetic resonance examination was performed at baseline (when tumor size was 
approximately 15 mm) and 24 h after treatment (or placebo).  After the baseline MR examinations, 
animals were randomly assigned to either the drug treatment or the control group. One day 
after the baseline MR imaging, each rat was perfused according to the ILP technique as reported 
by Manusama [17]. Briefl y, the animals were anesthetized with Hypnorm and ketamine and 50 
units heparin were injected intravenously. The femoral artery and vein of anesthetized rats were 
cannulated with silastic tubing. Collaterals were occluded by groin tourniquet and perfusion was 
started after the tourniquet was tightened. An oxygenation reservoir and a roller pump were 
included in the circuit. The perfusion was performed with 5 ml Haemaccel (Behring Pharma, 
Amsterdam, The Netherlands) and the hemoglobin content of the perfusate was 0.9 mmol/l. 
50 µg TNF-α (Boehringer, Ingelheim, Germany) in combination with 40 µg melphalan (Alkeran, 
Wellcome, Beckenham, UK) were added as boluses to the oxygenation reservoir (drug treatment 
group). In the control group no drugs were added to the perfusate. During the perfusion, the 
hind leg of the rat was kept at a temperature of 38-39˚C with a warm water mattress. Perfusion 
was maintained for 30 min at a fl ow rate of 1.8 ml min−1. A washout with 5 ml oxygenated 
Haemaccel was performed at the end of the ILP. In order to restore physiological limb perfusion, 
the femoral artery was decannulated and sutured. A second MRI examination using the same 
parameters and contrast medium as for the baseline examination was performed 24 h after ILP. 
After completing the MR examination, all animals were sacrifi ced by intravenous injection of 
ketamine.
Kinetic analysis of dynamic MRI data
The MR images were transferred, processed and analyzed us ing a GE AW2 workstation 
(General Electric Medical Systems, Milwaukee, WI, USA). Signal intensity values (SI) for 
each time point were obtained from multiple (3-6) regions of interest (ROIs) placed in the 
femoral vein, the phantom and the tumor periphery. The tumor periphery was defi ned 
as the peripheral zone of the tumor, 8-10 pixels thick. The size of the ROI was dependent 
on the size of the tumor. Corresponding ROI measurements were made in each of three 
adjacent images and were averaged. The mean signal intensities from the tumors and the 
blood in the femoral vein were corrected for potential variation over time by dividing the 
SI of each ROI by the SI of the phantom. Pre contrast longitudinal relaxation rates R1 (1/T1) 
estimates for tumors were obtained by curve fi tting based on fi ve sets of SPGR images. The 
pre-contrast R1 value for femoral vein blood was assumed to be 0.724 s−1 (1/1.38) based 
upon numerous previous measurements in rat blood [15]. Due to incomplete clearance of 
the contrast agent, the post-treatment pre-contrast R1 value for femoral vein blood had to 
be determined separately. Using fi ve additional rats, not included in the fi nal analysis, an 
average post-treatment pre-contrast R1 for femoral vein blood of 1.026 s−1 was found. Post-
contrast R1 values were calculated based on the observed signal intensities and knowledge 
of pre-contrast R1 values for each ROI as previously described [12]. The difference between 
the post-contrast R1 value at any time point and the pre-contrast R1, ∆R1(t), was assumed 
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to be directly proportional to the concentration of the contrast medium, either in the blood 
or in the tissue [15,18]. Although this assumption is limited in the presence of intermediate 
or slow water exchange, previous studies [15,18] suggest that this level of approximation is 
nonetheless acceptable, provided that a short TR is used (17 ms in this case). The ∆R1 data from 
blood and tumor were used for kinetic analysis to estimate the transendothelial permeability 
(KPS, ml×min−1 100 cc−1 tissue) and the fractional plasma volume of the tumor tissue (fPV, ml 
cc−1  tissue) using a two-compartment, bi-directional kinetic model as previously described in 
detail [12,19]. In this model, a mono-exponential function fi tted to the ∆R1 data from blood 
was used as an input function for the plasma response in the tumor tissue, after scaling for 
fractional plasma volume. The KPS values determined from the model were multiplied by 100, 
thereby scaling our permeability measure for 100 cc of tissue. All data fi tting was performed 
with the commercially available SAAM II computer program (SAAM Institute, Seattle, WA, USA), 
which employs standard variance-weighted nonlinear regression. The uncertainty of the 
estimates of the model parameters was determined from the covariance matrix at the least 
squares fi t.
Statistics
The paired two-tailed Student’s t-test was used to compare mean values of KPS and fPV in the 
same tumor before and after therapy (drug or sham). The unpaired two-tailed Student’s t-test 
was used to compare mean values for KPS and fPV between the control and the treated groups. 
A p-value of <0.05 was considered statistically signifi cant.
Results
The tumors grew in all implanted animals. The MR imaging was completed successfully in 11 
animals (four sham and seven drug-treated). Figure 1 shows an example of a tumor before and 
after ILP with TNF-α￦ and melphalan and a tumor before and after sham-ILP.
The mean values for KPS and fPV obtained in the pre-and post-therapy studies are shown in 
Table 1. The mean KPS values at baseline were 0.115 ± 0.044 ml x 100 cc−1 min−1 for the drug 
group and 0.086 ± 0.038 ml x 100 cc−1 min−1 for the control group (p = 0.28). At the follow-up 
examination, the mean KPS values decreased signifi cantly (p < 0.05) in the drug treated group 
(0.045 ±0.019 ml × min−1 100 cc−1) compared to baseline. In the control group, the mean KPS 
values did not signifi cantly differ from the baseline (0.096 ± 0.021 ml × 100 cc−1 min−1 vs. 0.086 
± 0.038 ml × 100 cc−1 min−1, p = 0.52). In addition, KPS post val ues were signifi cantly lower in the 
drug-treated group (0.045±0.019ml× 100cc−1 min−1) than in the control group (0.096 ± 0.021 ml × 
100 cc−1 min−1, p < 0.05) as illustrated in Fig. 2.
Mean fPV values were not signifi cantly different at baseline (0.088 ±0.033 ml cc−1 for the drug 
group ver sus 0.082 ± 0.027 ml cc−1 in the control group, p = 0.78). At the follow-up examination, 
the mean fPV values decreased signifi cantly (p < 0.05) in the drug treated group (0.024 ± 0.018 
ml cc−1) compared to baseline. In the control group, the mean fPV values did not signifi cantly 
differ (p = 0.08) from the baseline (0.043 ±0.034 ml cc−1). Post-therapy fPV values did not differ 
in the control group (0.043 ± 0.034 ml cc−1) from the drug-treated group (0.024 ±0.018 ml cc−1, p 
= 0.36), as illustrated in Fig. 3.
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Fig. 1a-d T1-weighted axial images after i.v. administration of albumin-(Gd-DTPA)45 showing an implanted 
sarcoma (small arrow). A phantom was placed in the field of view (thick arrow). a, b Pre (a) and post (b) 
ILP with TNF-α and melphalan. c, d Pre (c) and post (d) ILP with haemaccel (sham perfusion).
Table 1 MRI estimates of fractional plasma volume (fPV) and transendothelial permeability (KPS) for the 
drug-treated and control group.
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Discussion
Microvascular characteristics 
of tumors such as capillary 
permeability and plasma 
volume can be quantitatively 
assessed by contrast-
enhanced MRI by analyzing 
the kinetics of the distribution 
of the contrast medium 
in tumor tissue. These 
parameters can be estimated 
from kinetic analysis of 
dynamic enhancement data 
using simple models of the 
tissue as a compartmentalized 
system [19-22]. Usually two-
compartment tissue models 
are used, representing the 
blood plasma and the extra- 
vascular extracellular space. The contrast agent concentration, modeled as a function of 
time, can be derived from MR signal intensity data, assuming that changes in longitudinal 
relaxation rates R1 (1/T1) after administration of contrast medium are proportional to 
contrast agent concentration. Based on the observed MR signal intensities, these changes 
in R1 can be calculated. Thus the increase of the enhancement can be translated to 
contrast agent concentration and quantifi ed using kinetic modeling, providing estimates 
of microvascular characteristics. 
The measurement of these 
functional parameters enables 
an accurate noninvasive quan-
titative description of the 
microcirculation of individual 
tumors. The follow-up of the 
MRI-derived estimates of micro- 
vascular characteristics provides 
a tool for in vivo monitoring 
of the tumor response to 
therapy. Data from this pilot 
study indicate that the effects 
of anti-tumor treatment by 
isolated limb perfusion can be 
successfully monitored by 
MRI after 24 h. We found that 
dynamic MRI, enhanced with 
albumin-(Gd-DTPA)45, was able 
to detect signifi cant declines in 
Fig. 3 Fractional plasma volume (fPV) in ml cc-1 tissue at base-
line and follow-up examinations for the drug-treated and the 
con trol group. *statistically significantly different from baseline 
value (p < 0.05)
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Fig. 2 Transendothelial permeability (KPS) in ml × 100 cc-1 
min-1 tissue at baseline and follow-up examinations for the 
drug-treated and the control group. *statistically significantly 
different from base line value and from control group (p < 
0.05).
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the microvascular permeability of experimental soft-tissue sarcoma as a result of anti-
tumor therapy by isolated limb perfusion with a combination of TNF-α and melphalan. 
The estimated tumor microvascular permeability, KPS, to albumin-(Gd-DTPA)
45
 decreased 
signifi cantly (p < 0.05) compared to baseline in the animal group treated with TNF-α and 
melphalan. Moreover, KPS post values were signifi cantly lower in the drug-treated group 
than in the control group (p < 0.05).
Fractional plasma volume showed no evidence of signifi cant change as a result of therapy. 
Although there was a decrease in the fPV after ILP in the drug group, the post-therapy 
fPV values were not signifi cantly different in the drug and the control group. The higher 
sensitivity of KPS to anti-tumor therapy is consistent with results from other studies, 
which demonstrated no changes in fractional plasma volume of the tumor tissue 
following one week of anti-VEGF antibody treatment [23] or a VEGF receptor tyrosine 
kinase inhibitor treatment [24] using an experimental model of human breast cancer 
enhanced with albumin-(Gd-DTPA)
30
 [23,24] and SHU555C [24] as contrast agents.
The kinetic analysis was limited to the tumor periphery, which is typically the most 
vascularized and the least necrotic region of the tumor [25,26]. Results of previous studies 
have shown that the tumor periphery is the most representative region for oncologic 
activity [27], and the most responsive to angiogenesis inhibition [28], radiation therapy 
[29] and chemotherapy [13]. The ROIs in the tumor periphery were selected on a late post-
contrast image and in the same position on the baseline and follow-up studies. We did not 
analyze the whole tumor, since we expected tumor necrosis in the center after isolated 
limb perfusion, which could distort the tumor contrast-enhanced characterization.
In the present study, we were primarily interested in quantifying the short-term effects 
of ILP on the microvascular characteristics of the tumor; we did not take into account the 
long-term effects of ILP. In a future study, we plan to evaluate the effect of ILP in an even 
shorter time frame: within 0.5-1 h after treatment DCE-MRI will be performed. This way, 
the almost immediate effects of ILP on the microvasculature of the tumor can be studied.
The search for a contrast agent suitable for characterizing the vessels of tumors in a clinical 
setting has been extensive. Since the prototype macromolecular contrast medium albumin-
(Gd-DTPA) is not appropriate for human use [30,31], due to its potential immunologic 
response and the incomplete and prolonged elimination of gadolinium, the feasibility of 
several other contrast media to quantitatively assess the properties of tumor microvessels 
has been evaluated. Recently, several MR contrast media were studied with respect to 
their diagnostic potential for quantitative description of tissue microvessels. These 
contrast agents include ultra-small superparamagnetic iron oxide particles (USPIO) such 
as NC100150 (Clariscan, Nycomed Amersham, Oslo, Norway) [32] and SHU 555C (Resovist, 
Schering AG, Berlin, Germany) [33] and blood-pool agents such as MS-325 (Angiomark, 
Schering AG, Ber lin, Germany) [34] and P792 (Vistarem, Guerbet, Aulnay-sous-Bois, France) 
[35]. However, one limitation of the use of USPIO for characterization of tumor microvessels is 
the fact that the positive signal enhancement associated with T1 shortening is associated 
with negative enhancement induced by the T2* shortening [18,36]. Especially when higher 
doses of USPIO are used, the positive enhancement caused by the T1 shortening can be 
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overwhelmed by the T2* effects. A second factor that can negatively infl uence the use of 
USPIO in the quantitative estimation of the microvessel properties is the dependence 
of the T2* effects on the compartmentalization of the iron particles in the tissue [33].
To obtain further insight into the mechanisms underlying the positive results obtained with 
ILP in humans, extremity perfusion models were developed in rats using BN 175 sarcoma 
in brown Norway rats and ROS-1 osteosarcoma in WAG rats [17,37]. In both models, a 
strong synergistic anti-tumor effect was observed after ILP with TNF-α and melphalan. The 
observations from these studies confi rmed that TNF-α ￦ has its major effect on larger tumors 
with well-developed vasculature, in contrast with small tumors (diameters less than 3 mm) 
lacking a developed capillary bed [38,39]. TNF-α may exert its effect through the vasculature 
of the tumor, which is more abundant in larger tumors. Early endothelial damage and platelet 
aggregation were observed after ILP with TNF-α and melphalan and this is believed to 
lead to ischemic necrosis, which is in line with observations in patients [40]. The observed 
decrease in tumor vascular permeability in the present study in the group that underwent 
ILP with TNF-α and melphalan might be explained by the destruction of the tumor blood 
vessels. Previous studies have demonstrated the selective destructive effect of the ILP with 
TNF on tumor-associated vessels using pre-perfusion and post-perfusion angiography [41].
The data in this study support the hypothesis that estimates of transendothelial permeability 
are an appropriate measure of tumor microvascular changes in response to isolated limb 
perfusion, although a limited number of animals have been examined. Although albumin-
(Gd-DTPA)
45
 is a useful prototype for animal studies, this macromolecular contrast agent is 
considered unlikely for ultimate clinical use because of incomplete elimination. However, 
since several blood-pool contrast agents are at this moment under clinical investigation, 
examination of the feasibility of blood-pool enhanced MR in this ILP model seems to be of 
interest.
In conclusion, dynamic MRI enhanced with the macromolecular contrast agent albumin-(Gd-
DTPA)
45
 has shown a potential to measure, after 24 h, the effects of isolated limb perfusion 
on tumor microvasculature in an experimental model of soft-tissue sarcoma. Quantitative 
microvascular characterization of tumors with dynamic MRI using a blood-pool contrast 
agent could prove to be clinically useful in monitoring the changes induced by anti-tumor 
treatment and serve to provide an early and physiologically-specifi c indicator of biological 
activity of such a therapeutic approach.
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Chapter 11
summary and conclusion
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Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) offers the 
opportunity to quantitatively assess physiologic properties of tumor tissue. MRI enables 
the noninvasive investigation of the anatomy and function of the tumor microvessels 
and can help in distinction of malignant tumor blood vessels from normal vessels. The 
subject of this dissertation is the evaluation of the role of dynamic MRI enhanced with 
macromolecular contrast media in noninvasive characterization of the pathophysiology of 
tumor microvessels and in the monitoring of antiangiogenesis therapy. 
Chapter 1 provides a general introduction to this thesis.
Chapter 2 presents an overview of the current applications and limitations of macro-
molecular contrast media for quantitative MR characterization of tumor microvessels, 
investigated either in experimental animal studies or in clinical trials, with or without 
drug interventions. 
In chapter 3, a meta-analysis of quantitative MRI breast tumor characterizations acquired 
in three separate experimental studies of rodent breast cancers demonstrated that 
transendothelial permeability values based on MR data obtained from a region of interest 
limited to the periphery of tumors correlated signifi cantly better (r=0.784, P<0.001) with the 
tumor histologic grade than did KPS estimated from data analysis from regions of interest 
covering the whole tumor cross section (r=0.604). Based on these results, future efforts to 
characterize tumor grade based on MRI analysis should focus on regions of interest confi ned 
to the tumor periphery, at least as a major component in a more complete analysis.
In chapter 4, the utility of a new rapid clearance blood pool MR contrast medium (P792) 
for the assessment of microvessels characteristics was evaluated in a chemically induced 
rodent breast tumor model and compared to the prototype contrast agent albumin-(Gd-
DTPA)
30
. Using P792-enhanced data, neither the transendothelial permeability KPS nor 
the fractional plasma volume of the tumor tissue showed a signifi cant correlation with 
the tumor histologic grade or with the microvascular density counts (P>0.05). Conversely, 
using albumin-(Gd-DTPA)
30
, KPS values correlated signifi cantly (r=0.55, P<0.001) with the 
tumor grade and the microvessel density count (r=0.34, P<0.05). The analysis suggests 
that contrast media of relatively large (on the order of 90 kDa) molecular weight, such as 
albumin-(Gd-DTPA)
30
, are more accurate for the characterization of tumor microvessels.
In chapter 5, the potential of carboxymethyldextran-A2-Gd-DOTA, a slow clearance blood 
pool contrast medium, for characterization of tumor microvessels was evaluated in a 
chemically induced rodent breast tumor model of various malignancy grades. No signifi cant 
correlations were found between the MR-estimated transendothelial permeability (r=0.09, 
P>0.05) or plasma volumes (r=0.19, P>0.05) of the tumor tissue and the tumor histologic 
grade. Analysis of carboxymethyldextran-A2-Gd-DOTA-enhanced MR kinetic data failed 
to demonstrate feasibility for the differentiation of benign from malignant tumors or for 
image-based tumor grading. 
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In chapter 6, the diagnostic potential of USPIO for defi ning the properties of tumor mi-
crovessels was investigated. Transendothelial permeability KPS correlated signifi cantly 
(P<0.05) with the histologic grade of the experimental breast tumors of varying malig-
nancy for both the USPIO (r=0.36) and the reference macromolecule albumin-(Gd-DTPA)
30
 
(r=0.54). The study concluded that USPIO, a macromolecular particulate MR imaging con-
trast agent, could be applied successfully to characterize tumor vessels. 
In chapter 7, the ability of dynamic MRI enhanced with two macromolecular contrast me-
dia, USPIO and albumin-(Gd-DTPA)
30
, to monitor the effects of an antiangiogenic therapy 
with a VEGF tyrosine kinase inhibitor was investigated in a human breast cancer xeno-
graft. Control tumors increased signifi cantly (P<0.05) in size and in microvascular perme-
ability KPS based on MRI assays using both macromolecular contrast media. In contrast, 
tumor growth was signifi cantly reduced (P<0.05) in animals treated with the VEGF recep-
tor tyrosine kinase inhibitor and the KPS values declined slightly (P>0.05 for both contrast 
agents). Microvascular density counts correlated fairly (r=0.64) with the tumor growth and 
were statistically signifi cant higher (P <0.05) in the control than in the drug-treated group. 
MRI measurements of tumor microvascular permeability, using either of two macromo-
lecular contrast media, were able to detect effects of an antiangiogenic therapy. 
In chapter 8, the utility of six contrast media of different molecular weights for monitoring 
the microvascular changes caused by an antiangiogenic treatment was investigated. The 
experimental breast tumors grew signifi cantly (P<0.05) slower in the drug group treated 
with an anti-VEGF antibody. Mean values for the transendothelial permeability and tumor 
fractional plasma volume decreased signifi cantly (P<0.05) in de drug-treated group com-
pared to baseline values using intermediate (ZK181220 and Gadomer-17) or macromole-
cular contrast media (SHU555C and albumin-(Gd-DTPA)
30
), but did not change signifi cant-
ly using small molecular contrast media (Gd-DTPA and ZK159560). The study showed the 
potential of dynamic contrast-enhanced MRI to monitor the effects of an antiangiogenic 
treatment on tumor microvessels. Intermediate-sized contrast agents with a molecular 
weight of 20-30 kDa also allowed tumor microvessel characterization in a fashion similar 
to that in larger macromolecules. 
In chapter 9, a novel protein-binding contrast agent (B22956/1) was compared to 
a low molecular, clinically available contrast medium (ProHance￦) and a prototype 
macromolecular contrast agent, albumin-(Gd-DTPA) for monitoring the tumor response 
to antiangiogenic therapy with an anti-VEGF antibody. The transendothelial permeability 
of tumor microvessels KPS determined for B22956/1 decreased signifi cantly (P<0.05) 
in the animal group treated with the angiogenesis inhibitor compared to baseline, and 
progressed signifi cantly (P<0.05) in the control group. However, no signifi cant changes 
were distinguished using either the low- or macromolecular contrast agent. Data from this 
study indicate that dynamic MRI enhanced with B22956/1 can successfully monitor the 
effects of antiangiogenesis treatment with anti-VEGF antibody.
In chapter 10, the role of DCE-MRI enhanced with the prototype macromolecular contrast 
agent albumin-(Gd-DTPA)
45 
in monitoring the microvascular changes associated with iso-
lated limb perfusion was investigated in an experimental soft-tissue sarcoma. Transendo-
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thelial permeability KPS and fractional plasma volume of the tumors decreased signifi cant-
ly (P<0.05) in the drug-treated (TNF-α/melphalan) group compared to baseline. In addition, 
KPS post therapy was signifi cantly lower (P<0.05) in the drug-treated group than in the 
control group. The study demonstrated that tumor microvascular changes in response to 
isolated limb perfusion could be determined after 24 hours by DCE-MRI. 
Conclusion
The use of dynamic MRI enhanced with macromolecular media has the potential to 
improve the differentiation between benign and malignant tumors and to allow the non-
invasive grading of tumors. 
The studies included in the fi rst part of this thesis suggest that the specifi city of MR 
contrast agents for the defi nition and measurement of abnormal vascular permeability of 
tumor tissue increases with the molecular weight of the contrast agent. The permeability 
of tumor microvessels to contrast agents is infl uenced by the morphology of the vessel 
wall and the size of the applied contrast medium. Thus when evaluating the microvascular 
permeability to a specifi c contrast agent, the size of the MR contrast agent must be taken 
into account. If a contrast agent is too small (<1 kDa), like the widely used and well-
tolerated extracellular contrast agents represented by gadopentetate dimeglumine, 
differentiation based on contrast-enhancement properties between benign and malignant 
tissue is diffi cult. Contrast agents with a higher molecular weight that remain in the blood 
vessels for a longer time can improve the assessment of permeability, but they are still in 
preclinical evaluation or in clinical trials and are not currently approved for human use. 
The immediate challenge is to identify a macromolecular contrast agent that might be 
suitable for clinical development and that shows promise in animal studies for tumor 
characterization. Some of the requirements that need to be met in the design of the contrast 
medium include: 
1. The molecular weight of the contrast agent should be suffi ciently high that the
 contrast agent does not extravasate across the normal microvascular endothelial
 barriers, but it should diffuse across the distorted endothelium of tumor micro vessels.
2. The size of the contrast agent should be tolerated in humans.
3. The interaction of the contrast agent with the tissue should be minimal.
4. The contrast agent should be stable in vivo. 
5. The contrast agent should be completely cleared from the body. 
Dynamic MRI enhanced with macromolecular contrast media MRI is a promising technique 
for evaluating the therapeutic response to antiangiogenic drugs. The studies included in 
the second part of this thesis indicate that the effects of antiangiogenesis treatment could 
be monitored by MRI enhanced with: (1) contrast agents with high molecular weight like 
USPIO and albumin-(Gd-DTPA)30; (2) contrast media with intermediate molecular weight 
(ZK181220 and Gadomer-17); and (3) contrast agents with low molecular weight that 
bind reversibly to plasma proteins (B22956/1). In the future, DCE-MRI-based imaging 
assessments of angiogenesis could have widespread clinical applications. DCE-MRI might 
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objectify the effects of an antiangiogenic treatment, possibly even before morphological 
changes, such as reduction in tumor size, become apparent. 
The anticipated availability of clinically approved macromolecular contrast agents 
and the technological advances in the area of MRI systems, imaging techniques and 
pharmacokinetic modeling are expected to improve the characterization of tumors and 
the non-invasive evaluation of therapy effects in clinical practice.
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Dynamische magnetische resonantie (MR) tomografi e met intraveneus contrast biedt 
de mogelijkheid voor kwantitatieve evaluatie van de fysiologische eigenschappen van 
tumorweefsel. MR tomografi e maakt de niet-invasieve beoordeling van de anatomie en 
de functie van microbloedvaten in tumoren mogelijk. Ook kan de techniek bijdragen 
aan het onderscheiden van maligne en normale bloedvaten. Dit proefschrift evalueert 
de rol van de dynamische MR tomografi e met macromoleculaire contrastmiddelen, in de 
karakterisering van tumor microbloedvaten en in het monitoren van de anti-angiogenese 
behandeling.
Hoofdstuk 1 is de algemene inleiding op het proefschrift.
Hoofdstuk 2 geeft een overzicht van de gangbare toepassingen en beperkingen van 
macromoleculaire contrastmiddelen voor kwantitatieve karakterisering van microbloed-
vaten in tumoren middels MR tomografi e. Dit overzicht is gebaseerd op dierproeven en 
klinische studies, zowel met als zonder medicamenteuze behandeling.
Hoofdstuk 3 presenteert een meta-analyse van kwantitatieve karakterisering van 
mammatumor studies door middel van MR tomografi e. Hieruit blijkt dat berekening 
van de permeabiliteitwaarden van de vaatwand op basis van MR data van een region of 
interest (ROI) in de periferie van de tumor, beter correleert met de histologische gradering 
(r=0.784, P<0.001), dan de permeabiliteitwaarden gebaseerd op een ROI in de gehele tumor 
(r=0.604). Deze resultaten suggereren dat toekomstige pogingen om tumoren te graderen 
op basis van MR beelden zich zouden moeten richten op ROI`s in de periferie van de tumor, 
tenminste als een belangrijke component van een meer complete analyse.
In hoofdstuk 4 worden de toepassingen onderzocht van een nieuw bloodpool contrast-
middel met een snelle eliminatie (P792) voor de beoordeling van de eigenschappen van 
microbloedvaten. Dit contrastmiddel werd gebruikt in een knaagdier mammatumor en 
werd vergeleken met het prototype macromoleculaire contrastmiddel albumine-(Gd-
DTPA)
30
. Uit analyse van MR beelden na toediening van P792 bleek geen signifi cante 
correlatie te bestaan tussen enerzijds de histologische graad van de tumor en de 
permeabiliteit van de vaatwanden en anderzijds het fractionele plasmavolume van het 
tumorweefsel, of de  microvasculaire dichtheid (P>0.05).
Een signifi cante correlatie (r=0.55, P<0.001) tussen vaatwand permeabiliteit en de 
histologische graad van de tumor en de microvasculaire dichtheid (r=0.34, P<0.05) werd 
wel gevonden na toediening van albumine-(Gd-DTPA)
30
. Deze resultaten suggereren dat 
contrastmiddelen met een relatief hoog moleculair gewicht (circa 90 kDa), zoals albumine-
(Gd-DTPA)
30
, accurater zijn voor de typering van microbloedvaten in een tumor.
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Hoofdstuk 5 beschrijft een onderzoek naar de bruikbaarheid voor tumorkarakterisering 
van carboxymethyldextran-A2-Gd-DOTA, een blood pool contrastmiddel met een trage 
uitscheiding. Dit middel werd toegepast in een knaagdier mammatumor model met 
verschillende maligniteitsgraden. Er werd geen signifi cante correlatie gevonden tussen 
de MR-gebaseerde permeabiliteit van de vaatwand (r=0.09, P>0.05), of het plasmavolume 
van het tumorweefsel en de histologische graad van de tumor (r=0.19, P>0.05). Het 
differentiëren tussen maligne en benigne tumoren blijkt daarom niet goed mogelijk op 
basis van MR data, verkregen na toediening van carboxymethyldextran-A2-Gd-DOTA. 
 
De potentiële toepasbaarheid van ultrasmalle superparamagnetische ijzeroxide partikels 
(USPIO), een macromoleculair contrastmiddel, wordt onderzocht in hoofdstuk 6. De 
permeabiliteit van de vaatwanden berekend op basis van MR beelden na toediening van 
zowel USPIO (r=0.36) als albumine-(Gd-DTPA)
30
 (r=0.54), correleerde signifi cant (P<0.05) met 
de histologische graad van experimentele mammatumoren. De conclusie van deze studie is 
dat USPIO met succes gebruikt kan worden voor de karakterisering van tumorbloedvaten. 
Hoofdstuk 7 beschrijft hoe met behulp van MR beelden de effecten van een anti-angiogenese 
behandeling met een VEGF tyrosine kinase inhibitor kunnen worden gevolgd. Deze MR 
beelden werden verkregen van in knaagdieren geplaatste mammacarcinoom xenografts, 
na toediening van twee macromoleculaire contrastmiddelen (USPIO en albumine-(Gd-
DTPA)
30
). De tumoren behandeld met VEGF tyrosine kinase inhibitor groeiden signifi cant 
minder (P<0.05) dan de onbehandelde tumoren. De vaatwand permeabiliteitwaarden op 
basis van MR beelden na toediening van zowel USPIO als albumine-(Gd-DTPA)
30
, steeg 
signifi cant in de controlegroep (P<0.05). In tegenstelling tot de controletumoren, was de 
tumorgroei signifi cant lager (P<0.05) na behandeling met VEGF tyrosine kinase inhibitor. De 
permeabiliteitwaarden daalden minder uitgesproken (P>0.05) bij beide contrastmiddelen. 
De microvasculaire dichtheid, die vrij goed correleerde met de tumorgroei (r=0.64), was 
statistisch signifi cant (P<0.05) hoger in de controlegroep dan in de behandelde groep. De 
effecten van een anti-angiogenese behandeling kunnen worden vastgesteld met behulp 
van microvasculaire permeabiliteitmetingen, na de toediening van twee macromoleculaire 
contrastmiddelen. 
In hoofdstuk 8 wordt de toepasbaarheid onderzocht van zes contrastmiddelen van 
laag, intermediair en hoog moleculair gewicht, voor het vervolgen van microvasculaire 
veranderingen tijdens anti-angiogenese behandeling. De experimentele mammatumoren 
groeiden signifi cant (P<0.05) langzamer in de proefdieren behandeld met een anti-VEGF 
antilichaam. Na toediening van contrastmiddelen met een hoog (SHU555C and albumine-
(Gd-DTPA)
30
) of intermediair (ZK181220 en Gadomer-17) moleculair gewicht daalden 
de gemiddelde waarden van de permeabiliteit van de vaatwanden en het fractionele 
plasmavolume van de tumoren signifi cant (P<0.05) in de behandelde groep. De waarden 
daalden niet signifi cant na toediening van contrastmiddelen met een laag moleculair 
gewicht (Gd-DTPA en ZK159560). Deze studie toont aan dat de effecten van een anti-
angiogenese behandeling van de tumor microbloedvaten kunnen worden gevolgd met 
dynamische MR tomografi e. Contrastmiddelen met een intermediair moleculair gewicht 
van 20-30 kDa kunnen op een vergelijkbare manier worden toegepast bij de typering van 
tumor microbloedvaten als contrastmiddelen met een hoger moleculair gewicht. 
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In hoofdstuk 9 worden verschillende contrastmiddelen vergeleken voor het vervolgen van 
het effect van anti-VEGF antilichaam behandeling op tumoren. Het gaat hier om een nieuw 
contrastmiddel met eiwitbinding (B22956/1), een laagmoleculair, klinisch verkrijgbaar 
contrastmiddel (ProHance) en een prototype macromoleculair contrastmiddel, albumine- 
(Gd-DTPA). De permeabiliteit van microbloedvaten bepaald voor B22956/1 daalde signifi cant 
(P<0.05) in de groep behandeld met de anti-VEGF en steeg signifi cant (P<0.05) in de 
controlegroep. Er konden echter geen signifi cante veranderingen vastgesteld worden op basis 
van MR beelden na toediening van een laagmoleculair of hoogmoleculair contrastmiddel. 
Dit onderzoek suggereert dat de effecten van de anti-angiogenese behandeling met succes 
kunnen worden gevolgd met MR tomografi e na toediening van B22956/1. 
Hoofdstuk 10 beschrijft hoe dynamische MR tomografi e met toediening van het prototype 
macromoleculair contrastmiddel albumine-(Gd-DTPA)
45
 kan worden ingezet in het volgen 
van microvasculaire veranderingen, geassocieerd met geïsoleerde extremiteitperfusie. Hierbij 
wordt gebruik gemaakt van een experimenteel model van het weke delen sarcoom. 
De permeabiliteit van de vaatwand en het fractionele plasmavolume van deze tumoren 
daalde signifi cant (P<0.05) in de groep proefdieren behandeld met TNF-α ￦/melphalan. 
De permeabiliteitwaarden waren na de behandeling signifi cant lager in de behandelde 
groep (P<0.05) dan in de controlegroep. Dit onderzoek toont aan dat de microvasculaire 
veranderingen als gevolg van geïsoleerde extremiteitperfusie binnen 24 uur na het 
starten van de behandeling kunnen worden vastgesteld door middel van dynamisch MR 
tomografi e met albumine-(Gd-DTPA)
45
.
Conclusie
Met behulp van dynamische magnetische resonantie tomografi e met macromoleculaire 
contrastmiddelen is het mogelijk een beter onderscheid te maken tussen maligne en 
benigne tumoren, door microbloedvaten van tumoren te typeren. Het gebruik van deze 
methode biedt tevens mogelijkheden voor niet-invasieve gradering van de tumoren. 
De onderzoeken die beschreven zijn in het eerste gedeelte van dit proefschrift geven aan 
dat contrastmiddelen specifi eker zijn voor het defi niëren en meten van de abnormale 
vasculaire permeabiliteit van het tumorweefsel, naarmate het moleculair gewicht van het 
contrastmiddel stijgt. De permeabiliteit van tumor microbloedvaten voor contrastmiddelen 
wordt onder meer bepaald door de morfologie van de vaatwand en het moleculaire 
gewicht van het toegepaste contrastmiddel. Concluderend moet bij de evaluatie van tumor 
microbloedvaten middels MR tomografi e rekening gehouden worden met het moleculaire 
gewicht van het contrastmiddel. Als het contrastmiddel een laag moleculair gewicht 
heeft (< 1 kDa), zoals de breed toegepaste extracellulaire contrastmiddelen, waaronder 
gadopentetate dimeglumine, kan het onderscheid tussen benigne en maligne weefsel 
problematisch zijn. Contrastmiddelen met een hoger moleculair gewicht blijven langer 
endovasculair en kunnen de evaluatie van de permeabiliteit van de vaatwand verbeteren. 
Deze middelen bevinden zich echter nog in het stadium van preklinische, of klinische 
studies en hun gebruik is op dit moment niet toegestaan voor reguliere patiëntenzorg. 
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De uitdaging is het identifi ceren van een contrastmiddel dat geschikt is voor verdere 
klinische ontwikkeling en dat goede resultaten laat zien bij het typeren van tumoren in 
dierproeven. Het contrastmiddel zou moeten voldoen aan de volgende voorwaarden:
1. Het contrast middel moet een moleculair gewicht hebben dat zodanig hoog is dat het  
 contrastmiddel niet door het endotheel van normale bloedvaten kan passeren, maar  
 lekt door het beschadigde endotheel van tumorbloedvaten; 
2. Het moet goed verdragen worden door het menselijk lichaam; 
3. Het middel heeft een minimale interactie met het weefsel;
4. Het is stabiel in vivo; 
5. Het wordt volledig uitgescheiden.
Dynamische MR tomografi e met macromoleculaire contrastmiddelen is eveneens 
een veelbelovende techniek voor het volgen van de respons op behandeling met anti-
angiogenese medicatie. De onderzoeken die in het tweede gedeelte van dit proefschrift 
aan de orde komen laten zien dat de volgende contrastmiddelen daartoe geschikt 
zijn: (1) hoogmoleculaire contrastmiddelen zoals USPIO and albumine-(Gd-DTPA)
30
; (2) 
contrastmiddelen met een intermediair moleculair gewicht zoals ZK181220 and Gadomer-
17; en (3) laagmoleculaire contrastmiddelen met reversibele eiwitbinding zoals B22956/1. 
In de toekomst zou de evaluatie van angiogenese met behulp van dynamische MR 
tomografi e met gebruik van contrastmiddel uitgebreide klinische toepassingen kunnen 
hebben. Dynamisch MR onderzoek zou de effecten van anti-angiogenese behandeling 
kunnen objectiveren, zelfs voordat een afname in de tumorafmetingen vastgesteld kan 
worden. 
De verwachting is dat de typering van tumoren en de niet-invasieve evaluatie van de 
behandeling verder zal verbeteren door het beschikbaar komen van macromoleculaire 
contrastmiddelen voor gebruik in patiënten en door de technische vooruitgang op het 
gebied van MR tomografi esystemen, afbeeldingtechnieken en farmacologische modellen.
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